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Preface  
 
The work presented in this PhD thesis was conducted at the Department of Nephrology and 
Kidney Transplantation in close collaboration with the Department of Clinical Chemistry of 
Centro Hospitalar do Porto, Porto, Portugal. 
Because of the difficulties in obtaining funds for the prospective studies, the need for a period 
of interruption as a result the illness of a close relative, and my concurrent full-time 
employment, the work included in this PhD thesis was extended and performed from July 
2008 to October 2014.  
A PhD is a long, complex, meticulous, and, in most cases, laborious and painful process. The 
prospective cohort-based studies included in this thesis were purposely designed and 
completed for this PhD project and some of the biomarker analyses were performed for the 
first time in the Department of Clinical Chemistry. The financial support obtained for this part of 
the study was exhausted by the purchase of reagents. Thus, I had an active role in 
accomplishing of this task. Whenever a patient was called for transplant and agreed to 
participate in the study I was notified and then the study process was triggered. Every day for 
seven months, including weekends, I prepared and stored approximately 3000 blood samples 
(whole blood, serum, plasma and erythrocytes). And after that, I actively participated in the 
laboratory analyses, mainly in the oxidative stress measurements. 
This thesis cannot express the long days (and nights!) spent in the lab but it represents a 
culmination of work, writing and learning. I have been responsible for the design and 
organization of the study herein, as well as almost all aspects of the data collection and 
processing. I have learned how to elaborate and conduct research in a complex field, how to 
collaborate with other researchers as a team and how to conduct research as an individual. 
This PhD was a challenging as well as a rewarding journey during which I have gained 
important knowledge and valuable skills. I have been the main author for all publications. With 
the exception of the competing risks analysis, which was performed by Laetitia Teixeira, one 
of my co-authors, all statistical analyses were performed by me (some for the first time) and 
guided by my main supervisor Denisa Mendonça.  
This thesis is the report of this long process. It cannot account the long hours spent on 
computer with statistics and scientific writing. It cannot express the hope for good results and 
the sadness and tiredness with each manuscript rejection. But I hope that it expresses hard 
work, determination and persistence. Do not give up! I believe that this was the hardest lesson 
on this PhD journey.  
Isabel Fonseca,  
Porto, November 2014 
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Abstract 
Kidney transplantation is considered the treatment of choice for many patients with end-
stage chronic kidney disease; however, despite advancements in short-term allograft 
survival, long-term survival has not paralleled this improvement. Due to the inevitable 
ischemic damage and associated reperfusion injury, delayed graft function (DGF) is a 
common complication after kidney transplantation, which may negatively affect graft 
survival. Because serum creatinine (SCr) and other traditional markers of kidney injury are 
insensitive and delayed in the detection of the early stages of kidney damage and DGF, 
there has been a keen interest in the identification of novel biomarkers for the early 
detection of allograft dysfunction that could expedite treatment and improve long-term 
patient and graft survival. Biomarkers are characteristics that can be objectively measured 
in a biological sample. In clinical settings, biomarkers enable the diagnosis of a 
dysfunction or disease and, in some cases, they are used to monitor a treatment or to 
make a prognosis regarding the future outcome of a patient. The analysis of predictive 
factors of graft dysfunction and long-term kidney allograft failure focusing on novel 
biomarkers was the major motivation for this work. Thus, the general aim of this thesis 
was to investigate the potential of different biomarkers to reliably diagnose and predict 
early graft dysfunction and their effect on long-term kidney allograft failure as well as to 
gain insight into the underlying mechanisms of graft dysfunction.  
Patients and Methods: The study involved three cohorts of patients: two retrospective 
cohorts that included kidney transplant recipients selected from a database that contained 
transplant and follow-up information on kidney transplants performed between 1983 and 
2008 (for the first retrospective cohort) or 2012 (for the second retrospective cohort); and 
one prospective cohort that included 40 patients undergoing kidney transplantation 
between December 2009 and June 2010. The first retrospective cohort was used to 
validate the one-year SCr as a surrogate endpoint of long-term graft survival, and the 
second retrospective cohort was considered to analyze the impact of DGF (defined by the 
need for dialysis during the first week after kidney transplantation) on graft and patient 
survival using a competing risks approach. The studies based on the prospective cohort 
had a longitudinal observational design, which was initiated at the time of transplantation; 
this cohort was used to examine nine potential candidate biomarkers for the early 
diagnosis of DGF (one biomarker in urine and eight biomarkers in blood): cystatin C 
(CysC), neutrophil gelatinase-associated lipocalin (N.GAL), leptin and adiponectin, 
malondialdehyde (M.D.A), superoxide dismutase (S.OD), glutathione reductases (GR), 
peroxidases (GPx) and total antioxidant status (TAS). Five samples per patient were 
collected within the first week: 3 to 6 h prior to transplant surgery (pre-transplant); on the 
vi 
subsequent morning at approximately 8 to 12 h after graft reperfusion (day-1); and then 
on the second (day-2), fourth (day-4) and seventh (day-7) days after transplant, which 
resulted in five samples per patient. 
A linear mixed effects model was used to evaluate the longitudinal changes of the 
potential new biomarkers of early graft dysfunction over the first week after kidney 
transplantation and to identify the factors associated with these changes. The 
performance of the candidate biomarkers in the prediction of DGF was examined using 
receiver-operating characteristic (R.OC) curves. Survival analysis methods, including a 
survival analysis that accounted for competing risks were used to identify the predictive 
factors of long-term graft survival.  
Results: Of the large number of variables that were considered, the SCr levels at 1, 6 and 
12 months following kidney transplantation, as well as the changes between 1 and 6 
months and between 6 and 12 months were independently associated with late graft 
failure.  
The R.OC curves identified urinary NGAL, MDA and CysC on the first postoperative day 
as moderately (NGAL) and highly (MDA and CysC) accurate in the prediction of DGF. 
Both urinary NGAL (at days 4 and 7) and MDA (day-7) were independently associated 
with one-year graft function, adjusting for variables that typically affect graft function, 
including acute rejection episodes and re-admissions during the first post-transplant year. 
Leptin at day-1 was slightly better than SCr in the prediction of the need for dialysis within 
the first week post-transplant, whereas adiponectin, SOD, GR, GPx and TAS were not. A 
triple-biomarker approach that used SCr, CysC, and MDA measured 8 to 12 h after kidney 
transplantation, was the most informative combination, which resulted in an increased 
ability (AUC=0.96) to distinguish patients with graft damage who would require dialysis 
within the first week. The application of a subdistribution regression model for competing 
risks indicated that DGF by itself and independent of acute rejection had a detrimental 
effect on long-term graft survival, but not on patient survival. 
Conclusions: Independent of acute rejection, DGF per se was significantly associated 
with poor-graft survival, but not with patient survival. Urinary NGAL and serum CysC and 
MDA were early, noninvasive, and accurate predictors of both the need for dialysis within 
the first week of kidney transplantation and one-year graft function. A triple-biomarker 
approach using SCr, CysC and MDA were highly predictive of DGF. Combining 
biomarkers from different pathophysiologic pathways appears to be a rational and reliable 
strategy to optimize sensitivity and specificity and obtain additive diagnostic and 
prognostic information. 
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Resumo 
O transplante renal (TR) é considerado o melhor tratamento para a maioria dos doentes 
com necessidade de substituição da função renal. Apesar dos progressos alcançados, 
principalmente a nível da falência do enxerto nos primeiros seis meses após TR, a 
sobrevivência a longo prazo não tem acompanhado essa evolução. A ocorrência de 
atraso de função do enxerto (AF.E), nomeadamente por lesão provocada pela isquemia e 
reperfusão associada ao transplante, condiciona a evolução do pós-transplante e tem um 
impacto negativo nos resultados imediatos e a longo prazo do TR. O desenvolvimento de 
intervenções eficazes na prevenção e/ou atenuação da agressão precoce no enxerto 
renal tem sido limitado pela ausência de marcadores precoces da lesão e disfunção 
renal. Os biomarcadores são substâncias ou “entidades” objetivamente quantificáveis, 
indicadores do curso de um processo biológico normal ou da ocorrência de uma lesão ou 
processo patológico, sendo usados na prática clínica para diagnóstico, monitorização 
terapêutica, estratificação de risco e previsão de eventos. Tendo em conta que os 
marcadores tradicionais de lesão e função renal, como a creatinina sérica (SCr), são 
tardios e insensíveis para o diagnóstico atempado de AFE, têm sido procurados novos 
biomarcadores capazes de identificar precocemente a disfunção renal e promover uma 
intervenção atempada e uma melhoria da sobrevivência a longo-prazo do enxerto renal. 
A análise dos fatores preditivos de disfunção e perda do enxerto renal a longo prazo, com 
ênfase na investigação de potenciais biomarcadores da disfunção precoce do enxerto, 
expressa pelo AFE, e do seu efeito na sobrevivência renal a longo prazo foi a principal 
motivação e objetivo desta tese.  
Participantes e Métodos: O estudo envolveu três coortes: duas retrospetivas em que os 
participantes foram selecionados a partir da base de dados do TR da Unidade de 
Nefrologia e Transplante Renal do Centro Hospitalar do Porto de 1983 a 2008 (para a 
primeira coorte retrospetiva) ou 2012 (para a segunda coorte retrospetiva) e uma coorte 
prospetiva de 40 doentes convocados para TR entre Dezembro de 2009 e Junho de 
2010. A primeira coorte retrospetiva foi usada para validar a SCr observada durante o 
primeiro ano pós-TR como um marcador surrogate (substituto) da sobrevivência do 
enxerto renal a longo-prazo. A segunda coorte retrospetiva foi utilizada para avaliar o 
impacto do AFE (definida pela necessidade de diálise na primeira semana pós-TR) na 
sobrevivência do doente e do enxerto renal a longo prazo usando uma abordagem 
estatística baseada em eventos competitivos. Os estudos baseados na coorte prospetiva 
seguiram um desenho observacional longitudinal com início à data do transplante e 
pretenderam estudar nove potenciais biomarcadores para o diagnóstico precoce de AFE 
(um na urina e oito no sangue): a cistatina C (CysC), a lipocalina associada a gelatinase 
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dos neutrofilos (NGAL), alguns marcadores de stress oxidativo [malondialdeído (M.DA), 
glutationa peroxidase (GPx) e reductase (GR), superóxido dismutase (S.OD) e a 
capacidade antioxidante total (TAS)] e as adipocinas leptina e adiponectina. Foram 
colhidas 5 amostras por doente durante a primeira semana pós-TR: 3 a 6h antes do 
transplante; na manhã subsequente, aproximadamente 8 a 12 h após a reperfusão do 
enxerto renal (dia-1); e depois no segundo, quarto e sétimo dias pós-TR. A evolução 
longitudinal dos valores dos marcadores durante a primeira semana pós-TR e a 
identificação de fatores associados às alterações analíticas observadas nessa semana 
foram estudadas por modelos lineares de efeitos mistos. O estudo da performance dos 
biomarcadores no prognóstico de AFE foi efetuado com as curvas ROC. Métodos de 
análise de sobrevivência, incluindo a componente de eventos competitivos, foram usados 
para identificar fatores preditivos da sobrevivência do enxerto renal.  
Resultados: Ajustando para os fatores tradicionalmente associados à perda a longo 
prazo do enxerto renal, a SCr aos 1, 6 e 12 meses, assim como a diferença entre os 
valores de SCr entre primeiro e o sexto mês e entre o sexto e o primeiro ano associaram-
se de forma significativa e independente à perda de enxerto renal a longo-prazo. As 
curvas R.OC revelaram que o NGAL urinário, o MDA e a CysC séricos no primeiro dia 
pós-TR foram moderadamente (NGAL) e fortemente (MDA e CysC) mais sensíveis no 
diagnóstico de AFE. Tanto o NGAL urinário (aos dias 4 e 7), como o MDA (ao dia-7) se 
associaram de forma independente à função renal observada no primeiro ano pós-TR, 
ajustando para os fatores que tradicionalmente afetam a função do enxerto. Os valores 
de leptina no primeiro dia pós-TR apresentaram uma performance ligeiramente melhor 
que a SCr para predizer o AFE, o que não ocorreu com a adiponectina, SOD, GR, GPx e 
TAS. Um multimarcador composto por SCr, MDA e CysC resultou da combinação de 
marcadores com melhor capacidade preditiva 8 a 12h após o TR (AUC=0.96) para 
identificar os doentes com lesão do enxerto renal e predizer a necessidade de diálise 
durante a primeira semana pós-TR. A aplicação de modelos de regressão de 
subdistribuição para eventos competitivos permitiu demonstrar que o AFE isolado e 
independentemente da rejeição aguda tem um efeito deletério na sobrevivência do 
enxerto renal, mas não na sobrevivência do doente.  
Conclusões: O AFE por si só e independentemente da rejeição aguda associou-se a pior 
sobrevivência do enxerto renal, mas não do doente. O NGAL urinário, o MDA e a CysC 
séricos são marcadores precoces e preditores da necessidade de diálise durante a 
primeira semana pós-TR e da função renal ao primeiro ano. Um marcador composto triplo 
com SCr, CysC e MDA foi altamente preditivo de AFE. A combinação de marcadores 
procedentes de diferentes vias patofisiológicas é uma estratégia racional para optimizar a 
sensibilidade e a especificidade e obter informação diagnóstica e prognóstica adicional.  
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CHAPTER 1     General Introduction	  
 3 
 
BACKGROUND AND MOTIVATION FOR THE WORK IN THIS THESIS 
 
 
Kidney transplantation is considered the treatment of choice for almost all cases of renal 
failure, particularly because the quality of life and patient survival associated with 
transplantation are better than for chronic dialysis.1 Due to the new immunosuppressive 
drugs and consequent decrease in the rejection incidence, the short-term outcome of 
renal transplantation has improved substantially in the past 20 years. However, despite 
progress in short-term allograft survival, long-term survival has not paralleled that 
improvement.2-6  
At present, late failure of kidney transplants is an important clinical problem and one of the 
leading causes of end-stage renal disease.7 The rate of chronic graft loss after the first 
year remains significant and the actual kidney allograft half-life showed only a marginal 
improvement over the past decade.2, 3, 6, 8 The reasons for this slight improvement remain 
unclear. It is possible that some important determinants of long-term graft survival may not 
have changed sufficiently to improve the overall outcomes of kidney transplantation.9 
Patient death with a functioning allograft, mostly from cardiovascular disease, and chronic 
allograft failure are the two major causes of late transplant loss.10-12 The causes of chronic 
allograft failure are multifactorial and are influenced by numerous immunological and non-
immunological factors.2, 9 Generally, kidney transplants stabilize after recovering from the 
stress of implantation until declining of graft function due to specific diseases or 
conditions, such as recurrent renal disease, antibody-mediated rejection or a common 
process involving interstitial fibrosis and tubular atrophy, which is encompassed by the 
previous descriptive term “chronic allograft nephropathy” and, more recently, “fibrosis / 
atrophy”.9, 13-15  
Approximately half of deceased renal allografts are lost within 10 to 12 years after 
transplantation.16, 17 A patient submitted to kidney transplantation would wonder whether 
his or her transplanted kidney will work well and how long it will last. There are no 
answers to these questions. Clinicians lack appropriate non-invasive methods to predict, 
diagnose and reduce the risk of graft failure in the years following renal transplantation.  
When will it be possible to identify valuable markers for distinguishing patients who are at 
an increased risk of graft dysfunction or of losing their transplant? Can biomarkers signal 
early transplant dysfunction, a process that is often undetectable? Can biomarkers help 
clinicians fine-tune their prognoses? 
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Many donor, recipient and immunologic characteristics are consistently associated with 
poor long-term outcomes, namely female gender, black ethnicity, prolonged pre-transplant 
dialysis time, older donor age, deceased donor source, delayed graft function (DGF), and 
acute rejection.11, 18-21 The association of human leukocyte antigen (HLA) matching and 
panel reactive antibodies with the change in graft function suggests that immune 
mechanisms continue to have an effect on allograft function even among the long-term 
transplant recipients.22 Many of these factors coexist and act synergistically, and DGF is 
one of them.  
Delayed graft function is a well-known and the most common complication in the 
immediate post-transplantation period mainly in deceased renal allografts, almost 
invariably in the non-heart beating and in some live donor transplants.23-25  This condition 
is a continuous spectrum of ischemia-reperfusion-related acute kidney injury and 
describes dysfunction of the kidney allograft immediately after transplantation.23, 26 
Although not confirmed by some,27, 28 most studies have found associations between DGF 
and an increased risk for acute rejection and chronic allograft dysfunction,11, 29, 30 worse 
graft survival21, 30-35 and higher mortality.26, 36-38  
A range of factors could lead to DGF such as organ procurement (i.e. kidneys from non- 
heart-beating donors), donor characteristics (i.e. donors older than 55 years, donors with 
diabetes and/or high blood pressure), prolonged ischemia time, recipient factors (such as 
male gender, longer waiting time on dialysis, number of recipient’s previous transplants), 
renal toxicity, and ureteral obstruction, among others.39 With the present disparity between 
supply and demand for organs, transplantation is proceeding with more marginal kidneys 
and therefore the problem of DGF is likely to increase in the future. Thus, DGF poses a 
significant challenge to clinicians in the context of kidney transplantation. 
Ischemia/reperfusion injury after organ transplantation is a major cause of DGF, which is 
associated with prolonged hospital stay, additional invasive procedures, supplementary 
costs and greater risk of early and long-term graft loss.40 The association between DGF 
and worse outcomes has led to increased efforts to better understand the mechanisms of 
ischemia-reperfusion injury and to develop interventions to reduce its occurrence and 
impact. This has included initiatives to discover and use biomarkers to stratify the risk of 
DGF, to diagnose dysfunction early and to target any intervention to those patients who 
will benefit most. This was the primary motivation for this thesis.  
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Thus, the major portion of this work focuses on one critical event after transplantation that 
is detrimental to the long-term graft and patient survival, DGF, as an expression of acute 
graft dysfunction. The following are some of the questions that this work tried to answer: 
a) Are there biomarkers that are significantly different between patients undergoing DGF, 
versus those who are not?  
b) Can a specific combination or panel of biomarkers work together and be potentially 
utilized for the diagnosis of DGF? 
c) What can the identified biomarkers tell us about the underlying pathophysiology of this 
condition?  
d) What is the impact of DGF on the patient and long-term graft survival over decades 
when using a competing risks approach?   
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AIMS OF THIS DISSERTATION THESIS  
 
The analysis of predictive factors of graft dysfunction and long-term kidney allograft failure 
with a main focus on novel biomarkers was the major motivation for this work.  
Thus, the general aim of this thesis was to investigate the potential of different biomarkers 
to reliably diagnose and predict early graft dysfunction and their effect on long-term kidney 
allograft failure as well as to gain insight into the underlying mechanisms of graft 
dysfunction.  
The evaluation of the role of novel biomarkers on long-term graft failure requires a 
prospective approach that is impossible to achieve in a short-time period. On a short-term 
approach, alternative endpoints or short-term markers that can predict graft failure in the 
long-term may represent potentially useful surrogates and can be used in place of 
conventional endpoints. 
Thus, a phased approach was required to evaluate the clinical utility of novel biomarkers 
on long-term outcome, with the following design (Fig. 1) and specific aims: 
 
- Develop a surrogate marker for long-term graft survival and evaluate the impact of 
early graft dysfunction, expressed by DGF, on the long-term graft loss and patient 
survival.         (Retrospective studies) 
 
- Identify novel diagnostic biomarkers for early graft dysfunction by investigating the 
prognostic performance of the candidate biomarkers in the prediction of DGF and one-
year graft function.        (Prospective studies) 
 
  
 
 
 
 
 
 
 
 
               DGF: delayed graft function; SCr: serum creatinine 
 
Fig. 1: Research design of this PhD thesis  
 
Novel   
Biomarkers  
Surrogate  
Endpoint 
Definitive 
Endpoint 
    e.g: SCr, DGF                                  e.g: Graft Failure New potential biomarkers 
Prospective Studies Retrospective Studies 
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THESIS OUTLINE 
 
 
The present thesis is divided into six chapters. 
 
Chapters 1 and 2 contain the scientific background and motivation for the research 
performed in this thesis with respect to the investigation of novel graft dysfunction 
biomarkers.  
Chapter 1 is a general introduction to some of the achievements and problems of 
kidney transplantation and summarizes the main objectives and outline of the thesis.  
Chapter 2 is as an introductory chapter to the field of biomarkers with relevant 
definitions and emphasizes the importance of novel and early markers of graft 
dysfunction in the immediate post-transplantation period, focusing on the biomarkers 
investigated in the current study.  
The materials and methods are described in the original publications (I to VI), but some 
additional and more detailed information about the procedures and methodology are 
presented in Chapter 3. 
Chapter 4 presents an overview of the results and the original research papers included 
in this thesis as well as a review article. All published papers are reproduced with 
permission from the publisher. 
Paper I aimed to develop a surrogate marker for long-term graft survival in our center. 
Thus, factors associated with late kidney graft failure were identified and the predictive 
effect of serum creatinine (SCr) within the first year on long-term graft survival was 
examined.    
In Papers II, III and IV the aims were to evaluate longitudinal changes of potential new 
biomarkers of early graft dysfunction over the first week after kidney transplantation 
and identify factors associated with these changes, to assess the performance of these 
candidate biomarkers in predicting DGF, and to appraise the long-term prognostic 
value of these biomarkers on kidney allograft function, evaluated by one-year SCr. 
These papers addressed the objectives of the prospective component of this work. 
Paper V aimed to combine the studied biomarkers and develop a high sensitive 
approach to diagnose DGF. 
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The aim of Paper VI was to evaluate the controversial impact of DGF on long-term 
graft loss and patient survival using a competing events approach. 
 
Paper VII is an invited review article that presents a general discussion about 
biomarkers in kidney transplantation, integrating some of the findings and biomarkers 
studied in this thesis.   
Chapter 5 provides a general discussion of the main findings of the papers included in 
this thesis and also considers aspects and reflections that were not included in the 
papers. 
Chapter 6 provides a conclusion to the thesis and presents future perspectives. 
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BIOMARKERS 	  
A number of factors concerning donor, recipient and the peritransplant period influence 
the long-term graft outcome and have been widely discussed in the published literature.41-
46 Although the synergic action of immune and non-immune factors cannot be forgotten, 
this literature review chapter will focus on biomarkers dependent of peritransplant kidney 
injury processes.  
 
WHAT IS A BIOMARKER? 
Biomarker is a broad term that can be used to describe any indicator of a biological state. 
The term biomarker, or biological marker, was introduced in 1989 as a Medical Subject 
Heading (Me.SH) term and it was defined as “measurable and quantifiable biological 
parameters (e.g., specific enzyme concentration, specific hormone concentration, specific 
gene phenotype distribution in a population, presence of biological substances), which 
serve as indices for health- and physiology-related assessments.” More recently, in 2001, 
the definition was standardized by the Biomarker Definitions Working Group47, 48 as “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention.”  
These definitions correspond to two concepts: first, the objective measurement of a 
parameter in a biological sample, and second, its application to classifying a patient. 
Although the term “biomarker” is relatively new, biomarkers have been used in preclinical 
research and clinical diagnosis for some considerable time. Body temperature is a long-
standing and well-known biomarker for fever, for example.  
Several types of objective biomarker measurements can be performed on patients. In fact, 
biomarkers appear in every form. They can be anatomic, physiologic, biochemical, or 
molecular parameters that are associated with the presence and severity of specific 
diseases and they are detectable by a variety of methods including physical examination, 
laboratory assays, and imaging. Serum creatinine (SCr) and blood glucose levels are 
biomarkers, as are blood pressure, enzyme levels, tumor size measurements obtained by 
imaging techniques, and the presence of a gene mutation or the expression level of 
mRNA. Unlike what is commonly believed, biomarkers are not only molecules. A 
biomarker is any type of measurable change that may have clinical relevance.49, 50 And 
this list is far from exhaustive and countless measurements have been proposed as 
biomarkers.  
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USEFULNESS AND ADVANTAGES OF BIOMARKERS 
The goal of a biomarker measurement is to make a useful prediction about the 
classification of the patient. In practice, biological markers are used to determine the 
disease status, monitor the efficacy of a treatment or predict the future outcome of a 
patient. In any case, using the biomarker values, one would like to split the patients into 
two classes according to the status of interest. Patients are typically labeled according to 
a known test that was assessed with certainty, called a gold standard. After identifying 
specific and accurate biomarkers, future patients will be classified without the need for the 
gold standard, usually more expensive and risky. Biomarkers are often cheaper and 
easier to measure than “true” endpoints.  
Biomarkers usually provide information that is readily available and simple to interpret by 
clinicians.51 For example, a patient's blood pressure is easier to use than 
echocardiography for measuring left ventricular function, and it is much easier to perform 
echocardiography than to measure morbidity and mortality from hypertension in the long 
term. Biomarkers can also be measured more quickly and earlier. Blood pressure can be 
measured today, whereas it takes several years to collect mortality data.  
The usefulness of biomarkers is highlighted by the wide array of clinical settings, in which 
they are utilized, including disease diagnosis and prognosis. According to the Food and 
Drug Administration and regardless of the purpose for its use, biomarkers should be 
accurate, reproducible and standardized across different clinical settings. Ideally, a 
biomarker should be specific, sensitive, predictive, robust, simple, accurate, and 
inexpensive. In other words, it should be perfect and improve our understanding of a 
disease while providing new knowledge of pathological mechanisms, allowing for earlier 
diagnosis and the delivery of more efficacious and safer therapies possible.52, 53  
 
CLASSIFICATION OF BIOMARKERS 
Presently, it is not well established how biomarkers are categorized because they can be 
classified based on different parameters. Within the field of health care, biological markers 
are commonly classified based on the sequence of events from exposure to disease, 
including biomarkers of exposure, which are used in risk prediction, and biomarkers of 
disease, which are used in screening, diagnosis and prognosis.51 Clinically, biomarkers 
may be distinguished according to their uses; an early intervention biomarker is used for 
the early detection of disease to facilitate intervention, whereas a prognostic biomarker 
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correlated with outcomes and is used to identify patients who may benefit from an 
intervention.54  
The Biomarker Working Group further classified biomarkers based on their utility and this 
categorization is also commonly used in biomedical research:47, 48, 55 
- Type 0 biomarker: A marker of the natural history of a disease that correlates 
longitudinally with known clinical indices such as symptoms over the full range of 
disease states;  
- Type I biomarker: A marker that usually determines the biological effect of a 
therapeutic intervention according to the mechanism of action of that intervention 
(pharmacological, nutritional or any other), even though the mechanism might not be 
known to be associated with the clinical outcome.  
- Clinical endpoint: An outcome that represents the target measures of a study. A 
characteristic or variable that reflects how a patient fares or functions, or how long a 
patient survives. In renal transplantation, for example, the standard clinical endpoints 
are graft failure and death for late outcomes. 
- Surrogate endpoint biomarker (Type II biomarker): A marker that is intended to 
substitute a clinical endpoint. A surrogate endpoint is expected to predict the clinical 
benefit, harm, lack of benefit, or lack of harm on the basis of epidemiologic, 
therapeutic, pathophysiologic, or other scientific evidence. It is important to note that all 
surrogates are predictors, but not all predictors are surrogates.  
 
 
Biomarkers versus Surrogates 
It is important to distinguish, at the outset, the use of the term biomarker from that of 
surrogate endpoint or surrogate marker. The use of the term ‘surrogate marker’ in 
medicine dates from 1988,56 but it was preceded for some years by the term ‘biomarker’57 
and was succeeded and replaced by yet another term, ‘surrogate endpoint’.58 Surrogate 
endpoints may be a subset of biomarkers. Although all surrogate endpoints may be 
considered biomarkers, it is clear that only a few biomarkers will meet the requirements 
for achieving inclusion in this subset.  
A surrogate endpoint is one that is measured in place of the biologically definitive or 
clinically meaningful endpoint, and it usually tracks the progress or extent of the disease. 
Investigators choose a surrogate endpoint when the definitive endpoint is difficult to obtain 
or inaccessible due to cost, time, or the complexity of measurement. As explained by 
Lachenbruch54 “a ‘surrogate’ variable is one that is used in lieu of the true endpoint, to 
evaluate the outcome more rapidly, less expensively, and/or less invasively.” Some 
examples include CD4 counts in AIDS patients, tumor size reduction in cancer patients, 
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blood pressure in cardiovascular disease, intraocular pressure in glaucoma patients, and 
SCr in chronic kidney disease. 
Since approximately 1989, biostatisticians have investigated approaches to evaluating 
whether a biological parameter that might serve as a substitute or “surrogate” for a clinical 
endpoint in the study of a particular therapy for a particular disease.48 A “perfect” 
surrogate endpoint, as described by Prentice,59 can be measured simply and without 
invasive procedures, is related to the causal pathway for the definitive endpoint, yields the 
same statistical inference as the definitive endpoint, and  should be responsive to the 
effects of treatments. The disease affects the surrogate endpoint, which in turn affects the 
definitive endpoints. This is more than a correlation between the surrogate and the true 
clinical point. For example, to accept a classification scheme for a biopsy score as a 
surrogate endpoint for graft survival requires that the biopsy score not only correlates with 
outcome but that changes in the outcome due to treatment or any other intervention are 
reflected in the biopsies.54 Accepting a biomarker as a surrogate for a clinically definitive 
endpoint requires validation. To validate an endpoint as a legitimate surrogate endpoint, a 
meta-analysis is usually required because relationships presented in one study may not 
be generalizable to another.  Then, for use in clinical practice, each center should test 
whether that surrogate works well in the local scenario because populations have different 
characteristics and therapeutic interventions and treatments are different across countries 
and centers.  
 
SURROGATES AND BIOMARKERS IN KIDNEY TRANSPLANTATION  
One of the concerns in transplant research is to obtain insight into the factors that are 
associated with long-term allograft survival and to identify early markers of chronic 
allograft dysfunction, as well as potential interventional pathways. Long-term graft survival 
is an ideal endpoint, but evaluating an outcome in the long term is usually difficult and 
time-consuming. For this reason, an easier approach is to identify alternative endpoints or 
short-term markers that can predict the long-term survival and therefore act as potentially 
useful surrogates. This approach is widely used in clinical research on cancer and 
cardiovascular disease and has recently been applied in the context of renal disease.60  
Biomarkers used for screening or diagnosis also often represent surrogate manifestations 
of the disease or dysfunction. This is the case for oxidative stress markers in the process 
of renal ischemia-reperfusion injury following kidney transplantation. Both biomarkers and 
surrogates significantly contribute to early diagnosis, longitudinal prognoses, and outcome 
prediction. They often enable the detection of renal graft dysfunction when kidney injury is 
subclinical, allowing for faster evaluation of drug therapies, transplant techniques, and 
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patient care protocols. As a result, there has been a concerted effort within the transplant 
community to attain a diagnostic marker that may serve as a surrogate for eventual graft 
loss.  
 
Standard biomarkers for kidney damage  
Traditional non-invasive markers of kidney injury are insensitive and nonspecific in the 
detection of early stages of kidney injury. Standard biomarkers for kidney damage include 
the glomerular filtration rate (GFR), SCr and urea as well as several urine qualities such 
as proteinuria and hematuria. For decades, the increase in SCr has been the only 
detectable sign of a reduction in the GFR. At present, a decline in the SCr is still the 
traditional marker for detecting graft functional recovery after transplantation. However, 
this biomarker is an unreliable indicator of kidney function during an episode of acute 
injury.61 Serum creatinine changes are not specific for parenchymal damage and occur 
long after the event. It is estimated that more than 50% of kidney function is lost before 
the SCr rises, which makes SCr less sensitive to early kidney damage and the severity of 
dysfunction.61-63 As such, renewed efforts to improve long-term survival through enhanced 
monitoring and diagnosis of short and long-term graft dysfunction have directed attention 
to the search of better biomarkers. 
 
Why do we need new biomarkers for kidney transplantation? 
In organ transplantation, initial graft dysfunction is one of the most important early 
postoperative problems, which is mainly due to the unavoidable ischemia-reperfusion 
injury that occurs in the transplanted organ. In kidney transplantation, ischemic injury of 
the renal allograft is a critical early insult that augments the risk of acute tubular necrosis 
and long-term graft loss.64, 65 The development of effective interventions is constricted by 
the limited ability to detect graft dysfunction early. The delay period between initiation of 
injury and clinical and biochemical detection of renal damage calls for the use of more 
reliable and earlier markers of kidney graft damage. As previously stated, current clinical 
indicators of kidney injury, such as SCr, are inadequate for timely diagnosis and 
prognosis. Thus, the application of biomarkers in the field of kidney transplantation will 
allow for the detection of incipient graft dysfunction, refine diagnoses and enable more 
effective post-transplant management, potentially improving the short-term (e.g., delayed 
graft function, acute rejection) and long-term (e.g., allograft failure) outcomes.  
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LOOKING FOR NEW BIOMARKERS OF KIDNEY GRAFT DYSFUNCTION 
The search for new biomarkers is expanding at an unprecedented rate. Recent efforts to 
identify biomarkers in kidney transplantation with early diagnostic and prognostic potential 
have yielded several candidates, including neutrophil gelatinase-associated lipocalin 
(N.GAL), kidney injury molecule 1 (KIM-1), cystatin C, interleukin-18, clusterin, 
kariopherins, glutathione S-transferase iso-enzymes, liver-type fatty acid binding protein, 
alpha-1-microglobulin, C-terminal agrin fragment and haptoglobin.66-77 Nevertheless, due 
to the lack of evidence to support their use in routine, neither of these is currently used in 
clinical practice. And the search for an ideal marker continues.   
In this dissertation, nine candidate biomarkers were studied and they are briefly reviewed 
in the following paragraphs. 
 
CYSTATIN C 
Cystatin C (CysC) is a monomeric, non-glycosylated polypeptide chain of 120 aminoacids 
with a low molecular mass of 13.3 kDa. This cystatin is produced at a constant rate by 
nearly all-human nucleated cells and it can be found in virtually all tissues and bodily 
fluids, preferentially in the cerebrospinal fluid, seminal plasma, and milk.78, 79 Its 
concentration is the highest of all known low molecular weight cystatins in most of the 
extracellular fluids in humans at approximately 1–10 mg/L.78 Cystatin C is an endogenous 
cysteine proteinase inhibitor belonging to the type 2 cystatin superfamily. Cysteine 
proteases are enzymes that are responsible for many crucial physiological processes, 
such as intracellular protein degradation, apoptosis, major histocompatibility complex 
class II immune responses, prohormone processing and bone remodeling.80 By inhibiting 
the function of several cysteine proteases, CysC participates in the regulation of the 
balance of catabolism and modulates many of these normal body processes.81 Other 
functions for CysC include a role in the atherosclerotic process,82 antigen presentation,83 
defense against bacteria and viruses84 and as a growth factor for neural stem cells.85   
The main catabolic site of CysC is the kidney; more than 99% of the protein is cleared 
from the bloodstream by glomerular ultrafiltration and tubular reabsorption. Because it is 
not secreted by the tubules, its concentration in urine in normal states is remarkably lower 
and approximately 0.1 mg/L (Lofberg and Grubb, 1979; Poulik et al., 1983). As CysC is 
per se produced at a constant level, its concentration in the circulation remains nearly 
stable when kidney function is normal.79, 86 Consequently, the rate at which CysC C is 
filtered at the glomerulus is the primary determinant of the blood CysC level. Due to these 
properties, CysC was first suggested as a marker of the glomerular filtration rate (GFR) in 
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1985.87 Since then, CysC has been extensively investigated in multiple clinical studies on 
adults, children, and in the elderly. In almost all clinical studies, CysC demonstrated a 
better diagnostic accuracy than SCr in discriminating normal from impaired kidney 
function.88, 89 
In fact, CysC fulfills many criteria that are set for an ideal endogenous biomarker of kidney 
function. As a low molecular weight protein, it is almost freely filtered through the 
glomerular membrane and then completely reabsorbed and catabolized by the proximal 
tubular cells.86, 90, 91 In studies performed with mice, the plasma clearance of CysC is 94% 
that of 51Cr-EDTA and no secretion or reabsorption in the circulation occurs.86 Its plasma 
or serum concentration is less dependent on the muscular mass, inflammatory diseases, 
gender or diet, and these properties make it a good measure of the GFR compared to the 
traditional measurement of the SCr.92, 93 As a result of this finding, several prediction 
equations have been derived from both pediatric and adult patients to estimate the GFR 
from the serum CysC concentration.94, 95 Most of the studies that compared the CysC 
levels or CysC-derived equations with gold standard methods found CysC to be superior 
or at least equivalent to SCr.93 Some studies on selected patient groups with either 
reduced or rapidly changing muscle mass also demonstrated that CysC is a sensitive 
marker of the GFR independent of body composition.92   
Renal transplant recipients are a target group for whom the precise determination of GFR 
is crucial. Allograft function following renal transplantation is commonly monitored using 
SCr. However, plasma creatinine is far from being an ideal marker of the GFR, despite its 
convenience and low cost. Since the first publication in 1998,96 quite a few original clinical 
papers have addressed the question of the use of CysC in kidney transplantation. A good 
number of studies identified serum CysC (or CysC-based equations) as a promising, 
easily measurable marker to estimate the GFR with a higher diagnostic value than SCr (or 
creatinine-based equations) and 24-hour creatinine clearance for evaluating the GFR in 
the follow up of adult kidney transplant patients.97-99 Very recently, Masson et al99 
validated both CysC-based CKD-EPI equations (2012) in 670 kidney transplant recipients 
and concluded that both performed better than the serum creatinine-based CKD-EPI 
equation (2009).  
A drawback of the use of CysC in kidney transplantation is the routine use corticosteroids. 
Glucocorticoid medication can compromise the use of serum CysC in this population and 
it is important to take this into account when interpreting this serum marker. Glucocorticoid 
therapy is one of the few identified circumstances that have an impact on the production 
of CysC in a dose-dependent manner, leading to systematic underestimation of the 
GFR.100 Very large doses of glucocorticoids have been described to increase the 
production of CysC,100, 101 whereas continuous low and medium doses of glucocorticoids 
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do not seem to alter the production of CysC.102, 103 However, underestimations of GFR 
occur in some studies, e.g., with steroid dependent asthmatic patients.104 Hence, 
moderate and high-dose glucocorticoids can limit the usefulness of CysC soon after 
kidney transplantation.105  
For kidney transplant patients, early detection of decreased renal function is crucial so 
that measures to prevent further decreases in graft function can be taken. For this reason, 
the role of this marker in detecting post-transplant renal damage earlier than SCr has 
been investigated.106-110 During the early post-transplantation period, the serum CysC 
decreases more rapidly than creatinine.107, 111 As previously stated, glucocorticoids 
increase CysC concentrations and may lead to underestimation of the GFR; however, in 
stable renal graft recipients with low-dose immunosuppressive therapy, CysC is strongly 
correlated with the GFR and detects a GFR impairment earlier than SCr or creatinine-
based eGFR.100, 106, 107, 111-115  
In a prospective study of 30 consecutive patients with end-stage renal disease undergoing 
renal transplantation, Le Bricon and coworkers107 evaluated CysC as a marker of allograft 
function during the early postoperative transplantation period. Serum CysC was more 
sensitive than SCr for detecting decreases in the GFR and predicting DGF. Furthermore, 
a more prominent rise in the plasma CysC values allowed for a more rapid diagnosis of 
acute rejection or treatment nephrotoxicity with the potential for more timely intervention. 
A prospective study performed by Thervet et al 106 in another 30 renal transplant patients 
also found that CysC allowed for earlier diagnosis of renal function recovery than SCr, 
particularly in patients with DGF. These findings were also confirmed by Hall and 
coworkers108 in a cohort of 78 deceased-donor renal recipients, which showed that CysC 
outperformed SCr as a predictor of poor early graft function and the need for dialysis 
within the first week of kidney transplantation. Additionally, these authors demonstrated 
that CysC was a good prognostic marker of graft function at 3 months. In a recent article, 
Liu et al 110 evaluated the clinical value of CysC for the diagnosis of an acute rejection 
episode after renal transplantation in 76 recipients and concluded that CysC can predict 
an acute rejection episode after renal transplantation. In a recent multicenter study,99 
CKD-EPI formulae were compared for their accuracy in estimating the GFR, as 
determined by the gold standard, inulin clearance, in adult kidney transplant recipients 
(n=670) with stable graft function. This study used centralized, standardized assays for 
CysC and creatinine. Despite immunosuppressive treatment, formulae based on CysC 
and the combination of CysC and creatinine were less biased, more accurate and precise 
than the CKD-EPI-creatinine formula.  
Because renal tubular impairment diminishes or precludes the ability to catabolize CysC, 
measuring CysC in urine can be a good estimator of renal tubular dysfunction. This was 
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observed in a prospective multicenter study of 91 deceased-donor kidneys transplants.109 
Serial urine samples were collected for 2 days following transplant and on the first 
postoperative day urine CysC was a predictor of DGF and of 3-month allograft function. In 
summary, CysC either in serum or urine displays several good characteristics that make it 
a practical and reliable biomarker for the early detection of DGF. Among the markers 
addressed in this review, serum CysC is likely the most commonly used biomarker as well 
as the closest to the clinical validation in kidney transplantation.  
 
NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN 
Neutrophil gelatinase-associated lipocalin is one the most promising and extensively 
studied biomarkers of acute kidney injury in a variety of acute clinical settings.116-129 
Neutrophil gelatinase-associated lipocalin, also known as human neutrophil lipocalin or 
lipocalin-2, is a glycoprotein that belongs to the lipocalin family. Originally, NGAL was 
identified in neutrophils covalently bound to gelatinase, but this lipocalin is also expressed 
at low levels in other human tissues including the kidney, lung, liver and epithelial cells in 
response to various pathologic states.130 Human NGAL exists as a 25-kDa monomer, with 
a 45-kDa homodimer and is conjugated to gelatinase as a 135-kDa heterodimeric form, 
which is normally the main cellular source of circulating NGAL.130  
As stated by one of the main researchers of these molecules, “Lipocalins are small 
proteins that cells send out to bind things and carry them back”.131, 132 Effectively, this 
family comprises several proteins, such as α1-microglobulin, retinol-binding protein 4, 
prostaglandin D synthase, and nitrophorines, which are specialized in binding and 
transporting small hydrophobic molecules, such as vitamin A, free heme and heme groups 
that are complexed with nitric oxide.133-136  
The main features of NGAL were described by Goetz et al 131, 137, who discovered that the 
most important ligands of NGAL were siderophores, which are small iron-binding 
molecules. Bacteria produce siderophores to scavenge iron from the extracellular space 
and use specific transporters to recover the siderophore iron complex, ensuring their iron 
supply. These findings were consistent with the most important function attributed to this 
lipocalin, which is the inhibition of bacterial growth by the inhibition of iron-binding 
molecules that are important to specific bacteria.131, 137 Thus, NGAL behaves as a 
bacteriostatic agent in acute infections and, under physiological conditions, bacterial 
infections represent the most common condition associated with marked increases in the 
NGAL levels.138 But, beyond its microbial effect NGAL seems to have more complex 
activities.128, 139 Some systemic diseases that are not necessarily associated with infection 
were also associated with increased levels of serum NGAL, confirming that many other 
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tissues may express and release NGAL as an acute-phase factor signaling a condition of 
sustained injury, which is the case for inflammatory processes involving skin, intestine and 
certain types of cancer, like adenomas and inflamed epithelia of the bowel, 
adenocarcinomas of the breast, and urothelial carcinomas.140-149 Renal tubular injury is 
another pathologic state that induces the expression of NGAL and that increases its levels 
by approximately 1000-fold, which is rapidly apparent in both the urine and serum.128, 139, 
150 The relatively rapid time course of NGAL changes with respect to renal injury in 
comparison to SCr levels is one of the main advantages of NGAL, which makes this a 
superior or complementary biomarker in the diagnosis and prediction of acute kidney 
injury.117, 151-158   
The genesis and sources of serum and urinary NGAL in response to renal injury is a 
subject under study. It was demonstrated that NGAL exists in two separate body pools: 
the systemic and the renal pools. In the steady state, NGAL is normally expressed at very 
low concentrations in multiple cell types. Accordingly, in healthy individuals, NGAL is 
detectable in the systemic circulation only at low levels. In the kidney, circulating NGAL is 
filtered in the glomerulus and luminal NGAL is completely reabsorbed in the proximal 
tubule by a megalin-dependent pathway. Hence, only traces of NGAL are detectable in 
urine. During injury or inflammatory processes, NGAL is massively released from 
activated neutrophils and the urinary levels correlate with serum levels independent of the 
cause of increased NGAL production. However, when massive NGAL quantities are 
excreted in the urine this usually indicates injury and damage to the proximal tubular cells 
due to ischemia-reperfusion injury, hypoxia, nephrotoxins or chronic progressive 
changes.128, 150, 159 These kidney insults cause failure of absorption of the filtered NGAL 
leading to particularly high NGAL levels in urine, which is potentiated by the increased 
expression and secretion of NGAL from the nephron epithelia and from distant organs 
mainly the liver and the lungs.126, 128, 150, 160-163  
Ischemia-reperfusion injury is an inevitable consequence of the kidney transplantation 
procedure and can be considered as a form of post-transplantation acute kidney injury. 
For this reason, several studies have investigated the utility of NGAL for the diagnosis and 
prognosis of acute graft dysfunction following kidney transplantation, with promising 
results.69, 71, 72, 164-169 The values of NGAL collected shortly after renal transplantation were 
shown to predict the dialysis requirement within the first week, preceding the 
postoperative peak in SCr levels that typically does not occur before two to four days.69, 71, 
72, 164, 167, 170 Recently, the prognostic value of NGAL on graft function at one-year post-
transplantation was also examined.72, 171, 172 Different investigators reported consistent 
findings that NGAL may become one of the most important next-generation biomarkers in 
the diagnostic and clinical fields of acute graft dysfunction in renal transplantation (Table 1). 
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Table 1. NGAL in kidney transplantation: results from the main studies 
Reference Year Material/ Methods  Study  Reports 
Mishra 169  2006 Recipients: 25 pediatric Single center Patients developing DGF 
  Donor: deceased and living Prospective showed the most intense 
  Sample material: biopsies obtained Single marker NGAL staining during the 
  from kidneys grafts within 1 h after  previous biopsy 
  reperfusion   
Parikh164 2006 Recipients: 53 adults and pediatric Single center  NGAL values in DGF 
  Donor: deceased and living Prospective Urinary NGAL and IL-18 
are predictive biomarkers 
of DGF (AUC=0.90 for 
NGAL) 
  Sample material: urine Multimarker  
  Number of sample collections: 1 (NGAL and IL18) 
  
Timing: within first 24 h post-kidney 
transplantation    
  Definition of DGF: yes   
Hall 71 2010 Recipients: 91 adults Single center  NGAL values in DGF 
  Donor: deceased  Prospective Urinary NGAL and IL-18 
are predictive biomarkers 
of DGF   Sample material: urine Multimarker  
  Number of sample collections: 6 (NGAL,IL18,KIM1)  
  Timing: every 6h (first 2 days) No long-term follow-up (up to 3 months only) 
  Definition of DGF: yes   
Bataille 69 2011 Recipients: 41 adult Single center  NGAL values in DGF 
  Donor: living and deceased  Prospective Plasma NGAL level early 
and accurately predicted 
DGF after KTx   Sample material: plasma Single marker 
  Number of sample collections: 6   
  Timing: pre, post-KTx (first week) No long-term follow-up 
  Definition of DGF: yes   
Hollmen 173  2011 Recipients: 176 adults Single center Day 1 urinary NGAL  
  Donor: deceased  Prospective predicted DGF but not 
  Sample material: urine Single marker long-term function 
  Number of sample collections: 6 Long-term follow-up (1-year) 
  Timing: pre and post-KT (days 1, 3, 7 and 14)   
  Definition of DGF: yes   
Kusaka 167  2012 Recipients: 67 adults Single center Serum NGAL on first day  
  Donor: living and deceased  Retrospective is highly sensitive and  
  Sample material: serum Single marker specific marker predicting 
  Number of sample collections: 5   future graft function 
  Timing: pre-KTx and subsequent 4 days after KTx   
  Definition of DGF: yes   
Hall 171 2012 Recipients: 153 adults Multicenter Perioperative urine NGAL  
Extension   Donor: deceased  Prospective and IL-18 are associated 
  Sample material: urine Multimarker  with poor 1-year graft  
  Number of sample collections: 6 (NGAL, IL-18) function 
  Timing: every 6 h (first 2 days) Long-term follow-up (1-year) 
  Definition of DGF: yes   
Lee 170 2012 Recipients: 59 adults Single center NGAL is an early and 
  Donor: Deceased and living Retrospective sensitive marker of graft 
  Definition of DGF: yes Multimarker dysfunction while IL18  
   (NGAL, IL-18) showed limited values 
KTx: Kidney transplantation; DGF: delayed graft dunction; NGAL: Neutrophil gelatinase-associated lipocalin; 
IL-18: interleukin-18; AUC: Area under the curve. 
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OXIDATIVE STRESS 
Oxidative stress is one of the most important components of the ischemia-reperfusion 
process.174-176 It reflects an imbalance between reactive oxygen species (ROS) and 
cellular mechanisms for detoxifying the reactive intermediates or for repairing the resulting 
damage. Disturbances in the normal state can cause toxic effects through the production 
of peroxides and free radicals that damage all components of the cell.  
In kidney transplantation, oxygen free radicals are the most likely agents responsible for 
initiating the damage associated with reperfusion injury.177 Oxygen free radicals or, more 
generally, ROS are products of normal cellular metabolism. The average person has 
approximately 10,000–20,000 free radicals attacking each body cell every day. Free 
radicals are defined as molecules or molecular fragments containing one or more 
unpaired electron in atomic or molecular orbits, which gives a considerable reactivity to 
the free radical. The well-known radicals derived from oxygen, such as superoxide (O2−·), 
hydrogen peroxide (H2O2) and the hydroxyl radical (OH·) represent the most important 
class of radical species generated in living systems.178  
In physiological conditions, ROS are produced specifically to serve essential biological 
functions, such as defense against infections. In these conditions, the rates of free radical 
production and elimination are equal, leading to a steady state that is presumably 
tolerated by the cell. The antioxidant defense mechanisms can be divided into two major 
groups: i) endogenous, which are mainly enzymes, such as superoxide dismutases 
(S.OD), catalases, glutathione reductases (GR) and peroxidases (GPx); ii) and small 
molecules, which are mostly exogenous and act as free radical scavengers (vitamins A, 
C, and E, carotenoids and polyphenol).178 In some pathological conditions, an imbalance 
between ROS generation and the antioxidant capacity leads to enhanced ROS activity 
and oxidative stress. When these antioxidant mechanisms cannot counterbalance the 
levels of free radicals generated, cell damage and tissue injury can take place.179 
Reactive oxygen species may cause tissue injury via several mechanisms. Because they 
are potent oxidizing and reducing agents, ROS directly damage cellular membranes and 
modify several biological molecules, such as lipids, proteins, and nucleic acids. The 
byproducts of these reactions can serve as biomarkers of oxidative stress.174, 175 Of the 
many biological targets of oxidative stress, lipids are the most involved class of 
biomolecules. Lipid oxidation generates a huge variety of secondary products, including 
reactive carbonyl compounds like malondialdehyde (M.DA). This aldehyde is the principal 
and most studied product of polyunsaturated fatty acid peroxidation, and, for this reason, 
MDA is a marker that is widely used to assess lipid peroxidation.178, 179 Markers of 
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oxidative stress, including elevated levels of MDA and reduced antioxidant activity, have 
been reported in renal patients.180, 181 There is substantial literature on oxidative stress 
and renal disease but data about kidney transplantation in the early stages are scarce. 
The restoration of kidney function after transplantation can lead to improvement of the 
oxidative stress, but some studies report increased systemic biomarkers of oxidative 
stress in kidney transplant recipients,182, 183 specifically in the early phase of 
transplantation184, 185 and, thereafter, coexisting with chronic allograft tubular 
atrophy/interstitial fibrosis.182, 186   
It has long been suspected that oxidative stress contributes to the injury of ischemic and 
reperfused tissues.187 During the ischemic phase of ischemia-reperfusion injury, there is a 
depletion of ATP followed by a rapid increase in ROS, including superoxide, during 
reperfusion.188-190 In the setting of kidney transplantation, not only are there ischemic and 
reperfusion periods required for the preservation and implantation procedures but the 
placement of the kidney into an immune milieu can also act as an adjuvant for oxidative 
damage. Specifically in kidney transplants from deceased donors, brain death is 
associated with generalized ischemia due to a hyperactivity of the sympathetic system, 
which aims to maintain the cerebral perfusion pressure. During this ischemic phase, there 
is a depletion of the oxygen supply to renal cells and the endothelial and tubular epithelial 
cells are particularly vulnerable to oxygen depletion.191-194 Warm ischemia after kidney 
vessels clamping and the cold ischemia after refrigeration also reduce the oxygen and 
nutrients supply to tissues. Reperfusion of the ischemic kidney further worsens the state 
of oxidation with additional release of free radicals. Hence, ROS are generated during 
both phases of ischemia-reperfusion.187, 195   
As in other clinical conditions, if the scavenging capacity of the kidney is lower than the 
excessive ROS generated during ischemia-reperfusion injury, such oxidative imbalance 
may trigger a robust inflammatory response within the transplanted organ, leading to 
cellular destruction, tissue damage and graft dysfunction.185, 196 Thus, severe reperfusion 
injury is a risk factor for DGF and the detection of ROS could be an early warning of graft 
injury. Waller and coworkers studied blood samples in porcine kidney allografts before 
and after reperfusion injury and demonstrated that both plasma carbonyl and 8-
isoprostane (products of protein and lipid damage by free radicals, respectively) could be 
reliable biomarkers for predicting reperfusion injury.197 To the best of our knowledge, no 
similar studies were conducted on this topic in human kidney transplantation.  
A wide range of antioxidant enzymes may potentially exert a protective influence by 
limiting the production of ROS and the damage of oxidative stress following ischemia-
reperfusion injury of a kidney graft. The kidney has naturally occurring antioxidant 
enzymes to counteract the effects of oxygen free radicals. Superoxide dismutase 
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catalyzes the conversion of superoxide to the harmless hydrogen peroxide. Glutathione 
works in a similar manner, but it can also act on organic peroxides.198, 199 Oxygen free 
radical damage occurs despite the presence of scavengers indicating that the protective 
ability of these scavengers is overwhelmed.200, 201 There is some evidence that during the 
early phase of ATP depletion that typically occurs in ischemia, manganese superoxide 
dismutase (MnSOD), a major mitochondrial antioxidant that eliminates superoxide, is 
inactivated.202 Some studies performed on heart transplantation (animal model), have 
revealed a decrease in the antioxidant protein levels and a sequential loss in enzyme 
activity for MnSOD, catalase and GPx in acutely rejecting cardiac allografts.203, 204 To the 
best of our knowledge, there are no similar studies in humans. 
Conflicting results are reported in the literature on the activities of antioxidant enzymes in 
kidney transplant patients. Glutathione compounds and SOD have been reported to 
increase205, 206 decrease183 or not change207 following renal transplantation. Whitin et al 205 
reported a rapid increase in the plasma GPx activity after transplantation. The plasma 
GPx activity was two times higher 3 days after transplantation in adult patients who 
received a kidney transplant from a related donor and rapidly increased over the first 2 
weeks post-transplant in adult recipients from a deceased-donor and pediatric patients 
undergoing kidney transplantation from related donors. Zachara et al 206 have shown that 
plasma GPx activity increases rapidly 3 days after renal transplantation and doubles two 
weeks later. Both of these studies suggested that monitoring plasma GPx might be a 
useful marker for monitoring the transplanted kidney function and a valuable tool for the 
postoperative detection of DGF.  
Not only in the early post-transplant period but also in the longer-term, oxidants and 
antioxidants can be biomarkers of graft dysfunction with diagnostic accuracy. Oxidative 
stress is believed to be a common pathway that leads to both immunological and 
nonimmunological stress in the setting of kidney transplantation and to the development 
or progression of chronic allograft nephropathy. Increased plasma and intragraft levels of 
MDA and reduced antioxidant activity were found in kidney allografts with chronic tubular 
atrophy/interstitial fibrosis, which suggests the possibility of early detection even when 
graft dysfunction is undetectable with serum creatinine 182, 186, 208. Our understanding of 
oxidative stress has significantly advanced in the last decade, but these experimentally 
derived ideas have yet to be fully integrated into clinical practice.  
 
LEPTIN AND ADIPONECTIN 
White adipose tissue is now recognized as a multifunctional organ.209 In addition to its 
central role in lipid storage, white adipose tissue has a major endocrine function by 
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synthesizing a multitude of protein cytokines termed adipokines. Leptin and adiponectin 
are two adipokines that elicit generally opposing effects. Epidemiologic studies have 
highlighted the associations between hyperleptinemia and several metabolic and 
inflammatory factors involved in the development of cardiovascular disease, whereas 
adiponectin may possess antiatherogenic properties in individuals with normal kidney 
function, exhibiting a reverse association with cardiovascular risk.209-212 In chronic kidney 
disease the clinical significance and prognostic implications of leptin and adiponectin are 
not well understood. Uremic patients have increased circulating levels of both adipokines, 
which may result from an increase in their production and/or decrease in their renal 
clearance.213-222 
Leptin is one of the best-known adipokines. It is a small 16-kDa peptide that is mainly but 
not exclusively produced in the adipose tissue. It is a cytokine that is known to participate 
in multiple cellular and physiological processes and is currently believed to be involved in 
the regulation of appetite and energy expenditure.223 Under physiological conditions, 
leptinemia directly reflects the amount of body fat,224 and although not thoroughly 
demonstrated, renal clearance is considered to be the major route for leptin 
metabolism.214, 219 Some studies performed in animal and human models strengthen this 
hypothesis.214, 225-227 Cumin and coworkers226 have realized that bilateral nephrectomy in 
rats decreased the plasma leptin clearance by approximately 81%. Immediately after 
removing both kidneys, leptinemia increased approximately 4-fold after one hour and 
almost 10 times after four hours. In comparison, SCr also increased after the removal of 
both kidneys and doubled after 2 hours. These findings were validated in humans in a 
study by Zeng et al227 that also demonstrated that leptin is promptly and efficiently cleared 
from plasma by renal extraction.  
Adiponectin is a 28-kDa protein that is produced almost exclusively by adipocytes. In 
contrast to other adipokines, adiponectin is a paradoxical adipokine because circulating 
levels of it are decreased in subjects with obesity, diabetes mellitus and atherosclerosis. 
An inverse correlation between adiponectin and kidney function has been reported and, 
as in the case of leptin, the plasma levels of adiponectin are elevated in kidney failure,213, 
218, 228, 229 suggesting that the kidneys play a role in the biodegradation and/or elimination 
of this adipokine.216  
The role of the kidney in the biodegradation of leptin and adiponectin appears to be 
confirmed in studies conducted in kidney transplantation, where the circulating levels of 
these adipokines decreased after successful transplantation.230-235 Kokot et al 231 found 
normalization of leptinemia in the early post-transplant period. Landt et al 235 reported that 
the plasma leptin levels decreased to less than half the pre-transplant values 6 days after 
successful renal transplantation, reaching the levels obtained from the normal healthy 
CHAPTER 2     Literature Review 	  
	  
	  26 
adults. Another study from Howard et al 236 also found lower values of leptinemia in kidney 
transplantation recipients than in dialysis patients, although the values remained higher 
than in controls. Based on this growing evidence that leptin and adiponectin are primarily 
removed from circulation by the kidney, we hypothesized, to our knowledge for the first 
time, that higher levels of leptin and/or adiponectin could indicate poorer clearance and 
could be an early biomarkers of graft dysfunction, expressed as DGF.  
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MATERIAL AND METHODS  
 
Materials and methods are described in the original publications (I to VI), but due to the 
word limit of the manuscripts some additional and more detailed information about the 
procedures and methodology are presented here. 
 
3.1. STUDY DESIGNS  
This study involved three cohorts of kidney transplantation patients comprising two 
retrospective cohorts and one prospective cohort.  
Studies I and VI  
Retrospective cohort studies 
Studies II, III, IV, and V 
Prospective cohort studies within the first 7-days after kidney transplantation and one-year 
follow-up data on adverse outcomes. 
 
3.1.1. RETROSPECTIVE COHORT STUDIES (STUDIES I AND VI) 
 
Study samples  
Two retrospective cohorts of kidney transplant patients were studied; all adult recipients 
with more than one-year of follow-up after kidney transplantation, who were identified 
retrospectively from an electronic database from August 4, 1983 to December 31, 2008 
(first retrospective cohort used for study I, n=1273) and from August 4, 1983 to December 
31, 2012 (second retrospective cohort used for study VI, n=1281) were eligible for study 
inclusion.  
Exclusion criteria 
Recipients younger than 18 years old or who required multiorgan transplantation were 
excluded. Study VI (the second retrospective cohort) excluded also retransplants and 
recipients from living donors.  
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Data collection    
Since July 1983, the Department of Nephrology and Kidney Transplantation of Centro 
Hospitalar do Porto routinely registers the demographic and clinical data from each 
transplant in this center or received from other centers, providing a large cohort of renal 
transplant recipients available for follow-up studies. This database includes the following 
data: donor variables (gender and age at the time of death or kidney donation); recipient 
variables (age and gender, primary cause of renal disease, modality and duration of pre-
transplant dialysis, previous transplant history (first or prior), and panel-reactive 
antibodies); transplantation-related factors (living or deceased donor, number of HLA A, B, 
and DR mismatches between the donor and recipient, and the cold ischemia time); and 
some post-transplantation features (induction and maintenance immunosuppressive 
regimen, history of DGF, occurrence of acute rejection, status of kidney allograft, cause of 
graft loss, vital status, and cause of death).  
This database did not include information related to the post-transplant period, namely 
graft function within the first year. Therefore, to develop SCr as a surrogate marker for 
long-term graft survival study (study I), SCr levels at 1, 6 and 12 months were collected 
purposely by the author, from the paper or electronic medical records of each patient and 
registered in the electronic database. Additionally, for the purpose of this research, during 
2009 (study I) and 2014 (study VI) the recipients registered in the database were checked 
and updated according to death, readmission to dialysis or retransplantations. The patient 
and graft follow-up times were then calculated.   
 
3.1.2. PROSPECTIVE COHORT STUDIES (STUDIES II TO V) 
 
Study sample   
The prospective cohort included 40 recipients who received transplants from December 
2010 to May 2011 (studies II to V).  
Exclusion criteria 
Recipients younger than 18 years old or who required multiorgan transplantation were 
excluded from enrollment. After transplantation, recipients with primary graft failure were 
also excluded.   
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Sample size 
The prospective study was deemed exploratory. When the study protocol was designed, 
some of the candidate biomarkers were little studied or previously unstudied as early 
markers of kidney graft dysfunction. Given this, it would be imprudent and costly to recruit 
a larger cohort, particularly because each patient was subjected to five measurements of 
each marker. Therefore, based on costs, clinical and statistical issues the suitable sample 
size was set to 40 patients, representing half a year of the kidney-only transplant activity 
of our center.    
 
Recruitment procedures 
The recruitment of patients included in the prospective cohort lasted 6 months, from 
December 2010 to May 2011. During this time, consecutive patients with end-stage renal 
disease, who were undergoing living or deceased donor kidney transplantation in the 
Department of Nephrology and Kidney Transplantation of Centro Hospitalar do Porto were 
prospectively enrolled. On the day of transplantation (day 0), participants who met the 
inclusion criteria were asked to participate in the study by the nephrologist who called and 
received the patient for transplant surgery. This nephrologist, who was also part of 
research team, was responsible for explaining the objectives of the study as well as its 
risks and benefits. A briefing written explanation about the study was then given to each 
patient, and those who decided to take part signed the consent form, which was also 
dated and signed by the nephrologist researcher. After the information that a transplant 
was ongoing and the patient had agreed to participate, the mechanics of the study was 
initiated.   
 
Biological sample collection, preparation and storage 
Five total blood and urinary samples were collected per patient for the determination of 
biomarkers as follows: 3 to 6 h prior to transplant surgery (pre-transplant); on the morning 
following surgery, approximately 8 to 12 h after graft reperfusion (day-1); and then on the 
second, fourth, and seventh days after transplant.  
Blood and urine samples were collected using conventional procedures, using 
ethylenediaminetetraacetic acid (ED.TA) as anticoagulant or not, and were centrifuged 
shortly afterward. All of the serum, plasma, and urine samples were aliquoted and frozen 
within one hour after collection and were stored at -80°C until analysis. Erythrocytes were 
obtained by centrifugation of whole blood for 5 minutes at 5000 rpm and then plasma was 
removed. Then, erythrocytes were washed three times with 0.9% NaCl solution and 
centrifuged at 2000 rpm for 5 minutes after each wash. The whole blood samples, 
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erythrocytes and separated plasma/serum were aliquoted within one hour after collection 
and stored at -80ºC until assayed. All determinations were performed approximately one 
to two weeks after collection. 
 
Biomarker analyses/measurements 
Creatinine was measured as routine in serum (SCr) using a kinetic colorimetric assay 
based on a compensated Jaffé method using a calibrator for automatic systems (Cobas 
6000, Roche Diagnostics, Germany).  
Cystatin C was measured in serum via a particle-enhanced nephelometric immunoassay 
(Siemens Diagnostics, Germany). The normal range for this assay is 0.53-0.95 mg/l. 
Neutrophil gelatinase-associated lipocalin was measured in urine (uNGAL) using a two-
step chemiluminescent microparticle immunoassay on a standardized clinical platform 
(ARCHITECT, Abbott Diagnostics, Germany) and the normal upper limit for uNGAL in 
healthy volunteers is 132 ng/ml (95th percentile) with this assay. The coefficient of 
variation for this automated assay has been reported to be ≤5% and sensitivity (uNGAL 
concentration corresponding to a coefficient of variation of 20%) was found to be <2 
ng/ml. 
 
Adipokines   
Leptin was measured in serum using ELISA with kits from Mercodia (Uppsala, Sweden). 
Mercodia Leptin ELISA is based on the direct sandwich technique in which two highly 
specific monoclonal antibodies are directed against separate antigenic determinants on 
the leptin molecule. As for all assays, each laboratory should collect data and establish its 
own range of expected values and the reference ranges considered in our study were 2 to 
5.6 ng/mL for males and 3.7 to 11.1 ng/mL for females.  
Adiponectin was measured in plasma using Mercodia kits (Uppsala, Sweden). 
Mercodia Adiponectin ELISA is a solid phase, two-site enzyme immunoassay. It is based 
on the sandwich technique in which two monoclonal antibodies are directed against 
separate antigenic determinants on the adiponectin molecule. The normal concentrations 
were typically 3 to 300 ng/mL.  
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Oxidative Stress Markers   
Malondialdehyde was measured in fresh plasma samples using a commercial high-
performance liquid chromatography kit (Chromsystems, Munich, Germany). Preparation of 
samples was performed according to the manufacturer's instructions. A derivatisation step 
in which protein bound to MDA is hydrolyzed and converted into a fluorescent probe (60 
min at 95°C) was performed for the determination of MDA. The fluorescent probe was 
then cooled (2-8°C), centrifuged, mixed with a reaction solution and injected into the high-
performance liquid chromatography system. The isocratic separation via HPLC at 30°C 
using a “reversed phase“ column takes 4 minutes for each sample. The chromatograms 
were recorded with a fluorescence detector. The quantification was performed with the 
delivered calibrator, and the concentration was calculated via integration of the peak 
heights. The MDA values are given in µmol/L for plasma and the reference range is 0.77- 
0.93 µmol/L. 
Total Erythrocyte Superoxide Dismutase activity was measured in erythrocytes according 
to the protocol of Beauchamp and Fridovich using the RANSOD kit (Randox Laboratories, 
UK).237 This method employs xanthine and xanthine oxidase to generate superoxide 
radicals, which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride 
(I.N.T.) to form a red formazan dye. The superoxide dismutase activity is then measured 
by the degree of inhibition of this reaction. The activity value of SOD is expressed in U/g 
hemoglobin and the reference range is 1102 - 1601 U/g hemoglobin. 
Glutathione reductase was measured in plasma/serum using a kit supplied by Randox 
Laboratories Ltd. (Cat. No. GR2368) according the manufacturer's recommendations. 
Glutathione reductase is required for the regeneration of reduced glutathione, which is 
important for normal cellular metabolism. This enzyme is often discussed in association 
with glutathione peroxidase, which requires reduced glutathione for activation. Glutathione 
reductase catalyzes the reduction of glutathione in the presence of NADPH, which is then 
oxidized to NADP+. The oxidation of NADPH to NADP+ is accompanied by a decrease in 
the absorbance at 340 nm, providing a spectrophotometric means of detection that is 
directly proportional to the GR activity in the sample. The reference range is 33 to 73 U/L 
plasma/serum.  
Glutathione Peroxidase was measured in whole blood using a kit supplied by Randox 
Laboratories Ltd. (Cat. No. RS505) and the appropriate whole blood control (SC692). 
Whole blood (50 µl) was diluted with 1 ml RANSEL diluting agent and incubated for 5 min. 
One ml of double-strength Drabkin’s solution was added, and assays were performed 
within 20 min. The GPx activity was measured at 340 nm, using a sample volume of 5 µl 
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in a total reaction volume of 285 µl based on the Paglia and Valentine method. The 
Randox Ransel reference range for GPx activity is 27.5 - 73.6 U/g Hb. 
The Total Antioxidant Status (TAS) was measured in serum by total antioxidant 
quantification using ABTS+ (2,2'-Azino-di-[3-ethylbenzthiazoline sulphonate]) radical 
formation with the commercially available Randox Total Antioxidant Status test kit (Ref. 
NX2332, Randox Lab., Ltd., UK). The ABTS was incubated with peroxidase 
(metmyoglobin) and H2O2 to produce the blue-green colored radical cation ABTS+, which 
is measured at 600 nm. The antioxidants in the added sample cause the suppression of 
this color to a degree that is proportional to their concentration. The reference range was 
based on a European working population going from 1.30 to 1.77 mmol/L in plasma. 
 
3.2. CLINICAL DEFINITIONS  
The pre-transplant time on dialysis was calculated since the beginning of dialysis until the 
date of transplantation; in retransplants the time on dialysis between transplants was 
added.  
Expanded-criteria donors refer to older kidney donors (≥60 years) or donors 50 to 59 
years old with at least two of the following three features: history of hypertension, terminal 
SCr higher than 1.5 mg/dl, or death from a cerebrovascular event. 
The level of “HLA mismatches” was used to indicate the number of human leukocyte 
antigens at the A, B, and DR loci found in the donor that were not present in the recipient.  
Acute rejection was defined as either biopsy-proven rejection or anti-rejection treatment 
without biopsy.  
Delayed graft function was defined according to United Network for Organ Sharing as the 
requirement for dialysis within the first seven days after renal transplantation due to the 
absence or irrelevant improvement in graft function. Complementarily, graft function was 
considered “prompt or immediate” (non-DGF) if no dialysis was required during the first 
week after transplantation.  
 
3.3. ETHICS 
Both the retrospective and prospective studies were approved by the Institutional Review 
Board of Centro Hospitalar do Porto, which conducted a scientific and ethical evaluation, 
and were performed in accordance with the national rules and regulations as well as 
international guidelines. All patients included in the prospective studies gave informed 
consent to participate and data were de-identified by removing the patient names and 
hospital numbers. 
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3.4. STATISTICAL ANALYSIS 
The statistical analyses performed in each study are described in each article. Some of 
the statistical methodologies were purposely learned and trained for this work, and then 
an overview of these methodologies and the reasons for their use are explained in more 
detail here. 
 
Linear mixed effect model   
The studies II, III and IV had a longitudinal design and used the Linear Mixed Effect Model 
as statistical methodology. A longitudinal study generally yields multiple or “repeated" 
measurements on each subject. The main interest of this type of study is typically to 
characterize the way the outcome or potential exposures changes over time, and the 
predictors of the change. Multiple observations from the same subject are likely to be 
positively correlated and cannot be regarded as independent from each other.  The 
observations at level 1 (biomarker measurements) are clustered at level 2 (patients), 
generally making them correlated (fig. 2). Thus, specific statistical methods should be 
used to analyze longitudinal data.  
 
 
 
 
 
 
 
 
 
F
Fig. 2:  Example of an unbalanced repeated-measures study  
 
Traditionally, most researchers consider a repeated analysis of variance (ANO.VA) when 
they plan to analyze multiple observations from each subject. Generalized linear models 
(GLM), such as ANOVA and analysis of covariance (ANCOVA), are the most commonly 
used procedures to examine changes across time. However, these methods would 
accurately estimate the model parameters in only a balanced repeated-measures design 
(e.g., equal group sizes). This condition is not easy to fulfill in a clinical study and the use 
of traditional univariate and multivariate test statistics may increase Type I errors in the 
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condition of an unbalanced repeated-measures design.238, 239 Furthermore, in ANOVA the 
error variance, which characterizes the within-subjects variance, and the variance of the 
random effects, which characterizes the between-subjects variance, are treated as being 
homogeneous across subject groups or levels of covariates. When this homogeneity of 
variance assumption is violated, as it can happen with unbalanced data, the results of the 
analysis may not be trustworthy.240  
We used linear mixed-effects models with a maximum likelihood estimation to evaluate 
the changes in the nine studied biomarkers over time. These models, also known as 
individual growth curve models,238, 241 random regression models,242, 243 hierarchical linear 
models,244, 245 or multilevel models246 are extremely flexible and offer several advantages 
over traditional methods for the analysis of longitudinal data. First, this statistical 
technique does not require balanced data, which provides a more adaptable and powerful 
approach when handling unbalanced data (e.g., unequal sample size, inconsistent time 
interval, and missing data).238, 247 In our study, the number and spacing of measurement 
occasions were fixed (i.e., the same points in time for all individuals); however, missing 
measurements were identified within individuals, primarily regarding in uNGAL, because 
of the lack of urine samples in recipients with transient anuria. Missing data are a critical 
problem in clinical research. The use of a linear mixed model overcomes the limitation of 
other conventional statistical techniques that do not allow for missing observations. Both 
standard univariate GLM and multivariate analysis of variance (MANOVA) GLM require 
complete data. Thus, even if a single time-point measure is missing, the subject is 
discarded. With a few missing observations a great deal of data can be lost. One of the 
main advantages of mixed models is that we can use all existing data. If a score is 
missing, it is just missing. It has no effect on the other scores from the same patient. 
A second advantage of these models is that they enable the study of both intra and 
interindividual differences in the growth parameters (e.g., slopes and intercepts). These 
individual differences can be modeled by assuming different intercepts and slopes for 
each subject that is by adding an additional random effect for the subject. These random 
effects reflect each person’s growth or development across time, and the variance of 
these random effects indicate the degree of variation that exists in the subjects.240 In the 
mixed effects modeling approach, factors may be considered to have both fixed and 
random effects, whereas in the GLM, each factor must be considered either a fixed or 
random effect. Thus, in linear mixed models each recipient is assigned a different 
intercept value that is estimated by this type of modeling. This approach enables the non-
independence of measures to be determined by assuming a different “baseline” value for 
each subject.248 This approach is valuable, for example, in the field of uNGAL and serum 
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CysC because individuals vary not only in their initial status but also their rates and 
pattern of changes. Most methods for repeated-measure designs (e.g., multiple 
regression analyses, ANOVA, MANOVA) only focus on group differences in the patterns 
of change; however, variations in growth curve parameters may also exist at the individual 
level. When we have a design in which we have both fixed-effect parameters associated 
with one or more continuous or categorical covariates and random effects that are 
associated with one or more random factors, we have what is often referred to as a mixed 
model. The fixed-effect parameters describe the relationships of the covariates to the 
dependent variable for an entire population, and the random effects are specific to the 
clusters or subjects within a population.238, 247, 249  
Third, the estimation of the parameters of a statistical model is a key step in most 
statistical analyses and linear mixed model analyses estimate the parameters with greater 
precision, primarily when the number of time points increases. As previously discussed 
the mixed model equations are solved to obtain the fixed and random effects and error 
terms, which produce shrinkage estimators.250  This approach improves the reliability of 
the growth parameters by reducing the standard errors of the within-subject change in the 
growth parameter estimates.238, 247, 251  
Fourth, the effects of predictors on individual changes can flexibly be added in the growth 
curve models, which can be used to explore the causal links between the association of 
predictors and changes in outcome variables across time.244 This approach enables the 
inclusion of discrete or continuous predictors in the model, as well as time variants or time 
invariants. Time-variant predictors refer to independent variables that change over time 
(e.g., body mass index), whereas time-invariant predictors refer to independent variables 
that remain constant over time (e.g., gender or pre-transplant time on dialysis).  
Finally, mixed models for longitudinal data can model differences in variances, and not 
just means, across subjects and time-varying covariates. Thus, linear mixed models are 
more powerful than other methods (e.g., ANOVA, MANOVA, multiple regression 
analyses) in examining the effects associated with repeated measures because they can 
model the covariance matrix (i.e., fitting the covariance structure to the data) rather than 
imposing a certain type of structure as commonly used in traditional univariate and 
multivariate approaches. Sphericity or compound symmetry in the model can be assumed; 
however, we can also allow the model to select its own set of covariances or use different, 
and often more logical covariance structures.252-255  
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Survival analysis considering competing risks   
Survival analysis is commonly used in medical research and typically focuses on time to 
event data.256 Events are typically designated as “failures”, and the time to the event is 
designated as the “survival time”. This “survival time” is the time that takes an individual to 
fail because of a particular event, which is measured from an origin of time; it can be 
characterized by the hazard function, which represents the rate of occurrence of the event 
at a given time t, but primarily via the survival function, which represents the probability of 
surviving up to time t, that is, the probability that the event has not yet occurred before 
time t. If the patient does not have an event before the end of the study, the patient’s 
event time is right censored. In the presence of non-informative right censoring and given 
a random sample of observed individuals, both functions are empirically estimable through 
consistent quantities such as the Nelson-Aalen estimator for the hazard function or the 
Kaplan-Meier estimator (1-KM) for the survival function.256, 257 In kidney transplantation the 
1-KM is one of the most used methods to study graft and patient survival, which censors 
all but one type of outcome (typically graft failure or patient death). Thus, the probability of 
an event of interest (e.g. graft failure) is estimated in an ideal world where the other types 
of events do not exist (e. g. patient death). However, when competing risks are present 
these methods produce biased estimates of endpoint probabilities because they do not 
account for the various types of outcomes that can occur.258, 259 
In several clinical research settings the need to address multiple potential outcomes is 
nearly ubiquitous. Thus, several causes of failure are possible but the occurrence of one 
event precludes the occurrence of the other events (e.g. when failures are different 
causes of death, only the first cause can be observed).260 This situation is known as 
competing risks. When a competing risks situation is present, each subject can 
experience one of a number of different events and we are interested in the time to the 
event, as well as the event type.258 
In kidney transplantation, for example, graft loss can be defined as the absence of kidney 
function, which occurs any time after transplantation because of patient death or 
irreversible graft injury that requires chronic dialysis and/or retransplantation. After a 
kidney transplant, all recipients are at risk of both mutually exclusive events. Thus, 
competing risks are said to be present. Only the first event that occurs is observed, which 
is typically referred to as the “cause of failure”, and the occurrence of one event will 
prevent the other event from ever occurring. If a patient returns to dialysis because of the 
loss of a functioning graft, the other failure may, in fact, be observable (death after graft 
failure); however, this event is no longer the event of interest for the kidney transplantation 
setting, because the patient is now a “dialysis patient” (fig. 3). Traditionally, only one event 
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is chosen for analysis (graft failure or patient death), and the competing risk event is 
ignored and treated as a non-informative right-censored observation; furthermore, 
classical survival methods, such as Kaplan-Meier, are used for inference. However, this 
approach leads to bias and the true rate of the event is overestimated.258, 261  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3:  The distinctive outcomes after kidney transplantation 
 
Cumulative Incidence 
The estimation of the cumulative incidence function is of primary interest in most clinical 
studies. The Kaplan-Meier (KM) method can be used to obtain a nonparametric estimate 
of the cumulative incidence when the data consist of subjects who experience an event 
and the censoring mechanism is assumed to be non-informative (independent of the 
event time, or in other words, when the time at which a subject experiences an event is 
assumed to be independent of a mechanism that would cause the patient to be 
censored).262 Thus, unless the competing risk event is independent of the main event, the 
classical KM method and other standard methods would provide biased estimators for the 
different probabilities of interest. Furthermore, as discussed by Tsiatis,263 the 
independence between distinct causes of failure cannot be checked on the basis of the 
competing risks observed data. 
Specific methods are thus required for the estimation of survival probabilities in the 
presence of competing events. Several authors have discussed the topic of competing 
risks and the estimation of the cumulative incidence of an event. Gooley et al264 discussed 
the appropriateness of the cumulative incidence function (CI.F) in competing risks analysis 
as opposed to routinely using the 1-KM estimator. The CIF is defined as the probability of 
an individual experiencing an event by time t when other competing risks are acting on the 
individual. The authors pointed out that 1-KM is a function of the hazard for failures due to 
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the cause of interest only and do not depend on the hazard for failures due to the 
competing risks. Therefore, 1-KM is not interpretable as an estimate of the probability of 
failure as a result of the cause of interest when competing risks are present. In practice, 
the 1-KM treats patients who experience the competing risk prior to the event of interest 
as censored. Therefore, they are 'redistributed to the right' which incorrectly assumes that 
the cause of interest is still possible beyond the time at which the censoring occurred (fig. 
4).261 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4:  Survival analysis: classical vs. competing risks approaches. 
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In kidney transplantation, if the study event is, for example, graft failure as a result of the 
loss of functioning, the KM method attempts to predict what the graft failure probability 
would be if no patient ever died. This value would be higher than the actual value; 
however, to do this, KM method relies on the assumption of noninformative censoring for 
not only the patients who are alive, but also for the patients who have died, which is an 
assumption that is not true in this situation or in many other medical applications. Thus, 
the typical 1-KM estimate, which includes patient death that occurred prior to graft failure 
as non-informative censoring, attempts to estimate the probability of graft failure if no 
individual died. Therefore, the typical KM method applied to a competing risks situation 
overestimates the probabilities of graft failure and is thus inappropriate in the presence of 
competing risks (Fig. 4).258, 261, 262, 265, 266 
 
 
Regression analysis for competing risks 
There are two popular methods for regression analysis when competing risks are present: 
regression on the cause-specific hazards using the competing risks analogue to the Cox 
proportional hazards model and the regression model for the cumulative incidence 
function proposed by Fine and Gray.265 
The most commonly used method is a Cox model stratified on different competing risk 
events. This model is based on the cause-specific hazard function, which measures the 
instantaneous failure rate as a result of one risk at a time. It is routinely estimated by 
constructing the Cox models on cause-specific hazards and treating time to event from 
the other competing risks as censored. For each risk, the effects of prognostic factors are 
assessed as constant hazard ratios on the instantaneous failure rate of this risk.267  
An important function in the competing risk framework is the CI.F. However, many 
situations require more than a summary measure; some form of regression would be 
useful. The models based on CIF resemble a more “real world” situation and it is directly 
related to crude survival rates; thus, it is essential to decision makers. To estimate failure 
in the presence of competing risks, Fine and Gray265 proposed a proportional hazards 
model for the CIF, and this regression model has been widely used in medical 
research.268-271 
In the current study, the influence of DGF was evaluated using the cause-specific Cox 
proportional hazards regression model (based on the cause-specific hazard) and the Fine 
and Gray model (based on the subdistribution hazard) to analyze how the effects of this 
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covariate differed between these two approaches. Both results are valid; however, their 
interpretations are different and depend on the purpose of the study (etiology vs. 
prediction) as discussed in the manuscript of the study VI.266, 270, 272 
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4.1. STUDY I 
SERUM CREATININE AS A SURROGATE ENDPOINT FOR LONG-TERM GRAFT SURVIVAL 
Fonseca I, Almeida M, Martins LS, Santos J, Dias L, Lobato L, Henriques AC, Mendonça 
D. First-year renal function predicts long-term renal allograft loss. Transplant Proc. 2011; 
43(1):106-12.    
Printed with permission, Elsevier© July, 2014 
When the true endpoints occur late the use of good surrogate markers can substantially 
reduce the study duration because they are obtained sooner at a lower cost or less 
invasively than the long-term clinical efficacy endpoint. When using a surrogate endpoint, 
one would like to make the same inference as if a true endpoint has been observed. 
Among the renal transplant community a natural candidate for long-term graft loss is renal 
function, and some studies noted that graft function at one-year is a strong surrogate 
marker of late graft outcome. Because international trends might not be reflected in local 
populations and each center must assess what works best in their local reality, this study 
was performed to examine the predictive effect of renal function within the first year 
(expressed as the SCr level at 1, 6 and 12 months as well as the changes between those 
months) on the long-term graft survival, and to identify other independent factors that are 
associated with late failure in renal transplants. The main goal of this study was to 
establish SCr within the first year after kidney transplantation as a surrogate endpoint for 
the subsequent prospective studies that intended to identify markers of kidney graft 
dysfunction in the immediate postoperative period as follows: 
 
 
Novel Biomarkers >> Surrogate Endpoint >> Definitive Endpoint 
uNGAL 
CysC 
Leptin/Adiponectin 
Oxidative stress 
 SCr at 6 months 
SCr at 12 months 
 Graft failure 
Patient Death 
 
 Studies II to V     Study I 
 
The main results are expressed below: 
  Among a large number of variables that were taken into consideration, the SCr levels at 
1, 6 and 12 months following kidney transplantation as well as changes between 1 and 6 
months and between 6 and 12 months were independently associated with late graft 
failure using Cox multivariable analysis.  
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  Other significantly factors associated with late graft failure were a younger age of the 
recipient, older age of the donor, acute rejection, female gender, adjusting for other 
factors usually associated with graft loss, such as pre-transplant time on dialysis, HLA 
mismatches, and DGF occurrence. 
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First-Year Renal Function Predicts Long-Term Renal Allograft Loss
I. Fonseca, M. Almeida, L.S. Martins, J. Santos, L. Dias, L. Lobato, A.C. Henriques, and D. Mendonça
ABSTRACT
Purpose. We performed a retrospective study to examine the impact on long-term graft
survival of first-year posttransplantation renal function, as evaluated by serum creatinine.
Patients and Methods. We analyzed data from 1,273 adult kidney transplants performed
between 1983 and 2008. All recipients !18 years old were included if their grafts had
survived beyond 1 year, excluding patients simultaneously transplanted with other organs.
Cox proportional hazards multivariable analysis was used to examine the relationship
between first-year posttransplantation renal function and death-censored graft loss,
adjusted for other variables. Renal function in the first year was expressed as serum
creatinine levels at 1, 6, and 12 months as well as the change in creatinine between those
3 periods.
Results. Posttransplantation 1-month serum creatinine levels and change between 1 and
6 months were independent predictors of long-term graft loss. Multivariable analysis also
identified donor age (increasing), acute rejection episode occurrence, recipient age at
transplantation (decreasing), and gender (female) as independently predictive of graft
failure, adjusting for other factors usually associated with graft loss, namely, pretransplan-
tation time on dialysis, HLA mismatches, and delayed graft function. The predictive effect
of creatininemia was sustained at 6 and 12 months, after adjusting for these covariates.
Conclusions. Posttransplantation serum creatinine levels at 1, 6, and 12 months were
independent predictors of graft survival, suggesting that they could be considered as
surrogate endpoints for long-term death-censored graft loss.
Renal transplantation is the treatment of choice forpatients with end-stage renal disease. In the past two
decades, progress in surgical procedures, medical care, and
immunosuppression have significantly improved the short-
and long-term results of organ transplantation.1,2 Neverthe-
less, grafts continue to fail over time, and chronic dysfunc-
tion remains the leading cause of late allograft loss among
surviving recipients.3
One of our concerns is to obtain insight into the factors
associated with long-term allograft survival to identify early
markers of chronic allograft dysfunction as well as potential
interventional pathways. Long-term graft survival is an ideal
endpoint, but evaluating an outcome in the long term
usually requires a time-consuming process. For this reason,
an easier approach seeks to identify alternative endpoints
or short-term markers that predict long-term survival and
therefore can be considered as potentially useful surro-
gates. This approach is widely used in clinical research on
cancer and cardiovascular disease, and recently it has been
applied in the context of renal disease.4
There has been a research focus among the transplant
community to obtain a diagnostic marker that may serve as
a surrogate for eventual graft loss.5–7 A natural candidate
for this surrogate endpoint is renal function. Creatinine
levels and changes in creatinine levels within the first year
after transplantation have been shown to be important
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Centro Hospitalar do Porto, Hospital de Santo António (I.F.,
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parameters influencing and predicting long-term graft sur-
vival.7–12 However, not all studies support the validity of
serum creatinine as a predictor of long-term graft loss.
Serum creatinine underestimates deterioration of glomer-
ular filtration rate and changes only occur at a late stage in
the progression of graft dysfunction. For these reasons,
some authors consider creatinine to be a poor predictor of
both chronic allograft dysfunction and graft loss.13–15
The present retrospective analysis of a single-center
experience was intended to examine the predictive effect on
long-term graft survival, of renal function within the first
year, as expressed by serum creatinine level at 1, 6, and 12
months and the change between those months, as well as to
identify other independent factors associated with late graft
failure. This study is the first attempt of our Unit to develop
a surrogate endpoint for subsequent studies that will intend
to identify earlier sensitive markers of renal allograft dys-
function.
SUBJECTS AND METHODS
Study Population and Data Collection
This study of 1,273 kidney transplants performed at the Renal
Transplantation Unit of Centro Hospitalar do Porto, Hospital
Santo António, Porto between August 4, 1983, and December 31,
2008 excluded recipients of multiorgan transplants (kidney/pan-
creas and kidney/liver), pediatric patients (!18 years old at trans-
plantation), and losses within the first year. Recipient, donor, and
transplantation characteristics were mainly obtained from our
electronic database, which holds longitudinal information of all
renal transplantations since 1983. The following data were col-
lected: donor variables (gender and age at time of death or kidney
donation); recipient variables (gender, primary cause of renal
disease, pretransplantation time on dialysis, age at time of trans-
plantation, first or prior transplantation, and panel-reactive anti-
bodies); transplantation-related factors (living or deceased donor,
number of human leukocyte antigen (HLA) A, B, and DR mis-
matches, and cold ischemia time); and posttransplantation features
(immunosuppressive regimen, history of delayed graft function,
occurrence of acute rejection, status of kidney allograft, cause of
graft loss, vital status, and cause of death). Serum creatinine levels
at 1, 6, and 12 months were obtained from the medical records and
from the hospital electronic laboratory database. All patients were
followed from transplantation until death, readmission to dialysis,
retransplantation, or May 2010. The study was approved by our
Institutional Review Board. Data were deidentified by removing
patient names and hospital numbers.
Definition and Categorization of Variables
Pretransplantation time on dialysis was calculated from the begin-
ning of dialysis to the date of transplantation; in retransplants we
added the time on dialysis between transplants.
The term “mismatch” was used for the number of HLA antigens
that donor and recipient did not have in common. Female donor
mismatch was labeled when a male recipient received a kidney
from a female donor, so patients were grouped as female donor to
male recipient or all other combinations (female to female, male to
male, or male to female). Donor O blood group mismatch was
considered when a non-O blood type person was a recipient of a
kidney from an O donor blood type, so patients were grouped as O
donor to non-O recipient or all other combinations.
Delayed graft function was defined by the need for dialysis in the
first week after transplantation owing to an absence or a significant
improvement in graft function. Acute rejection episode was defined
as either biopsy-proven rejection or antirejection treatment with-
out biopsy. Graft survival was censored for patient death with a
functioning allograft or the end of the study (May 2010). Graft loss
was defined as return to dialysis or retransplantation without
returning to dialysis. Late graft loss was defined as graft loss beyond
the first-year follow-up.
The sample was divided into 4 cohorts based on times in which
immunosuppressive medications were introduced into clinical
practice: era 1, before 1990, azathioprine and cyclosporine (no
microemulsion); era 2, between 1990 and 1995, cyclosporine
microemulsion; era 3, between 1996 and 2000, mycophenolate
mofetil introduction and wide use of antithymocyte globulin;
and era 4, after 2000, sirolimus availability and wide use of
tacrolimus.
Renal function in the first year after-transplantation was ex-
pressed as serum creatinine level at 1, 6, and 12 months, as well as
the change in creatinine from 1 to 6 months ("Cr1–6) and from 6 to
12 months ("Cr6–12). Serum creatinine levels were also categorized
as: !1, 1–1.5, 1.5–2.0, 2.0–2.5, and !2.5 mg/dL.
Statistical Analyses
Continuous variables are expressed as mean values (standard
deviation) and categoric variables as proportions. Graft loss due to
chronic allograft failure was the endpoint. For this reason, graft
survival was censored for patient death with a functioning allograft.
Statistical analysis of death-censored graft survival was performed
using several multivariable Cox proportional hazard models. Time
to event (graft loss) incorporated in models excluded the first year
after transplantation, owing to time dependency of serum creati-
nine during that year. Multivariable models were built both in a
stepwise hierarchic manner, testing the significance of added terms
by using the forward likelihood ratio method, and by using the
entry method in a second block to guarantee that donor, recipient,
and transplantation variables recognized to influence allograft
survival in the current literature would be included and the effects
adjusted for all variables in the model.
Recipient age (continuous and grouped), gender, pretransplan-
tation time on dialysis, number of transplants performed (#1 vs 1),
donor age (continuous and grouped); source of donor organ (living
vs cadaveric donor), number of HLA mismatches, female donor
mismatch (female donor–male recipient vs all other combinations),
O donor blood type mismatch (O blood type donor vs all others),
transplantation era, occurrence of delayed graft function, and
occurrence of an acute rejection episode were the variables ad-
justed in the multivariable graft survival analysis. Recipient age was
treated as continuous (years of age) and as a categoric variable (age
higher or less than 55 years and age quartiles). The quartiles of
recipient age were tested because of the small number of recipients
#55 years at the time of transplantation.
Serum creatinine levels were included in the models as both
continuous and categoric variables, the relative difference in serum
creatinine level from 1 to 6 months ("Cr1–6) and from 6 to 12
months ("Cr6–12) as continuous variables. To avoid colinearity,
serum creatinine levels at 1, 6, and 12 months were used in different
models, as well as change of levels between 1 and 6 and between 6
and 12 months. We tested potentially interacting variables. Pre-
specified multiplicative interactions included serum creatinine lev-
els by history of delayed graft function and occurrence of an acute
rejection episode. Cox analyses are expressed as hazard rates (HR)
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and 95% confidence intervals (CIs). All statistical analyses were
performed by using the Statistical Package for the Social Sciences,
version 18.0 (SPSS, Chicago, IL, USA). A P value of !.05 was
assumed to indicate a statistically significant association.
RESULTS
Patient Characteristics
The demographic and clinical characteristics of the 1,273
adult renal transplants patients who met the criteria for
inclusion and were enrolled are summarized in Table 1. At
the time of transplantation, the mean recipient age was 40.7
years (range, 8–75 y). Almost 11% of patients were retrans-
plants; only 6.1% received a kidney from a living donor. The
mean number of HLA mismatches was 3.1 " 1.6. There
were 171 patients (13.4%) who underwent transplantation
before 1990 (time of azathioprine and cyclosporine, no
microemulsion), 339 (26.6%) between 1990 and 1995 (time
of cyclosporine microemulsion), 320 (25.1%) between 1996
and 2000 (time of mycophenolate mofetil and antithymo-
cyte globulin), and 443 (34.8%) after 2000 (time of tacroli-
mus and sirolimus).
The causes of graft loss are shown in Table 2. Chronic
allograft dysfunction occurred in 249/416 graft failures
(59.9%); it was the leading cause of kidney allograft loss.
Recipient death the second cause of late failure, occurred in
149 patients (35.8%), and 857 patients (67.3%) still had
functioning allografts at the censoring date.
Factors Affecting Long-Term Survival of the Grafts after
the First Year
Proportional hazards Cox regression was used to investigate
independent factors affecting long-term survival of the
grafts that had reached 1 year to estimate the HR of graft
failure. To assess the independent association of renal
function in the first year after transplantation and long-term
graft loss, several multivariable models were built. Owing to
colinearity, serum creatinine levels at 1, 6, and 12 months
were tested in various models, as well as #Cr1–6 and
#Cr6–12.
Model Development
All variables known to potentially influence long-term graft
survival were considered for inclusion in the multivariable
models. Accordingly, recipient age, gender, pretransplanta-
tion time on dialysis, and number of transplants performed
($1 vs 1), donor age, source of donor organ (living vs
cadaveric donor), number of HLA mismatches between
donor and receptor, female and O donor blood type
mismatches, transplantation era, occurrence of delayed
graft function and occurrence of an acute rejection episode
were the covariates entered into the multivariable Cox
proportional hazards models in addition to 1-month serum
creatinine levels and #Cr1–6.
On the basis of these models, we observed that the
1-month serum creatinine levels and #Cr1–6 were signifi-
cantly associated with death-censored graft failure (HR for
each 1 mg/dL increase at 1 month, 1.909; 95% CI, 1.622–
2.246; and HR for each 1 mg/dL increase between 1 and 6
months, 1.832; 95% CI, 1.535–2.186; Table 3). The analyses
also identified increasing donor age, female recipient, and
history of acute rejection episode as significant predictors of
graft failure, as well as decreasing age of the recipient.
Donor age, treated as a continuous variable, showed a
borderline effect on graft loss (HR for each 1 year increase,
1.020; 95% CI, 1.010–1.029; P ! .001), but considering a
cutoff of 55 years, in a separate model, donors $55 years
old were 2.5-fold more likely to be associated with graft
failure due to chronic dysfunction compared with donor
!55 years old (HR, 2.5; 95% CI, 1.7–3.6; P ! .001). In
relation to recipient age, which was included as a continu-
ous variable, the hazard of long-term graft loss decreased
with age (HR, 0.975; 95% CI, 0.962–0.989; P ! .001). This
observation was also sustained when the recipient age was
divided into quartiles: The first and second quartiles were
significantly associated with chronic graft loss (!32 y and
32–40 y, respectively). Using the cutoff value of recipient
age lower versus higher than 55 years, as widely used in the
literature, the effect of recipient age was not significant.
Table 1. Patient Demographic and Clinical Characteristics
(n ! 1,273)
Characteristic
Donor
Donor age (y, mean " SD) 34 " 15.7
Donor age !55 y (n, %) 162 (12.8)
Living donor (n, %) 78 (6.1)
Recipient
Recipient age (y, mean " SD) 40.7 " 11.9
Recipient age !55 y (n, %) 185 (14.5)
Recipient age 1st quartile (!32 y, n, %) 320 (25.1)
Recipient age 2nd quartile (32–40 y, n, %) 319 (25.1)
Recipient age 3rd quartile (40.1–50 y, n, %) 316 (24.8)
Recipient age 4th quartile ($50 y, n, %) 318 (25.0)
Recipient female (n, %) 505 (39.7)
Previous dialysis time (y, mean " SD) 4.2 " 3.9
Preemptive (n, %) 18 (1.4)
Retransplants (n, %) 135 (10.6)
HLA mismatches (mean " SD) 3.1 " 1.6
After transplantation
Delayed graft function history (n, %) 384 (30.2)
Acute rejection occurrence (n, %) 293 (23.0)
Table 2. Causes of Graft Loss
Characteristic n (%)
Graft lost 416 (32.7)
Death with functioning graft 149 (11.7)
Graft functioning at May 31, 2010 857 (67.3)
Reason for graft lost (n % 416)
Recipient death 149 (35.8)
Chronic allograft dysfunction 249 (59.9)
Recurrent disease 8 (1.9)
Rejection after suspending immunosuppression 4 (1.0)
Other 6 (1.5)
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Other factors, including pretransplantation time on dial-
ysis, number of transplants, female donor, O donor blood
type mismatch, number of HLA mismatches, transplanta-
tion era, and delayed graft function, were not significantly
associated with graft failure, after adjusting for the other
variables in the model. We excluded from the model
potentially interacting variables owing to nonsignificant
effects: namely, the occurrence of delayed graft function or
an acute rejection episode with serum creatinine levels.
The predictive effect of serum creatinine was maintained
when levels at the first month were replaced by those at 6
and 12 months (Tables 4 and 5). Adjusting for the same
variables sixth-month serum creatinine level and !Cr6–12
were significantly associated with death-censored graft fail-
ure: HR for each 1 mg/dL increase at 6 months, 2.407; 95%
CI, 2.019–2.870; and HR for each 1 mg/dL increase be-
tween 6 and 12 months, 2.080; 95% CI, 1.736–2.492 (Table
4). Similar findings were verified with 1-year serum creati-
nine levels, which were also significantly associated with
death-censored graft failure: HR for each 1 mg/dL increase
at 1 year, 2.267; 95% CI, 1.935–2.589; (Table 5).
An additional analysis used the variables previously in-
corporated with serum creatinine as a categoric variable, ie,
serum creatinine levels "1 mg/dL considered as the refer-
ence grouping class. Considering serum creatinine at 1
month, only levels !2.5 mg/dL were significantly associated
with graft loss (HR, 2.502; 95% CI, 1.096–5.712; P " .03),
but at 6 and 12 months, serum creatinine !1.5 mg/dL had
predictive effects for graft failure (Table 6).
DISCUSSION
Over the past 30 years, improvements in the prevention and
treatment of acute rejection episodes and infections have
raised first-year kidney transplantation survival to #90%.
Nevertheless, a steady decline in graft survival beyond the
first year still occurs; many kidneys are lost owing to chronic
dysfunction.
Research has focused on finding sensitive and predictive
markers to identify patients at high risk for chronic graft
dysfunction, seeking to adjust procedures and hopefully
extend kidney life. Owing to the need for long follow-up
times, surrogate endpoints for late allograft failure are
lacking. Clinically, chronic graft dysfunction describes the
inexorable decline in renal function with time. Serum
creatinine levels within the first year after transplantation
Table 4. Multivariate Cox Proportional Hazard Analysis of the Hazard of Long-Term Allograft Loss Censored for Death (Including
Serum Creatinine Level at 6 months and !Cr6–12)
Long-Term Allograft Loss Censored for Death
HR* 95% CI P Value
Serum creatinine level at 6 mo (1 mg/dL increase) 2.407 2.019–2.870 ".001
!Cr6–12 (1 mg/dL increase) 2.080 1.736–2.492 ".001
Donor age (1 y increase) 1.020 1.010–1.029 ".001
Acute rejection (occurrence vs no occurrence) 1.484 1.110–1.985 .008
Recipient age (quartiles; reference, 4th quartile) .005
1st vs 4th quartile ("32 vs #50 y) 2.302 1.423–3.725 .001
2nd vs 4th quartile (32–40 vs #50 y) 2.126 1.309–3.451 .002
3rd vs 4th quartile (40.1–50 vs #50 y) 1.677 0.991–2.838 .054
Recipient gender (female vs. male [reference]) 1.341 1.006–1.787 .045
*Adjusted for pretransplantation time on dialysis, transplantation era, number of transplants performed (first vs regraft), source of donor organ (living vs cadaveric
donor), number of HLA mismatches, history of delayed graft function (yes vs no), female donor mismatch (female donor to male recipient vs all other combinations),
and donor O mismatch (O blood type donor to non-O receptor).
Table 3. Multivariate Cox Proportional Hazard Analysis of the Hazard of Long-Term Allograft Loss Censored for Death (Including
Serum Creatinine Level at 1 month and !Cr1–6)
Long-Term Allograft Loss Censored for Death
HR* 95% CI P Value
Serum creatinine level at 1 mo (1 mg/dL increase) 1.909 1.622–2.246 ".001
!Cr1–6 (1 mg/dL increase) 1.832 1.535–2.186 ".001
Donor age (1 y increase) 1.020 1.010–1.029 ".001
Acute rejection (occurrence vs no occurrence) 1.591 1.189–2.128 .002
Recipient age (quartiles; reference, 4th quartile) .007
1st vs 4th quartile ("32 vs #50 y) 2.249 1.397–3.621 .001
2nd vs 4th quartile (32–40 vs #50 y) 1.911 1.183–3.086 .008
3rd vs 4th quartile (40.1–50 vs #50 y) 1.541 0.921–2.578 .099
Recipient gender (female vs male [reference]) 1.373 1.031–1.827 .030
*Adjusted for pretransplantation time on dialysis, transplantation era, number of transplants performed (first vs regraft), source of donor organ (living vs cadaveric
donor), number of HLA mismatches, history of delayed graft function (yes vs no), female donor mismatch (female donor to male recipient vs all other combinations),
and donor O mismatch (O blood type donor to non-O receptor).
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have been used as an early marker and surrogate endpoint
for long-term graft loss.7–12
We sought to analyze the ability of serum creatinine
measurements at 1, 6, and 12 months to predict death-
censored graft survival, to then substitute this distant clin-
ical event seeking to identify early markers of graft dysfunc-
tion. Our analysis confirmed serum creatinine within the
first year after transplantation to be an important indepen-
dent parameter influencing long-term survival. We ob-
tained similar results when treating serum creatinine levels
as a categoric variable, observing an increased HR for graft
loss for higher creatinine levels.
There are a number of ways to measure or estimate renal
function. All have advantages and disadvantages regarding
costs, feasibility, and accuracy. Serum creatinine is a simple,
inexpensive, widely available, and easily reproducible pa-
rameter for both single-center and large multi-institutional
studies. In addition, and as required for an ideal laboratory
biomarker, an elevation of serum creatinine indicates kid-
ney damage and precedes the onset of chronic graft dys-
function.4
Several retrospective studies have shown that elevated
posttransplantation serum creatinine levels are associated
with an increased risk of late graft failure.7,11–13,16 Post-
transplantation renal function within a few days after
transplantation or at the time of discharge from the hospital
has been associated with long-term survival.11,12 Hariharan
et al analyzed data from a large cohort of adult recipients
who received renal transplants from living and cadaveric
donors in the United States between January 1988 and
December 1998.7 Data were obtained from all 256 kidney
transplant programs as reported to the Organ Procurement
and Transplantation Network/United Network for Organ
Sharing. They revealed a correlation between serum creat-
inine levels at 6 and 12 months and long-term graft failure.
An increment of 1.0 mg/dL in serum creatinine at 1 year
after transplantation increased the odds of graft failure by
63%. When this was accompanied by a change in creatinine
of 0.5 or 1.0 mg/dL from 6 months to 1 year, the HR of graft
failure increased to 2.26 and 3.13, respectively. Hariharan et
al concluded that increases in serum creatinine at 1 year
and enhanced changes between 6 and 12 months progres-
Table 5. Multivariate Cox Proportional Hazard Analysis of the Hazard of Long-Term Allograft Loss Censored for Death (Including
Serum Creatinine Level at 1 Year)
Long-Term Allograft Loss Censored for Death
HR* 95% CI P Value
Serum creatinine level at 12 mo (1 mg/dL increase) 2.267 1.985–2.589 !.001
Donor age (1 y increase) 1.021 1.012–1.030 !.001
Acute rejection (occurrence vs no occurrence) 1.504 1.128–2.007 .005
Recipient age (quartiles; reference, 4th quartile) .009
1st vs 4th quartile (!32 vs "50 y) 2.210 1.367–3.574 .001
2nd vs 4th quartile (32–40 vs "50 y) 2.112 1.303–3.423 .002
3rd vs 4th quartile (40.1–50 vs "50 y) 1.706 1.012–2.875 .045
Recipient gender (female vs male) 1.346 1.008–1.798 .068
Recipient gender was excluded from the model (P # .068).
*Adjusted for pretransplantation time on dialysis, transplantation era, number of transplants performed (first vs regraft), source of donor organ (living vs cadaveric
donor), number of HLA mismatches, history of delayed graft function (yes vs no), female donor mismatch (female donor to male recipient vs all other combinations),
and donor O mismatch (O blood type donor to non-O receptor).
Table 6. Multivariate Cox Proportional Hazard Models of the Hazard of Long-Term Allograft Loss Censored for Death (Serum
Creatinine Level Treated as Categoric Variable)
Long-Term Allograft Loss Censored for Death
HR* 95% CI P Value
Serum creatinine level at 1 mo (reference, !1 mg/dL)
!2.5 vs !1 mg/dL 2.502 1.096–5.712 .029
Serum creatinine level at 6 mo (reference, !1 mg/dL)
1.5–2.0 vs !1 mg/dL 2.263 1.088–4.707 .029
2.0–2.5 vs !1 mg/dL 3.882 1.747–8.628 .001
!2.5 vs !1 mg/dL 9.554 4.185–21.812 !.001
Serum creatinine level at 12 mo (reference, !1 mg/dL)
1.5–2.0 vs !1 mg/dL 2.950 1.245–6.990 .014
2.0–2.5 vs !1 mg/dL 4.765 1.936–11.727 .001
!2.5 vs !1 mg/dL 13.971 5.507–35.444 !.001
As in the models in Tables 3–5, donor age, recipient age and gender, occurrence of acute rejection, $Cr1–6, and $Cr6–12 were significant predictors for graft survival
(data not shown).
*Adjusted for pretransplantation time on dialysis, transplantation era, number of transplants performed (first vs regraft), source of donor organ (living vs cadaveric
donor), number of HLA mismatches, history of delayed graft function (yes vs no), female donor mismatch (female donor to male recipient vs all other combinations),
and donor O mismatch (O blood type donor to non-O receptor).
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sively increased the risks of graft failure.7 Kasiske et al also
confirmed serum creatinine to be a predictor of graft failure
in a study that evaluated the first decline in inverse creati-
nine as a surrogate marker for graft survival.16 Serum
creatinine values were collected over a maximum follow-up
of 22 years among 101 consecutive renal transplant recipi-
ents; 30% chronic decline in inverse serum creatinine was
reported to be a good predictor of late renal allograft
failure.16
Serum creatinine has also been validated as a surrogate
endpoint in kidney transplantation clinical trials.17 Fitzsim-
mons et al demonstrated the predictive value of serum
creatinine levels during the first 6–12 months, reporting
rates of graft loss over 3 years of 19.3% and 17.0% for
patients with serum creatinine values !1.5 mg/dL at 6 and
12 months, respectively.17 For patients with serum creati-
nine levels !2 mg/dL at 6 and 12 months, the 3-year graft
losses were 24.6 and 26.5%, respectively.17 Paraskevas et al
established that serum creatinine at 1 year after transplan-
tation was the best predictor of graft survival, also corrob-
orating this parameter as a surrogate endpoint for long-
term outcomes after kidney transplantation.18
But not all studies agree with the validity of serum
creatinine as a predictor of long-term survival. Some work-
ers consider creatinine to be a flawed marker, owing to its
variability by gender, race, recipient age, and body
weight.13,14 After adjusting for gender and age in our
analysis, both donor and recipient serum creatinine levels
had predictive effects on long-term posttransplantation
survival. We did not adjust for race because almost all of
our kidney recipients were white.
Several authors have reported that isolated values of
serum creatinine lose significance in the Cox model when
variables expressing evolution of the renal function are
introduced.8,19 Kaplan et al noted that the rate of change in
graft function within the first year after tranplantation
explained the poor predictive value of 1-year serum creat-
inine.15 This proposal was not supported by our study.
Isolated levels of serum creatinine at 1, 6, and 12 months
maintained their significance even after including the
course of creatinine in the first 12 months after transplan-
tation, expressed as "Cr1–6 and "Cr6–12.
Some clinical studies have reported that, creatininemia is
a poor predictor of both chronic transplant dysfunction and
long-term graft failure, because changes in serum creatinine
occur at a late stage in the progression of graft dysfunc-
tion.13,14 We agree that when serum creatinine starts to rise,
chronic structural lesions are already present and it may be
too late for effective intervention strategies. But as a
predictor for long-term graft failure, this parameter can be
used as a surrogate endpoint for prospective studies to
identify early biomarkers to predict renal function decline,
allowing earlier identification or prediction of chronic
transplant dysfunction and/or occurrence of graft failure.
In addition to first-year renal function, we identified
donor age, recipient age and gender, and history of acute
rejection episodes as the most important factors predicting
long-term kidney allograft survival. As expected, female
recipients, recipients of grafts from older donors, and
patients who experience acute rejection episodes were more
likely to develop chronic graft dysfunction and graft failure
than those without these conditions. Somewhat unexpect-
edly, the hazard of death-censored graft loss decreased with
increasing recipient age at transplantation. This finding is
not new in kidney transplantation.20,21 We can not forget
that, for all analyses, patient death with a functioning graft
was not considered to be a graft failure, because the aim of
the present study was identification of predictors for graft
loss due to organ-related problems. In view of the fact that
the most frequent cause of graft failure among older
patients is death with a functioning allograft, the HR of
graft loss decreased with recipient age. One-fourth of our
patients were #32 years old at transplantation, so they had
more time to develop chronic graft dysfunction than older
patients. In contrast, recipients!50 years old had less time.
As widely known, delayed graft function can have a
negative impact on both short- and long-term graft survival.
In the present study, when the data were entered into a
multivariable analysis, neither delayed graft function nor
HLA mismatches predicted graft loss. It is possible that
first-year graft function diluted the impact of delayed graft
function, because serum creatinine levels were the strongest
predictor of chronic graft dysfunction in all models.
Serum creatinine within the first posttransplantation year
shares many features of surrogate endpoints accepted in
other domains, including biologic plausibility and a strong
relationship to the clinical endpoint. Our study confirmed
that the association of serum creatinine with prognosis was
independent of several other predictive factors. We think
that these findings are important to establish creatinine
levels as a surrogate endpoint that will reflect long-term
renal transplant outcomes and be a reliable substitute for
prospective studies designed to identify earlier and more
sensitive markers of graft dysfunction.
In conclusion, in the search for new markers of graft
dysfunction, it is of great significance to choose a suitable
endpoint for analysis. The present study was the first
approach to validate serum creatinine levels within the first
year after transplantation as an alternative endpoint of late
chronic graft dysfunction. The findings confirmed that renal
function in the first year after transplantation can be
regarded as a variable predicting long-term renal graft
survival.
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4.2. STUDY II 
NGAL: A PROMISING MARKER OF GRAFT DYSFUNCTION AND A PREDICTOR OF ONE-YEAR 
GRAFT FUNCTION  
Fonseca I, Oliveira JC, Almeida M, Cruz M, Malho A, Martins LS, Dias L, Pedroso S, 
Santos J, Lobato L, Henriques AC, Mendonça D. Neutrophil Gelatinase-Associated 
Lipocalin in kidney transplantation is an early marker of graft dysfunction and is 
associated with one-year renal function. J Transplant. 2013; 2013: 650123. doi: 
10.1155/2013/650123.  
 
When this study was designed only two studies on this topic had been published in the 
field of kidney transplantation.164, 169 When the sample collection was initiated (December 
2010) a third study was published71 (Hall et al. 2010). In other words, very little was known 
at that time about the usefulness of NGAL in the renal transplant setting.   
The primary goals were to examine the longitudinal changes of the uNGAL within the first 
week after kidney transplantation, evaluate uNGAL as an early marker of delayed graft 
function, and determine its association with one-year graft function. Urinary NGAL was the 
first biomarker studied within the prospective component of the PhD studies using the 
same cohort. Forty adult, consecutive patients with ERSD undergoing kidney transplant 
surgery were prospectively enrolled.  
  Eighteen of them (45%) experienced DGF and displayed median uNGAL concentrations 
that were persistently higher at all measured timepoints compared than those in patients 
with immediate recovery of their graft function (non-DGF).  
  The curve of reduction of the uNGAL levels appeared very different between patients 
with and without DGF. Shortly after transplantation, patients with DGF displayed a 
significant increase in the uNGAL levels reaching median levels higher than 800 ng/ml 
and a reduction from the fourth day. In recipients with prompt graft function, the uNGAL 
levels decreased immediately and rapidly until reaching median values below 150 ng/ml 
within the first 24 h after transplantation.   
  The association of DGF with longitudinal changes in uNGAL was studied using a linear 
mixed-effects model, by controlling for variables that were found to be associated with 
uNGAL with bivariate analysis. The pre-transplant time on dialysis, time measurement of 
uNGAL and DGF were independently associated with the uNGAL levels, and the prompt 
function recipients had, on average, lower levels of uNGAL at all timepoints. According 
to our estimation, for a patient with a dialysis time of approximately 4.1 years, the initial 
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values of uNGAL (3-6 h after transplantation) are approximately 242 ng/mL higher in 
patients who went on to develop DGF, and these values increase even more in the 
subsequent days. A significant interaction between the time of measurement and DGF 
confirmed that longitudinal changes in the uNGAL levels depend on whether the 
recipient had or had not undergone DGF.   
  Receiver-operating characteristic (R.OC) curves showed uNGAL on the first 
postoperative days were moderately accurate in predicting DGF with areas under the 
ROC curves (A.UC-R.OC) of 0.77 and 0.88, respectively, 3 to 6 h and 8 to 12 h after 
surgery and were highly accurate for the second, fourth, and seventh day (0.96, 0.99 
and 0.93, respectively). The diagnostic performance of uNGAL was better than of SCr at 
all timepoints and was quite similar to that of CysC.  
  The prognostic value of early uNGAL values on long-term allograft function (one-year 
after kidney transplantation) evaluated via SCr was tested using multivariable linear 
regression analysis. Urinary uNGAL measured on the fourth and seventh days were 
independent predictors of one-year graft function, adjusting for established variables that 
usually affect graft function, including acute rejection episodes and re-hospitalizations 
that occurred during the first post-transplant year. 
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Urinary neutrophil gelatinase-associated lipocalin (uNGAL) has been suggested as potential early marker of delayed graft function
(DGF) following kidney transplantation (KTx). We conducted a prospective study in 40 consecutive KTx recipients to evaluate
serial changes of uNGALwithin the first week after KTx and assess its performance in predicting DGF (dialysis requirement during
initial posttransplant week) and graft function throughout first year. Urine samples were collected on post-KTx days 0, 1, 2, 4, and
7. Linear mixed and multivariable regression models, receiver-operating characteristic (ROC), and areas under ROC curves were
used. At all-time points, mean uNGAL levels were significantly higher in patients developing DGF (푛 = 18). Shortly after KTx
(3–6 h), uNGAL values were higher in DGF recipients (on average +242 ng/mL, considering mean dialysis time of 4.1 years) and
rose further in following days, contrasting with prompt function recipients. Day-1 uNGAL levels accurately predicted DGF (AUC-
ROC = 0.93), with a performance higher than serum creatinine (AUC-ROC = 0.76), and similar to cystatin C (AUC-ROC = 0.95).
Multivariable analyses revealed that uNGAL levels at days 4 and 7were strongly associated with one-year serum creatinine. Urinary
NGAL is an early marker of graft injury and is independently associated with dialysis requirement within one week after KTx and
one-year graft function.
1. Introduction
Delayed graft function (DGF) is an important complication
of kidney transplantation (KTx) that adversely affects allo-
graft survival. Despite substantial improvements in the field
of KTx, the incidence of DGF is rising with the growing
practice of accepting expanded criteria donors to increase
transplantation rates [1–6]. Delayed graft function predis-
poses kidney graft to acute and chronic rejection, contributes
to progressive allograft dysfunction, and increases the risk of
premature graft loss [7–11].
Reliable biomarkers enabling early discrimination of
DGF in KTx are lacking, which impairs timely therapeutic
interventions. Traditionally, acute graft dysfunction is diag-
nosed by measuring serum creatinine, but this parameter
is an unreliable indicator of kidney function during an
episode of acute injury [12]. One of the most promising
biomarkers of acute kidney injury is neutrophil gelatinase-
associated lipocalin (NGAL), which is released to blood
from activated neutrophils during inflammatory processes.
In steady situations, this lipocalin is found in urine only in
trace. Massive NGAL quantities excreted in urine (uNGAL)
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usually indicate damage of proximal tubular cells [13–15].
Graft injury due to ischemia-reperfusion is an inevitable
consequence of KTx procedure and can result in varying
degrees of early graft dysfunction, which can be considered
a form of posttransplantation acute kidney injury. For this
reason, several studies investigated the utility of NGAL for
the diagnostic and prognostic of acute graft dysfunction
following KTx [16–27]. Recently, the prognostic value of
uNGAL on graft function at one-year after transplantation
was also examined and presented conflicting findings [22,
28].
In order to support the usefulness of uNGAL as a reliable
marker of graft injury and to clarify the role of this promising
biomarker in the prediction of kidney function beyond the
first week after transplant, we conducted a prospective study
to
(a) evaluate longitudinal changes of uNGAL levels over
the first week after KTx and identify factors associated
with these changes;
(b) assess the performance of uNGAL in predicting DGF
(defined as the requirement for dialysiswithin thefirst
7 days after transplantation);
(c) appraise the long-term prognostic value of uNGAL
measured within one week posttransplantation on
kidney allograft function, evaluated by one-year
serum creatinine.
2. Subjects and Methods
Consecutive patients with end-stage renal disease, undergo-
ing living or deceased KTx at Centro Hospitalar do Porto,
fromDecember 2010 toMay 2011were prospectively enrolled.
Recruitment excluded patients less than 18 years old and
those who required a combined pancreas or liver KTx. After
transplant, patients with primary graft failure related to
surgical causes were excluded. This study was approved by
Institutional Review Board of Centro Hospitalar do Porto.
Each participant provided written informed consent before
enrolment.
2.1. Sample Collection and Measurements. Urine samples for
NGAL determination were collected 3 to 6 h after surgery
(uNGAL0 or baseline); on the following morning, nearly
8 to 12 h after graft reperfusion (uNGAL1 or first day);
and then at second (uNGAL2), fourth (uNGAL4), and
seventh days (uNGAL7), for a total of five samples for each
patient.The same laboratory technician, who was blinded to
patient information, performed uNGALmeasurements using
a two-step chemiluminescent microparticle immunoassay
on a standardized clinical platform (ARCHITECT, Abbott
Diagnostics).
Serum creatinine levels were determined preoperatively,
daily until hospital discharge, and at 1, 3, 6, and 12months
after transplantation to evaluate later graft function. Serum
creatinine measurements were performed by Jaffe´ method
(RocheDiagnostics). Cystatin Cwasmeasuredwith a particle
enhanced immunonephelometric method (Siemens Diag-
nostics) at the same time points as uNGAL, except for
baseline.
2.2. Definitions. Delayed graft function was defined, accord-
ing to United Network for Organ Sharing, as the requirement
for dialysis within the first seven days after KTx, due to
an absence or irrelevant improvement in graft function.
Complementarily, graft function was considered “prompt”
(non-DGF) if no dialysis was required during the first week
after transplantation.
Acute Rejection was defined as either biopsy-proven
rejection or antirejection treatment without biopsy.
Estimated Glomerular Filtration Rate (eGFR) was calcu-
lated using theRule’s refittedMDRD formula [29], considered
to have an improved diagnostic performance and better
accuracy of the true GFR in KTx recipients [30].
Creatinine Reduction Rate (%) was calculated as the
difference between serum creatinine at day 2 (or day 4) and
day 1, divided by serum creatinine at day 1, multiplied by 100.
Graft function at one year was evaluated by the average
of the two serum creatinine levels measured closer to one
year after KTx (e.g., by the average values seen at 12 and
13months). It was thought that this would reflect more
accurately the usual graft function, since a single measure
could bemore easily inflated by acute situations, like a urinary
infection for example. Two grafts were lost at seventh and
eighth months and the last serum creatinine presented by
these patients prior to dialysis restart was considered as being
the one-year creatinine.
2.3. Statistics. Kolmogorov-Smirnov test was performed to
assess deviation from normal distribution. Quantitative vari-
ables were summarized asmean and standard deviation (SD),
or asmedian and 25th–75th quartiles (interquartile range) for
variableswith skewed distribution. Categorical variableswere
reported as percentages.
Statistical analysis was performed in five steps. Firstly,
a cross-sectional bivariate analysis was done to compare
groups and study the association between uNGAL and
demographic/clinical variables. Continuous variables were
compared using either parametric (t-test) or nonparamet-
ric (Mann-Whitney) tests. Associations between categorical
variables were analyzed using the 휒2 test and Fisher’s exact
test as appropriate. Correlations between uNGAL and con-
tinuous variables were assessed using Pearson correlation
and uNGAL levels were log-transformed (ln) before analysis.
Spearman correlationwas used to analyze uNGAL and serum
creatinine reduction ratio on posttransplant days 2 and 4.
Secondly, we used a longitudinal analysis to study uNGAL
kinetics and modelling it as a response variable on time. A
linear mixed-effects model was used to study the association
of DGF with serial changes of uNGAL (log-transformed),
controlling for donor status (living/deceased), recipient’s age,
time on dialysis, and time measurement of uNGAL. The
interaction between DGF and uNGAL time measurement
was included in the model, as such a significant interaction
would suggest that DGF affects the uNGAL levels trajectory.
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Thirdly, receiver-operating characteristics analysis was
performed to estimate the sensitivity and specificity of
uNGAL (as well as serum creatinine and cystatin C) to
predict DGF.The optimal cut-off points were determined by
maximizing the sum of sensitivity and specificity.
Fourthly, multivariable logistic regression analysis was
undertaken to evaluate whether uNGAL levels were indepen-
dently associated with DGF. Pretransplant variables known
to be associated with DGF and considered potential con-
founders were included in the models. To avoid collinearity
each time point uNGAL was included separately in different
models. The final models were fitted using a backward
selection procedure.
Fifthly, multivariable linear regression was used to
describe the independent association of uNGAL with renal
function at 12months evaluated by serumcreatinine, adjusted
for the variables that usually predict graft function, including
donor status, rehospitalizations, and acute rejection episodes
throughout the first year. Linear regression models used
log-transformed uNGAL and serum creatinine levels. As in
logistic models, uNGAL at each time point were included
separately in models to avoid collinearity.
All statistical analyses were done with SPSS version 20.0
and a significance level of 0.05 was considered.
3. Results
During time recruitment, 42 patients were enrolled. Two
recipients had renal artery thrombosis and were excluded in
the first two posttransplantation days. Therefore our study
sample included 40 recipients. Baseline data are shown in
Table 1.
3.1. Urinary NGAL. The first urine sample (uNGAL0) was
obtained from 30 patients. On the following days, urine
samples were collected from 35 patients at the first, second,
and seventh days, and from 36 patients at the fourth day.
All of our subjects provided at least two urine samples.
Only, one patient provided merely two urine samples and the
remaining 39 subjects provided 3 ormore urine samples (with
20 patients providing all five samples).
Daily median uNGAL levels did not differ significantly
between male and female recipients, except for the seventh
day where female uNGAL levels were significantly higher.
Concerning donor status, uNGAL levels were higher in
deceased donor recipients at all-time points, but only sta-
tistically significant at second day. Except for the seventh
day, uNGAL levelswere significantly andpositively correlated
with cold ischemia time (푟 = 0.45, 푃 = 0.02; 푟 = 0.36,푃 = 0.04; 푟 = 0.56, 푃 = 0.001; 푟 = 0.46, 푃 = 0.006, resp.,
at baseline, first, second, and fourth days).
At most time points, uNGAL was positively and signif-
icantly correlated with recipient age (푟 = 0.39, 푃 = 0.02;푟 = 0.39, 푃 = 0.02; 푟 = 0.44, 푃 = 0.007; resp., at first, second,
and seventh days) and pretransplant dialysis time (푟 = 0.48,푃 = 0.008; 푟 = 0.37, 푃 = 0.03; 푟 = 0.43, 푃 = 0.01; 푟 = 0.33,푃 = 0.024; resp., at baseline, first, second, and seventh days).
No significant correlation was found with HLA mismatches
and with donor age and serum creatinine.
Urinary NGAL levels were significantly and positively
correlated with serum creatinine at all-time points (data not
shown). Furthermore, except for uNGAL0, all the remaining
uNGAL levels were significantly and negatively correlated
with changes in serum creatinine between the second and
first days, and also between the fourth and thefirst days: lower
uNGAL values were associated with higher reductions rates
in serum creatinine (data not shown).
Median length of hospitalization after transplantationwas
12 days (IQR: 7–22) and uNGAL levels were highly correlated
with length of hospital stay at all-time points (푟 = 0.48, 푃 =0.002; 푟 = 0.64, 푃 < 0.001; 푟 = 0.79, 푃 < 0.001; 푟 = 0.77,푃 < 0.001; 푟 = 0.82,푃 < 0.001, resp., at baseline, first, second,
fourth, and seventh days).
3.2. DGF and uNGAL Longitudinal Changes. Eighteen recip-
ients (45%) had DGF, three of these were from living donors,
and 22 (55%) had prompt graft function. Concerning tradi-
tional predictors of DGF and except for cold ischemia time,
no significant differences were found between DGF/non-
DGF in relation to baseline characteristics and induction
therapy (Table 1). Mean age was significantly higher in
patients with DGF (56 (11) versus 43 (16) years in non-DGF
recipients, 푃 = 0.006). As expected, patients with DGF had
higher serum creatinine levels (Table 2) and lower creatinine
reduction ratios on posttransplant days 2 and 4.
Similar to serum creatinine, median uNGAL concen-
trations were consistently higher in DGF group compared
with non-DGF group at all measured time points (Table 2
and Figure 1). In patients with prompt graft function, the
longitudinal changes of uNGAL were characterized by an
initial phase with a rapid decline and then a phase with a
slower decrease continuing throughout the posttransplant
week.This pattern of changes was different inDGF recipients:
uNGAL levels increased frombaseline to the followingmorn-
ing after transplantation and remained elevated throughout
most of the follow-up period.
A linear mixed-effects model was used to study the
association of DGF with longitudinal changes of uNGAL,
controlling for variables found to be associated with uNGAL
by bivariate analysis. Pretransplant time on dialysis, time
measurement of uNGAL, and DGF were independently
associated with uNGAL levels. Adjusting for the remaining
variables, donor status and recipient age lost their statistical
significance andwere removed from thefinalmodel (Table 3).
Delayed graft function was significantly associated with
uNGAL levels, with prompt function recipients having on
average lower levels of uNGAL at all-time points. According
to our estimation, for a patient with dialysis time of approx-
imately 4.1 years, the initial values of uNGAL (3–6 h after
transplantation) are about 242 ng/mL higher in patients who
went on to develop DGF, and these values will rise even
more in the following days. A significant interaction between
time of measurement and DGF confirmed that longitudinal
changes of uNGAL levels depend on whether the recipient
had DGF or not. To clarify the meaning of this interaction,
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Table 1: Summary of baseline and clinical characteristics in kidney transplant donors and recipients (total sample and categorized by delayed
or prompt graft function).
Total (푛 = 40) DGF (푛 = 18) Non-DGF (푛 = 22) 푃 value
Donor
Age (yr) 51.2 ± 11.4 51.1 ± 13.4 51.2 ± 9.9 0.172
Male gender 26 (65) 14 (78) 12 (54.5) 0.125
Living donor 11 (27.5) 3 (16.7) 8 (36.4) 0.165
Expanded criteria donors 3 (7.5) 1 (5.6) 2 (9.1) 0.541
Serum creatinine (mg/dL) 0.81 ± 0.18 0.85 ± 0.21 0.78 ± 0.16 0.318
Donor-recipient
HLA mismatches 3.39 ± 1.24 3.38 ± 1.07 3.41 ± 1.46 0.941
Cold ischemia time (h) 12.1 ± 7.9 15.2 ± 7.8 9.6 ± 7.3 0.035∗
Living donor 2.8 ± 0.5 2.5 ± 0.5 3.0 ± 0.5 0.204
Deceased donor 16.2 ± 5.9 18.1 ± 5.1 14.1 ± 6.2 0.088
Recipient
Age (yr) 49.2 ± 15.2 56.3 ± 10.9 43.3 ± 15.9 0.006∗
Male gender 26 (65) 11 (61) 15 (68) 0.641
Caucasian 40 (100) 18 (100) 22 (100) —
BMI (Kg/m2) 24.8 ± 4.9 26.2 ± 4.4 23.6 ± 5.0 0.091
Previous transplant 2 (5) 0 (0) 2 (9.1)
Time on dialysis (yr) 4.4 ± 4.7 5.6 ± 6.2 3.4 ± 2.3 0.135
Pretransplant therapy
Dialysis 38 (95) 18 (100) 20 (90.9) 0.296
Preemptive transplantation 2 (5) 0 (0) 2 (9.1)
Cause of kidney disease
IgA nephropathy 7 (17.5) 2 (11.1) 5 (22.7) —
Glomerulonephritis 6 (15.0) 4 (22.2) 2 (9.1) —
Diabetic nephropathy 5 (12.5) 3 (16.7) 2 (9.1) —
Autosomal dominant polycystic kidney disease 3 (7.5) 3 (16.7) 0 (0) —
Unknown 4 (10.0) 1 (5.6) 3 (13.6) —
Others 15 (37.5) 5 (27.8) 10 (45.5) —
Peak PRA (%) 5.5 ± 15.1 5.0 ± 15.0 5.9 ± 15.5 0.853
0 29 (72.5) 14 (77.8) 15 (68.2) —
1–25 8 (20.0) 3 (16.7) 5 (22.7) —
26–75 3 (7.5) 1 (5.6) 2 (9.0) —
Current PRA (%) 2.3 ± 8.6 3.1 ± 11.7 1.6 ± 4.9 0.585
0 34 (85) 15 (83.3) 19 (86.4) —
1–25 5 (12.5) 2 (11.1) 3 (13.6) —
26–50 1 (2.5) 1 (5.6) 0 (0) —
Induction regimen
Antithymocyte globulin (ATG-F) 4 (10) 1 (5.6) 3 (13.6) 0.613
Basiliximab/daclizumab 30 (75) 14 (77.8) 16 (72.7) 0.789
Immunosuppression at time of discharge
Steroids 38 (95.0) 18 (100) 20 (90.9) 0.296
Tacrolimus 38 (95.0) 17 (94.4) 21 (95.5) 0.886
Cyclosporine A 2 (0.05) 1 (5.6) 1 (5.6) 0.884
Values are expressed as mean ± standard deviation or absolute numbers and percentages. Comparisons between continuous variables were done using
parametric (푡-test) or nonparametric (Mann-Whitney) tests; associations between categorical variables were analyzed using the 휒2 test and Fisher’s exact test
as appropriate; ∗푃 < 0.05.
Abbreviations: HLA: human leukocyte antigen; BMI: body mass index; PRA: panel reactive antibody.
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Table 2: Serial levels of serum creatinine and uNGAL through the first posttransplant week, according to graft function (delayed or prompt).
Serum Creatinine
(mg/dL)
Median, (IQR)
Prior transplantation 1st day
∗
(푛 = 40, 18 DGF) 2nd day(푛 = 40, 18 DGF) 4th day(푛 = 40, 18 DGF) 7th day(푛 = 40, 18 DGF)
DGF (푛 = 18) 7.5(6.0–11.7) 8.2(6.5–9.3) 7.5(5.9–8.5) 6.9(6.1–8.0) 6.4(5.3–8.9)
Non-DGF (푛 = 22) 7.8(5.1–9.4) 6.3(4.6–7.9) 4.3(2.8–6.1) 2.5(1.6–3.2) 1.9(1.4–2.4)
Urine NGAL (ng/mL)
Median, (IQR)
3 to 6 h after surgery
(푛 = 30, 13 DGF) 1st day∗(푛 = 35, 14 DGF) 2nd day(푛 = 35, 15 DGF) 4th day(푛 = 36, 15 DGF) 7th day(푛 = 35, 16 DGF)
DGF (푛 = 18) 647(328–1648) 866(500–1256) 834(510–2632) 851(549–1643) 407(106–1249)
Non-DGF (푛 = 22) 256(105–446) 129(64–306) 80(29–138) 47(36–91) 34(26–57)∗1st day = 8 to 12 h after surgery; values are medians and interquartile range (25th to 75th percentile).
Abbreviations: uNGAL: urinary neutrophil gelatinase associated lipocalin; IQR: interquartile range; DGF: delayed graft function; non-DGF: prompt function.
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Figure 1: Evolution of uNGAL levels through first week after
transplantation, according to graft function.Abbreviations: uNGAL:
urinary neutrophil gelatinase associated lipocalin; DGF: delayed
graft function.
Figure 2 shows the predicted uNGAL trajectories over time
for four hypothetical subjects: two recipients who developed
DGF (one with 4 years of dialysis and one with 10 years), and
two other patients with prompt graft function (similar time
on dialysis, 4 and 10 years). Hypothetically, the remaining
variables were equal in all four patients. The predicted
uNGALvalueswere estimated using the coefficients estimates
of Table 3 (e.g., the predicted uNGAL values at the first day
for a recipient with 4 years of dialysis with prompt function =
exp [(5.46 − 2.14) + 0.94 + 0.4 + (0.076 ∗ 4 years of dialysis)]
= 158 ng/mL).
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Figure 2: Predicted uNGAL values over time of four hypothetical
subjects, estimated from multiple linear mixed model presented
in Table 3. Abbreviations: uNGAL: urinary neutrophil gelatinase
associated lipocalin;DGF: delayed graft function; non-DGF: prompt
graft function.
3.3. Prediction of DGF by uNGAL Levels (ROC analy-
sis). Receiver-operating characteristic (ROC) curves showed
uNGAL on the first postoperative days were accurate in
predicting DGF (Tables 4 and 5). Table 4 displays the derived
sensitivities, specificities, and predictive values for uNGAL
at the cutoff concentrations that provided the maximum
sum of sensitivity and specificity. Regarding the areas under
the ROC curves (AUC), the ability of uNGAL to predict
DGF was moderately accurate at baseline and first day, and
highly accurate at second, fourth, and seventh days (Table 5,
Figure 3). In the first two posttransplant days the diagnostic
performance of uNGAL was better than of serum creatinine,
and quite similar to that of cystatin C.The reduction in serum
creatinine between first and second days resulted in AUC
= 0.78 [0.64–0.92] and was worse than uNGAL for DGF
prediction.
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Table 3: Results of the final linear mixed model for dependent variable ln(uNGAL) (푛 = 171 observations derived from 40 patients).
Coefficient estimate P value 95% CI
Intercept 5.46 <0.001 4.94 5.98
Graft function
DGF = 0 (prompt graft function) −2.04 <0.001 −2.64 −1.44
DGF = 1 (with DGF-reference) 0 — — —
Time
Time (3 to 6 h after surgery) 0.47 0.088 −0.07 1.00
Time (1st day) 0.94 0.001 0.41 1.47
Time (2nd day) 1.01 <0.001 0.49 1.53
Time (4th day) 1.02 <0.001 0.50 1.54
Time (7th day-reference) 0 — — —
Time∗DGF
Time (3 to 6 h after surgery)∗DGF = 0 1.40 <0.001 0.68 2.13
Time (1st day)∗ DGF = 0 0.40 0.257 −0.29 1.10
Time (2nd day)∗ DGF = 0 −0.37 0.295 −1.06 0.32
Time (4th day)∗DGF = 0 −0.73 0.039 −1.42 −0.03
Time (7th day)∗DGF = 0 (reference) 0 — — —
Time on dialysis 0.076 0.003 0.03 0.12
Abbreviations: uNGAL: urinary neutrophil gelatinase associated lipocalin; ln: natural logarithm; DGF: delayed graft function (DGF = 0, no delayed graft
function).
Table 4: Sensitivity, specificity, and predictive values for DGF using specific uNGAL cut-off values.
Time after transplant uNGAL cutoff (ng/mL) Sensitivity (%) Specificity (%) PPV NPV
Shortly after surgery (3 to 6 h) 479 77 88 87 79
1st day (8 to 12 h after surgery) 286 100 76 81 100
2nd day 277 93 90 90 93
4th day 232 93 95 95 93
7th day 63 94 84 86 93
DGF: delayed graft function; uNGAL: urinary neutrophil gelatinase-associated lipocalin; PPV: positive predictive value; NPV: negative predictive value.
3.4. Independent Association of uNGAL Levels and DGF
(Multivariable Analyses). Multivariable logistic regression
analyses revealed that uNGAL levels remained independently
associated with DGF at most time points, after adjusting for
clinically relevant risk factors for DGF (Table 6). Further-
more, recipient age was the other significant independent
predictor of DGF in almost all models. To be more clinically
relevant, estimates of DGF risk were converted to every
50 ng/mL of increase in uNGAL or per each 5 years of
increase in age, instead of estimates per each unit of increase.
3.5. Within One-Year after Kidney Transplantation. During
the first year, 10 KTx recipients were rehospitalized account-
ing for a total of 19 hospital admissions. There was one
rehospitalization in six patients, two in two patients, three
in one patient, and six rehospitalizations in one patient
with a psychological disorder and suicidal ideation. The
causes of rehospitalization were infection in five admissions
(mostly, urinary tract infection), renal dysfunction in six, and
nonrenal causes in the remaining eight admissions (suicidal
ideation, acute pulmonary edema, and neutropenia).
Excluding the recipient with several rehospitalizations
due to psychological decompensation, the length of hospital
stay of the remaining recipients admissions was 7 [3] days,
and no significant differences were found between recipients
from living or deceased donors.
The acute rejection episodes were collected throughout
the first posttransplant year. Ten recipients (25%) had an
acute rejection episode during inpatient hospitalization for
transplant surgery, and only one patient was rehospitalized
one month after KTx with an acute rejection episode con-
firmed by biopsy.
At one year after transplantation, all patients were alive
but two grafts were lost. At this time, the median plasma
creatinine was significantly higher in DGF group compared
to non-DGF: 1.6mg/dL [IQR: 1.2–2.5] versus 1.3mg/dL [IQR:
1.0–1.5], 푃 = 0.049.
3.6. Prognostic Value of First-Week uNGAL Levels in One-Year
Graft Function. The correlation between uNGAL collected in
the first week after KTx and serum creatinine at one year
was explored. Except for uNGAL collected within the first
24 h after transplantation, uNGAL levels were positively cor-
related with serum creatinine evaluated at time of discharge,
and also at 1, 3, 6, and 12months. Likewise, uNGAL levels at
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Table 5: Area under the receiver-operating characteristic curve at
each time point for uNGAL, serum creatinine, and serum cystatin
C for predicting DGF.
Time after
transplant AUC (95% CI) 푃 value
Urine NGAL
(ng/mL)
Shortly after
surgery (3 to 6 h) 0.77 (0.58–0.97) 0.010
1st day (8 to 12 h
after surgery) 0.88 (0.77–1.0) <0.001
2nd day 0.96 (0.90–1.0) <0.001
4th day 0.99 (0.97–1.0) <0.001
7th day 0.93 (0.86–1.0) <0.001
Serum
creatinine
(mg/dL)
Prior
transplantation 0.56 (0.38–0.74) 0.514
1st day (8 to 12 h
after surgery) 0.77 (0.61–0.93) 0.007
2nd day 0.90 (0.79–1.0) <0.001
4th day 0.95 (0.87–1.0) <0.001
7th day 0.93 (0.81–1.0) <0.001
Serum
cystatin C
(mg/L)
1st day (6 to 12 h
after surgery) 0.90 (0.79–1.0) <0.001
2nd day 0.96 (0.88–1.0) <0.001
4th day 0.95 (0.89–1.0) <0.001
7th day 0.93 (0.83–1.0) <0.001
DGF: delayed graft function; uNGAL: urinary neutrophil gelatinase-
associated lipocalin.
days 2, 4, and 7 were inversely correlated with eGFR at 6 and
12months (data not shown).
The prognostic value of early uNGALvalues on long-term
allograft function (one year after KTx) was tested by mul-
tivariable analysis. In multivariable linear regression models
for serum creatinine at 12months, uNGAL measured on the
fourth and seventh days were independently associated with
one-year graft function, adjusting for established variables
that usually affect graft function, including acute rejection
episodes and rehospitalizations that occurred during the first
posttransplant year (Table 7).
4. Discussion
The major finding of this study is that uNGAL is a promising
biomarker for allograft dysfunction that can be easily and
noninvasively assayed in the early posttransplant period. We
prospectively evaluated uNGAL in a cohort of 40 kidney
allograft recipients during the first posttransplant week. At all
measured timepoints, uNGAL levelswere consistently higher
in patients who developed DGF, including the earliest levels
obtained from the first urine sample collected approximately
3 to 6 h after transplant surgery. At this time, clinical diagnosis
of DGF is yet not possible, but a simple and noninvasive
test can already recognize kidney dysfunction and stratify
patients according to likelihood of requiring posttransplant
dialysis.
It would be ideal to diagnose graft dysfunction with an
early and highly sensitive biologic marker of renal tubular
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Figure 3: Receiver-operating characteristic curves for uNGAL,
serum creatinine and changes in serum creatinine, and serum
cystatin C measured at posttransplant days 1 and 2 for predicting
delayed graft function. Abbreviations: uNGAL: urinary neutrophil
gelatinase associated lipocalin; Creat: serum creatinine; Cyst: serum
CystatinC;Creat2-Creat1: creatinine reduction rate between thefirst
and the second day.
injury. One of the most promising markers is NGAL, and our
findings provide further information for the use of uNGAL as
a diagnostic and prognostic tool for DGF. According to our
estimation, uNGAL values shortly after transplant surgery
will be much higher in patients who went on to develop
DGF and will rise further in the following days. In contrast,
patients with prompt function will have lower levels, which
decrease consistently along the week.The kinetics of changes
in these recipients compared to those who presented DGF is
quite different. It seems that, not only the baseline levels, but
also the pattern of uNGAL longitudinal changes can reflect
graft dysfunction.
The association between higher NGAL levels and DGF
after KTx has been previously published [16, 20, 22, 24, 25].
But the findings are not consistent regarding the kinetics of
uNGAL according to DGF. Hollmen et al. [22] found initial
levels of uNGAL higher inDGF patients, but on the following
day a decrease was observed, as it happened with recipients
with prompt function. As mentioned before, our study
did not confirm this declining in DGF patients. Recipients
who went on to develop DGF had initial higher levels of
uNGAL that rise further on the following posttransplant
days, differing from patients with prompt graft function.
Our findings are in agreement with results reported by Hall
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Table 6: Association of uNGAL with delayed graft function by multivariable analysis (logistic regression).
Delayed graft function
OR adjusted∗ 푃 value 95% CI
Model 1 (uNGAL at 3 to 8 h after surgery)
uNGAL0 (per 50 ng/mL of increase) 1.15 0.044 1.01–1.31
Recipient age (per 5 years of increase) 1.49 0.054 0.99–2.24
Model 2 with (uNGAL at day 1)
uNGAL1 (per each 50 ng/mL of increase) 1.22 0.012 1.05–1.42
Recipient age (per 5 years of increase) 1.99 0.022 1.11–3.57
Model 3 (uNGAL at day 2)
uNGAL2 (per each 50 ng/mL of increase) 1.35 0.004 1.10–1.66
Model 4 (uNGAL at day 4)
uNGAL4 (1 ng/mL increase) 3.01 0.035 1.08–8.40
Model 5 (uNGAL at day 7)
uNGAL7 (per each 50 ng/mL of increase) 1.43 0.050 1.01–2.04
Recipient age (per 5 years of increase) 1.73 0.038 1.03–2.90
Note: results given by logistic regression (backward Wald test).
Abbreviations: OR: odds ratio; 95% CI (95% confidence interval); uNGAL: urinary neutrophil gelatinase-associated lipocalin.∗Adjusted for pretransplant time on dialysis, recipient gender and age, and donor age.
Table 7: Significant factors associated with serum creatinine at one year after kidney transplantation.
Regression coefficient adjusted∗ 푃-value 95% CI
Model with uNGAL at day 4
Donor gender (male versus female) 0.042 0.004 0.015–0.069
Donor age (years) 0.011 0.008 0.003–0.020
uNGAL4 (ln, ng/mL) 0.067 0.045 0.002–0.132
Model with uNGAL at day 7
Time on dialysis (ln, ng/mL) 0.042 0.004 0.015–0.069
Donor age (years) 0.018 0.002 0.008–0.029
uNGAL7 (ln, ng/mL) 0.138 0.007 0.041–0.235
Note: results given by multiple linear regression; serum creatinine (ln) at 12 months as the dependent variable. Only the significant variables associated with
serum creatinine are displayed. Abbreviations: uNGAL: urinary neutrophil gelatinase-associated lipocalin.∗Adjusted for donor status, donor age, recipient age and gender, pretransplant time on dialysis, rehospitalizations, and acute rejection episodes throughout the
first year.
et al. [24]. It seems that, above and beyond the markedly
higher levels of uNGAL in patients with graft dysfunction,
the contrasting pattern of uNGAL longitudinal changes can
distinguish recipients who will need dialysis in the first week
posttransplantation.
To the best of our knowledge, this is the first report
that used linear mixed analysis in describing longitudinal
changes of uNGAL in the first week following KTx. Multiple
observations of a variable on a particular patient are likely
to be positively correlated, so they should not be treated as
independent measurements. Although models that take this
design into consideration are more complicated, they are also
more specific and powerful since they permit the study of
changes over time. Linear mixed analysis not only permits
to model individual changes over time, but also is able to
distinguish within-subject from between-subject sources of
variation [31].
In accordance with previously published data [16, 20–
22, 24], we confirmed the good performance of NGAL in pre-
dicting graft dysfunction in the early posttransplant period.
Using ROC analysis, our study also corroborates uNGAL
as a good diagnostic marker on identifying patients with
graft dysfunction and who subsequently required dialysis.
TheAUC-ROC for uNGALwasmoderately accurate forDGF
prediction within the first day after transplant, and it was
excellent at day 2 and day 4. We also determined the paired
sensitivity and specificity for the cutoff value of uNGAL,
calculated to be closest to the left upper corner of the ROC
space to predict DGF. At 8 to 12 h after surgery, a cutoff of
286 ng/mL had 100% sensitivity and 76% specificity for the
identification of DGF. Within the second day, uNGAL levels
higher than 277 ng/mL predicted DGF with a sensitivity
of 93% and specificity of 90%. Other studies showed also
impressive results. Parikh et al. [16] in a study that included 53
patients undergoing KTx, measured NGAL in urine samples
collected within the first 24 h following transplantation and
reported an AUC-ROC of 0.9, similar to ours obtained 8
to 12 h after surgery. Another study [24] conducted in 91
recipients evaluated uNGAL within 6 h after transplantation
and predicted subsequent DGF with an AUC-ROC = 0.81.
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Most recently, Hollmen et al. [22] undertook a large cohort
study that included 176 KTx recipients. Urine was collected
before transplant, at then at days 1, 3, 7, and 14, and uNGAL
was measured at each time point. The authors found and
AUC-ROC = 0.74 at day 1.
We report a superior performance of uNGAL level for
predicting DGF over serum creatinine measured at the same
time. UrinaryNGALmeasured at the first day predictedDGF
with an AUC-ROC of 0.93, which is markedly better than an
AUC-ROC = 0.76 shown by serum creatinine measured in
the same day, and also than an AUC-ROC = 0.83 obtained
from creatinine reduction ratio from first to second day,
but quite similar to cystatin C (0.95), a marker considered
more accurately to detect changes in renal function [32–
35]. Furthermore, our analyses also revealed that uNGAL
levels predicted DGF, even after adjusting for pretransplant
variables known to be traditionally associated with DGF.
Besides DGF, the other factors that significantly influ-
enced uNGAL levels were previous time on dialysis, recip-
ient’s age at time of transplantation and cold ischemia
time. These three variables were positively correlated with
uNGAL values. Mishra and coworkers [17] have shown
that the immunohistochemical staining intensity for NGAL
was strongly correlated with cold ischemia time and NGAL
expression was significantly increased in deceased donor
biopsies. We found that uNGAL levels were higher in graft
recipients fromdeceased donors, but only significantly higher
at the second day. It is known that prolonged cold preserva-
tion of kidneys can lead to severe injury, which is critical in
the success of deceased-donor kidney transplantation [36].
However, there is a progressive effort of our transplant team
to avoid prolonged cold preservation. Maybe this attempt
attenuated the effect of cold ischemic injury in kidneys
from deceased donors, which become comparable to living
donors concerning uNGAL values. An interesting finding
of our study was that uNGAL levels at all-time points were
correlated with length of hospital stay. It is well known
that the occurrence of DGF prolongs the recipient’s hospital
stay. And it is worthy of note to realize that patients with
early higher levels of uNGAL will expect longer time of
hospitalization, probably due to graft dysfunction.
As other studies [16–19, 24, 26, 37], we confirmed that
uNGAL levels were inversely correlated with eGFR and
positively correlated with serum creatinine at each measured
time point. We also showed that not only in the first week,
but longer after that, uNGAL levels measured in the first
seven days after KTx were still predictive of graft function
throughout the first year after transplantation. Even after
adjusting for donor status, acute rejection episodes, hos-
pitalizations occurred in the first year, and other known
variables that usually affect graft function, uNGAL evaluated
at days four and seven were predictive of one-year serum
creatinine, which can be considered a surrogate marker of
long-term graft survival [38, 39]. In contrast, Hollmen and
coworkers study [22] did not find any correlation between
uNGAL and renal function at one year. In their study, uNGAL
collected in the first two weeks after transplantation was only
correlated with renal function up to 3months. Our results do
not corroborate this lack of correlation and are in agreement
with a recent study that also associated perioperative uNGAL
levels to one-year allograft function [28].
Our study has several strengths. First, it is a prospective-
cohort design study. Second, we measured uNGAL at several
time points within the first posttransplant week, and not at
one single point. Longitudinal studies have the advantage of
providing detailed information about how a marker changes
over time; however the studies present some statistical com-
plexities, since the customary assumption that all observa-
tions are independent usually does not hold. And this was the
third strength of our study: the use of longitudinal methods
to handle the serial changes of uNGAL. A fourth strength was
the technical determination that we have chosen to measure
NGAL. We used a commercially available kit for uNGAL
determination (Abbott Architect NGAL), which is simple to
implement in routine practice and it is considered one of the
best methods for detecting acute kidney injury [40].
Similarly to other authors [16, 22], we have chosen to
measure NGAL in urine, instead of blood, since uNGAL
represents tubule damage in the kidney rather than filtration
from blood [14, 41]. An increased level of NGAL in urine
usually indicates injury of proximal tubular cells and seems
to be more specific compared to serum NGAL, which can be
produced by other organs and released into the circulation
following a transplant surgery [42]. Other advantages of
urinary diagnostics include the noninvasive nature of sample
collection and the reduced number of interfering protein
[43]. However, despite the undoubtedly value of urinary
markers of kidney injury, their use in transplant recipients
can be also a drawback because of possible transient graft
anuria, which may preclude the availability of urine and
consequently the lack of sample to measure NGAL. Due
to the shortcoming of urine biomarkers in anuric KTx
recipients, some studies have evaluated the performance of
serum/plasma NGAL in predicting graft function recovery
after KTx [21, 27]. As we did not measure serum/plasma
NGAL values, we could not compare their effectiveness in
predicting DGF in our sample. In our study, 4 or 5 recipients
were anuric in each measurement, resulting in 12% of our
patients not having urine sample to determine uNGAL in that
particular time point. The measurement of serum/plasma
NGAL could have been a valuable alternative in these
recipients, since it could also be obtained noninvasively in
patients who required dialysis during the transient period of
anuria.
Similar to other areas in medicine, in kidney transplan-
tation early diagnosis and timely intervention will improve
outcomes. Ischemic injury of the renal allograft is a critical
early insult that increases the risk of acute tubular necrosis
and long-term graft loss. If DGF could be detected in
the early hours after surgical procedure, maybe a tailored
and more individualized intervention could be achieved.
Perioperative fluid management must ensure the restoration
and maintenance of the intravascular volume, in order to
obtain an appropriate graft function. Aggressive hydration
has been recognized to be effective in avoiding DGF, but
fluid overload may also precipice the need of dialysis with
the risk of hipovolemia and consequent renal ischemia.
Early identification of DGF patients could allow to be more
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judicious and to modify postoperative fluid management
in favor of maintaining just adequate filling pressures to
maintain adequate intravascular volume and prevent fluid
overload [44]. Regarding immunosuppression, the induction
protocol chosen for this group of patients should have the
associated effect of decreasing DGF rates, by suppressing
leukocyte-rich vascular congestion and endothelial injury,
and the introduction of calcineurin inhibitors could be
avoided or delayed due to their vasoconstrictive properties.
Cytomegalovirus (CMV) infection has also direct and indi-
rect effects on transplant graft function, and some previous
evidence has been published relating the association between
the use of ganciclovir and the lower occurrence of DGF
[45]. Nowadays, the prophylaxis with valganciclovir should
be other aspect taken into account in recipients that we know
they will develop DGF, since this prophylaxis may do more
than just delay the occurrence of CMV disease.
Several studies were done in renal transplantation to
identify early biomarkers for the diagnosis of DGF. However,
there is still no routine application of any of these markers
in clinical transplantation.The present study clearly support
that uNGAL represents an early marker of graft injury and
is strongly associated with dialysis-based diagnosis of DGF
and one-year graft function. Other studies are necessary to
clarify the genesis and sources of plasma and urinary NGAL
and validate the accuracy of uNGAL as a diagnosticmarker of
renal graft injury and predictor for DGF in assorted centres,
across different practices and sets of variables.
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4.3. STUDY III 
OXIDATIVE STRESS IN KIDNEY TRANSPLANTATION  
Fonseca I, Reguengo H, Almeida M, Dias L, Martins LS, Pedroso S, Santos J, Lobato L, 
Henriques AC, Mendonça D. Oxidative Stress in Kidney Transplantation: 
Malondialdehyde is an early predictive marker of graft dysfunction. Transplantation 2014; 
97: 1058-65.           
Printed with permission, Wolters Kluwer Health Lippincott Williams & Wilkins© July, 2014 
Ischemia-reperfusion injury is an inevitable phenomena of kidney transplantation and 
oxidative stress is a significant component of this process. Oxygen free radicals and 
impaired antioxidant activity are some of the most likely agents responsible for initiating 
the damage associated with reperfusion injury in kidney transplantation. Given this, and 
following the same methodology of the study II, this research was designed to evaluate 
longitudinal changes of a lipid peroxidation marker (MD.A) and some antioxidant 
parameters (TAS, SOD, GPx, and GR) in the first week after kidney transplantation and to 
identify the factors that are associated with these changes as well as investigate their 
accuracy in predicting DGF and one-year graft function as evaluated by SCr. 
The main results are described below: 
  After transplantation, the mean MDA levels were consistently higher in DGF patients at 
all timepoints than in non-DGF recipients, but no differences were found in relation to 
the antioxidant parameters.  
  Using a linear mixed-effects model to analyze the longitudinal changes of MDA by the 
two groups of patients (DGF/ non-DGF) by controlling for variables that were found to be 
associated with MDA levels by bivariate analysis (donor status and recipient age), we 
confirmed the independent association of DGF with the MDA levels. The donor status 
and recipient age lost their statistical significance and were removed from the final 
model. The time measurement of MDA and DGF were the only independent factors 
associated with the MDA levels, and recipients who had prompt function had, on 
average, lower levels of MDA at all timepoints. According to our estimation, the first 
values of MDA after transplantation were 0.16 µmol/L higher in patients who went on to 
develop DGF. A significant interaction between the time of measurement and DGF 
confirmed that longitudinal changes in the MDA levels depend on whether the recipient 
developed DGF or not. 
  The effect of DGF on the progression of antioxidant parameters over time was not 
statistically significant. 
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  Receiver-operating characteristic analyses were performed to assess the potential of 
oxidative markers to predict DGF. Only the MDA levels at all post-transplant timepoints 
predicted the need for dialysis within the first week. The level of MDA at day-1 was a 
very good predictor for the early diagnosis of DGF (AUC=0.90), and its diagnostic 
accuracy was better than the performance of SCr (AUC=0.73) and quite similar to that of 
CysC (AUC=0.91), which is considered a marker with a great sensitivity for detecting 
impaired renal function and kidney tubular injury.  
  The prognostic value of early values of MDA on long-term allograft function (one-year 
after kidney transplantation) as evaluated by SCr was tested by multivariable regression 
analysis. The MDA levels measured on day-7 were independent predictors of the one-
year graft function after controlling for established variables that usually affect graft 
function. The levels of MDA before Kidney transplantation and on post-transplant 
remaining days were not significant predictors of the one-year SCr. 
 
 
 
ERRATA:  
Page 75. Paper III, Fig. 1, after the ROC curves graph and before the legend, the table with the 
biomarkers AUCs was not printed in the paper. 
 
  AUC (95% CI) P-Value 
  Day 1 (8-to-12 h after surgery)   
MDA (µmol/L)   0.90 (0.81 - 0.99)  < 0.001 
Serum Creatinine (mg/dl)  0.73 (0.58 - 0.89) 0.012 
Serum Cystatin C (mg/L)  0.91 (0.82 - 1.00)  < 0.001 
Change from pre-transplant to first day after KTx   
MDA (µmol/L)   0.84 (0.70 - 0.97)  < 0.001 
Serum Creatinine (mg/dl)  0.69 (0.52 - 0.87) 0.036 
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Oxidative Stress in Kidney Transplantation:
Malondialdehyde Is an Early Predictive Marker of
Graft Dysfunction
Isabel Fonseca,1,2,3,6 Henrique Reguengo,4 Manuela Almeida,1,2 Leonı´dio Dias,1 La Salete Martins,1,2
Sofia Pedroso,1 Josefina Santos,1,2 Luı´sa Lobato,1,2 Anto´nio Castro Henriques,1,2 and Denisa Mendonc¸a3,5
Background. Oxidative stress is one of the most important components of the ischemia-reperfusion process after
kidney transplantation (KTx) and increases with graft dysfunction.
Methods. This prospective study was conducted on 40 consecutive KTx recipients to evaluate time-dependent
changes in oxidative stress-related parameters within the first week after KTx and to assess their performance in
predicting delayed graft function (DGF=dialysis requirement during initial posttransplant week) and graft function at
1 year. Blood samples were collected before (day 0) and after KTx (days 1, 2, 4, and 7). Total antioxidant capacity,
plasma levels of malondialdehyde (MDA), and activities of glutathione peroxidase, glutathione reductase and su-
peroxide dismutase were measured. Multivariable linear mixed and linear regression models, receiver-operating
characteristic (ROC), and areas under ROC curves (AUC-ROC) were used.
Results. At all time points after KTx, mean MDA levels were significantly higher in patients developing DGF (n=18).
Shortly after KTx (8Y12 hr), MDA values were higher in DGF recipients (on average, +0.16 Kmol/L) and increased
further on following day, contrasting with prompt functioning recipients. Day 1 MDA levels accurately predicted DGF
(AUC-ROC=0.90), with a performance higher than SCr (AUC-ROC=0.73) and similar to cystatin C (AUC-
ROC=0.91). Multivariable analysis revealed that MDA levels on day 7 represented an independent predictor of 1-year
graft function. Antioxidant enzyme activities were not significantly changed during the study period and were not
predictors of 1-year graft function.
Conclusions. Increased MDA levels on day 1 after KTx might be an early prognostic indicator of DGF, and levels on
day 7 might represent a useful predictor of 1-year graft function.
Keywords: Oxidative stress, Malondialdehyde, Kidney transplantation, Kidney graft dysfunction.
(Transplantation 2014;97: 1058Y1065)
Ischemia-reperfusion (I/R) injury is a complex phenome-non in kidney transplantation (KTx) that can cause graft
dysfunction and determine both the early and long-term
outcomes of transplant recipients. Oxidative stress is one
of the most important components of I/R process (1Y3).
Reactive oxygen species (ROS) are products of normal cel-
lular metabolism that are completely inactivated by antiox-
idant defense mechanisms during physiological conditions.
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The antioxidant defense system can be predominantly divided
into endogenous enzymes, such as superoxide dismutases
(SOD), catalases, glutathione reductases (GR) and peroxi-
dases (GPx), and exogenous small molecules, such as carot-
enoids and vitamins A, C, and E (4). In some pathologic
conditions, an imbalance between ROS generation and anti-
oxidant capacity can result in enhanced ROS activity and
oxidative stress (5).
Markers of oxidative stress, including elevated levels of
malondialdehyde (MDA) and reduced antioxidant activity,
TABLE 1. Summary of baseline and clinical characteristics in kidney transplant donors and recipients (total sample and
categorized by delayed or prompt graft function)
Total (n=40) DGF (n=18) Non-DGF (n=22) P
Donor
Age (yr) 51.2T11.4 51.1T13.4 51.2T9.9 0.172
Male sex 26 (65) 14 (78) 12 (54.5) 0.125
Living donor 11 (27.5) 3 (16.7) 8 (36.4) 0.165
Expanded criteria donors 3 (7.5) 1 (5.6) 2 (9.1) 0.541
Serum creatinine (mg/dL) 0.81T0.18 0.85T0.21 0.78T0.16 0.318
Donor-recipient
HLA mismatches 3.39T1.24 3.38T1.07 3.41T1.46 0.941
Cold ischemia time (hr) 12.1T7.9 15.2T7.8 9.6T7.3 0.035*
Living donor 2.8T0.5 2.5T0.5 3.0T0.5 0.204
Deceased donor 16.2T5.9 18.1T5.1 14.1T6.2 0.088
Recipient
Age (yr) 49.2T15.2 56.3T10.9 43.3T15.9 0.006*
Male sex 26 (65) 11 (61) 15 (68) 0.641
White 40 (100) 18 (100) 22 (100) V
BMI (kg/m2) 24.8T4.9 26.2T4.4 23.6T5.0 0.091
Previous transplant 2 (5) 0 (0) 2 (9.1)
Time on dialysis (yr) 4.4T4.7 5.6T6.2 3.4T2.3 0.135
Pretransplant therapy
Dialysis 38 (95) 18 (100) 20 (90.9) 0.296
Preemptive transplantation 2 (5) 0 (0) 2 (9.1)
Cause of kidney disease
IgA nephropathy 7 (17.5) 2 (11.1) 5 (22.7) V
Glomerulonephritis 6 (15.0) 4 (22.2) 2 (9.1) V
Diabetic nephropathy 5 (12.5) 3 (16.7) 2 (9.1) V
Autosomal dominant polycystic kidney disease 3 (7.5) 3 (16.7) 0 (0) V
Unknown 4 (10.0) 1 (5.6) 3 (13.6) V
Others 15 (37.5) 5 (27.8) 10 (45.5) V
Peak PRA (%) 5.5 T 15.1 5.0 T 15.0 5.9 T 15.5 0.853
0 29 (72.5) 14 (77.8) 15 (68.2) V
1Y25 8 (20.0) 3 (16.7) 5 (22.7) V
26Y75 3 (7.5) 1 (5.6) 2 (9.0) V
Current PRA (%) 2.3 T 8.6 3.1 T 11.7 1.6 T 4.9 0.585
0 34 (85) 15 (83.3) 19 (86.4) V
1Y25 5 (12.5) 2 (11.1) 3 (13.6) V
26Y50 1 (2.5) 1 (5.6) 0 (0) V
Induction regimen
Antithymocyte globulin (ATG-F) 4 (10) 1 (5.6) 3 (13.6) 0.613
Basiliximab/Daclizumab 30 (75) 14 (77.8) 16 (72.7) 0.789
Immunosuppression at time of discharge
Steroids 38 (95.0) 18 (100) 20 (90.9) 0.296
Tacrolimus 38 (95.0) 17 (94.4) 21 (95.5) 0.886
Cyclosporine A 2 (0.05) 1 (5.6) 1 (5.6) 0.884
Values are expressed as meanTstandard deviation or absolute numbers and percentages. Comparisons between groups of continuous variables were done
using parametric (t test) or nonparametric (Mann-Whitney) tests; associations between categorical variables were analyzed using the W2 test and Fisher’s exact
test as appropriate; *PG0.05.
HLA, human leukocyte antigen; BMI, body mass index; PRA, panel reactive antibody.
* 2014 Lippincott Williams & Wilkins Fonseca et al. 1059
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have been reported in renal patients (6Y9). The restoration
of kidney function after KTx can improve oxidative stress
(10), but certain studies (11, 12) have reported increased
systemic biomarkers of oxidative stress in KTx recipients,
particularly in the early phase (13, 14) and thereafter, coin-
ciding with chronic allograft dysfunction (11, 15Y18). De-
spite a significant amount of literature on oxidative stress
and renal disease, data regarding KTx in the early stages re-
main limited. Therefore, we investigated the time-dependent
changes in the antioxidant defense system during the first
week after transplantation by measuring the overall antioxi-
dant status (TAS) and the activity of the predominant anti-
oxidant enzymes as a response to lipid peroxidation evaluated
by MDA levels.
The purposes of this study were as follows:
to assess whether oxidative markers differ between patients
(pretransplant and 1 week posttransplant) and control
subjects (healthy blood donors);
to evaluate longitudinal changes of MDA, TAS, SOD, GPx,
and GR within the first week after KTx and identify
factors associated with these changes;
to investigate the association of MDA/antioxidant parame-
ters with DGF (defined as dialysis requirement within
the first posttransplant week) and their accuracy in
predicting DGF; and
to examine the relationship between any of the oxidative
markers measured during the first week posttransplant
and the 1-year allograft function, evaluated by serum
creatinine (SCr) levels.
RESULTS
Study Cohort
During recruitment, 42 patients were consecutively
enrolled. Two recipients had primary graft failure and were
excluded during the first 2 days. Therefore, the final study
sample included 40 patients. Baseline demographical and
transplant data are shown in Table 1.
Oxidative Stress Markers
We initially compared oxidative markers evaluated in the
40 ESRD patients scheduled for KTx with those of 30 healthy
subjects with similar ages (a control group of blood donors).
Before KTx, the patients presented with significantly increased
mean (SD) MDA levels (0.40 [0.12] vs. 0.26 [0.09] Kmol/L,
PG0.01), TAS (1.79 [0.19] vs. 1.39 [0.53], PG0.001), SOD (1971
[630] vs. 1208 [254] U/g Hb, PG0.001) and GR (63 [12] vs.
52 [7.0] U/L, PG0.001) compared with controls. No significant
differences were detected in GPx.
The evolution of oxidative parameters during the first
posttransplant week is summarized in Table 2. Compared
with before transplant, mean (SD) MDA levels significantly
decreased at first day (0.40 [0.12] vs. 0.36 [0.12] Kmol/L,
P=0.031), and a reduction of approximately 28% was ob-
served on the seventh posttransplant day (0.40 [0.13] to
0.28 [0.13] Kmol/L, PG0.001). Levels of TAS, SOD, GPx, and
GR did not exhibit any significant changes within the first
posttransplant week.
None of the oxidative stress markers differed signifi-
cantly between male and female patients at any time point.
Mean MDA levels were increased in deceased donor re-
cipients at all time points, although the increases were only
statistically significant on second and fourth days. No sig-
nificant differences were found in antioxidant parameters.
Recipient age was positively correlated with MDA
levels at days 4 and 7 (respectively, r=0.46, P=0.004; and
r=0.39, P=0.013). Time on dialysis, donor age, and cold is-
chemia time were not correlated with MDA levels or with
any antioxidant marker. Levels of MDA and SCr, but not of
the antioxidant markers, were positively correlated at most
of time points (data not shown).
TABLE 2. Time-course of oxidative stress biomarkers within the first week after kidney transplantation
Prior-KTx 1st day* 2nd day 4th day 7th day
Mean (SD) (n=40) (n=40) (n=40) (n=40)
MDA (Kmol/L) Overall 0.40 (0.12) 0.36 (0.12) 0.28 (0.10) 0.29 (0.13) 0.28 (0.13)
DGF (n=18) 0.42 (0.12) 0.45 (0.10) 0.33 (0.10) 0.40 (0.13) 0.37 (0.13)
Non-DGF (n=22) 0.39 (0.12) 0.29 (0.09) 0.24 (0.08) 0.23 (0.07) 0.19 (0.05)
TAS (mmol/L) Overall 1.79 (0.19) 1.74 (0.21) 1.68 (0.35) 1.73 (0.37) 1.77 (0.30)
DGF (n=18) 1.80 (0.16) 1.73 (0.24) 1.70 (0.25) 1.82 (0.21) 1.89 (0.24)
Non-DGF (n=22) 1.78 (021) 1.76 (0.19) 1.74 (0.22) 1.75 (0.28) 1.66 (0.32)
SOD (U/g Hb) Overall 1966 (638) 1894 (596) 1984 (578) 1947 (457) 1997 (580)
DGF (n=18) 1842 (559) 1837 (622) 1876 (538) 1928 (439) 2158 (604)
Non-DGF (n=22) 2068 (691) 1943 (584) 2071 (608) 1959 (478) 1944 (413)
GR (U/L) Overall 63 (12) 50 (14) 51 (17) 56 (16) 62 (14)
DGF (n=18) 66 (12) 54 (19) 57 (20) 63 (18) 69 (15)
Non-DGF (n=22) 61 (12) 47 (9) 48 (7) 53 (10) 56 (10)
GPx (U/g Hb) Overall 58 (15) 59 (13) 62 (15) 62 (14) 60 (14)
DGF (n=18) 58 (13) 59 (11) 62 (14) 64 (15) 60 (14)
Non-DGF (n=22) 58 (17) 60 (15) 62 (17) 60 (14) 60 (14)
*1st day=8 to 12 hr after surgery; the values are the mean and standard deviation.
KTx, kidney transplantation; MDA, malondialdehyde; TAS, total antioxidant status; SOD, superoxide dismutase; GR, glutathione reductase; GPx,
glutathione peroxidase; SD, standard deviation.
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Delayed Graft Function and Acute Rejection
Eighteen (45%) and 22 (55%) patients had DGF and
prompt graft function, respectively. The DGF rate was
higher in grafts from deceased donors, but this difference
was not statistically significant (51.7% vs. 27.3%, P=0.286).
In terms of traditional DGF predictors and except for cold
ischemia time, no significant differences were found be-
tween DGF/non-DGF in relation to baseline characteris-
tics and induction therapy (Table 1). The mean age was
significantly higher in patients with DGF (56 [11] vs.
43 [16] yr, P=0.006).
Ten recipients had an acute rejection episode during
inpatient hospitalization for transplantation, and acute re-
jection was more frequently diagnosed in patients with DGF
than in those with prompt function (44% vs. 9%, P=0.025).
DGF and Longitudinal Changes in Oxidative
Stress Markers
Before transplantation, no significant differences were
found between patients with DGF or non-DGF regarding
any of the evaluated oxidative stress markers. After trans-
plantation, mean MDA levels were consistently higher in
DGF patients at all time points, compared with non-
DGF recipients (Table 2). No differences were found
between DGF and non-DGF recipients in relation to anti-
oxidant parameters.
Longitudinal Changes in MDA Levels According
to Graft Function
A linear mixed-effects model was used to analyze the
longitudinal changes in MDA of the 2 groups of patients
(DGF/non-DGF), by controlling for variables found to be
associated with MDA by bivariate analysis (donor status and
recipient age) and confirmed the independent association of
DGF with andMDA levels. Donor status and recipient age lost
their statistical significance and were removed from the final
model. Time measurements of MDA and DGF were the only
independent factors associated with MDA levels (Table 3).
Delayed graft function was significantly associated with MDA
levels: recipients with prompt function presented reduced
average MDA levels at all time points. According to our es-
timation, the first MDA values after transplantation were
0.16 Kmol/L higher in DGF patients. A significant interaction
between time of measurement and DGF confirmed that the
pattern of longitudinal changes in MDA levels depend on
whether the recipient had DGF.
Because DGF occurs more frequently in KTx from
deceased donors, we performed the same analysis consid-
ering only deceased donor transplants, and the results were
similar (see SDC, http://links.lww.com/TP/A919). According
to our estimation and after excluding living donors, the first
MDA levels after KTx were, on average, 0.144 Kmol/L higher
in DGF patients who underwent a deceased-donor transplant.
The effect of DGF on the progression of antioxidant
parameters over time was not statistically significant, even
when we considered only deceased-donors transplants.
Prognosis of DGF by Oxidative Stress Markers
(ROC Analysis)
Receiver-operating characteristic (ROC) analyses were
performed to assess the potential of oxidative markers to
predict DGF. Only MDA levels predicted the need for dial-
ysis within the first week. The MDA levels on day 1 repre-
sented an optimal predictor for the early diagnosis of DGF
(AUC=0.90), as well as the changes in MDA levels between
preoperative and first posttransplant day (AUC=0.84) (Fig. 1).
The diagnostic performance of MDA on day 1 was better
than diagnostic performance of SCr (AUC=0.73) and similar
to that of cystatin C (CystC, AUC=0.91), which is considered
a marker with greater sensitivity for the detection of im-
paired renal function. The reduction ratio in MDA levels
between pretransplant and day 1 resulted in an AUC of 0.84
for identifying DGF, which was better than the reduc-
tion ratio of SCr on the same day (AUC=0.69). In analyzing
TABLE 3. Results of the final linear mixed model for dependent variable MDA levels (n = 194 observations derived from
40 patients)
Estimate P 95% CI
Intercept 0.368 G0.001 0.318 0.418
Graft function
DGF=0 (immediate graft function) Y0.170 G0.001 Y0.238 Y0.102
DGF=1 (with DGF - reference) 0 V V V
Time
Time 0 (pretransplant) 0.053 0.089 Y0.008 0.115
Time 1 (1st day) 0.079 0.012 0.018 0.141
Time 2 (2nd day) Y0.034 0.279 Y0.095 0.028
Time 3 (4th day) 0.030 0.363 Y0.036 0.097
Time 4 (7th day- reference) 0 V V V
Time*DGF
Time 0*DGF=0 0.134 0.002 0.050 0.217
Time 1*DGF=0 0.013 0.257 Y0.070 0.097
Time 2*DGF=0 0.077 0.295 Y0.007 0.161
Time 3*DGF=0 0.029 0.039 Y0.058 0.116
Time 4*DGF=0 (reference) 0 V V V
MDA, Malondialdehyde; DGF, delayed graft function.
* 2014 Lippincott Williams & Wilkins Fonseca et al. 1061
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the ROC curve of MDA on day 1, the optimal sensitivity and
specificity occurred at a value of 0.365 Kmol/L (sensitivity,
83%; specificity, 82%; positive and negative predictive value,
82 and 71, respectively).
During the First Year After KTx
Within the first year after KTx, 10 KTx recipients were
rehospitalized, accounting for a total of 19 hospital admis-
sions. The causes of rehospitalization were infection in five
admissions (predominantly urinary tract infections), renal
dysfunction in six, and nonrenal causes in the remaining eight
admissions (suicidal ideation, acute pulmonary edema, and
neutropenia). Records from the acute rejection episodes
throughout the first posttransplant year were reviewed, and
only one patient was rehospitalized at 1 month after KTx with
an acute rejection episode. At 1 year, all of the patients were
alive, but two grafts of DGF recipients were lost.
Predictive Value of MDA Levels on 1-Year
Allograft Function
At 1 year after KTx, the median (IQR) SCr was signifi-
cantly higher in patients with DGF (1.58 [1.20Y2.52] vs. 1.26
[1.05Y1.52] mg/dL, P=0.049) and a correlation with MDA at
day 7 was found (Fig. 2). The prognostic value of early MDA
values on long-term allograft function (1 year after KTx) was
tested using multivariable analysis, including all patients (DGF
and non-DGF). In multivariable linear regression models for
1-year SCr, MDA levels measured on day 7 were indepen-
dent predictors of 1-year graft function after controlling for
established variables that generally affect graft function, in-
cluding acute rejection and rehospitalizations occurring during
the first posttransplant year (Table 4). Levels of MDA before
KTx and on remaining posttransplant days were not significant
predictors of 1-year SCr.
DISCUSSION
In this prospective cohort study, we report the inde-
pendent association of high levels of plasma MDAwith DGF
with poor 1-year allograft function. To the best of our
knowledge, this study is the first to demonstrate this asso-
ciation in KTx recipients.
Oxidative stress is involved in the pathophysiology of
renal injury in I/R (1, 2, 19). As in other clinical conditions, if
the kidney scavenging capacity is insufficient for an excess of
ROS production, such an oxidative imbalance might trigger an
inflammatory response within the transplanted organ, leading
to tissue damage and graft dysfunction (2, 13, 20). Because of
the composition of renal lipids, which predominantly comprise
long-chain, polyunsaturated fatty acids, lipid peroxidation rep-
resents one of themost widespread hypothesized causes of ROS-
mediated cell injury (21). Despite the controversy of whether
lipid peroxidation is the cause or an epiphenomenon of in-
jury, the fact is that increased lipid peroxidation is observed
in I/R injury. Moreover, MDA is the principal product of
polyunsaturated fatty acid peroxidation, reflecting the I/R
stress of grafts (5, 22). In our study, recipients who developed
DGF presented increased MDA levels during the first week
after KTx, which seem to reflect the postischemic tissue
damage of DGF kidneys. Compared with pretransplant,
these patients presented higher MDA levels at 8 to 12 hr after
KTx, in contrast to recipients with prompt graft function
whose MDA levels continuously decreased throughout the
TABLE 4. Significant predictors of serum creatinine at 1 year after kidney transplantation
Regression coefficient P 95% CI
Serum creatinine at 1-year posttransplantation (ln)
Time on dialysis (ng/mL) 0.048 G0.001 0.024Y0.072
MDA measured on day-7 (Kmol/L) 1.338 0.003 0.475Y2.201
Rehospitalizations (yes vs. no) 0.361 0.007 0.107Y0.615
Results are given by multiple linear regression (a stepwise method) after including donor status, recipient and donor age, pretransplant time on dialysis,
rehospitalizations and acute rejection episodes throughout the first year; serum creatinine (ln) at 1-year after transplant as the dependent variable.
MDA, malondialdehyde.
FIGURE 1. Receiver-operating characteristic curves for
plasma MDA, serum creatinine, and cystatin C levels mea-
suredat the first dayafterKTxandchanges inMDAandserum
creatinine levels from pretransplant to day-1 after KTx for
predicting delayed graft function. The table lists the areas
under the ROC curves of MDA, serum creatinine, and serum
cystatinC for predictingDGF, aswell as the AUCROCofMDA
and serumcreatininechangesbetweenbaseline and first day
after transplant. MDA, malondialdehyde; SCr, serum creati-
nine; Cyst, serum cystatin C;MDA or SCr change (day 1Yday
0), Serum creatinine or MDA reduction rate between pre-
transplant and the first day after transplant (the difference
between MDA or SCr on day 1 and day 0, divided by MDA
or SCr on day 0, multiplied by 100); AUC, area under the
ROC curves.
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week. The independent association of DGF with longitudinal
changes in MDAwas confirmed using a general linear mixed
model approach, which also corroborated that DGF can
model the trajectory of MDA changes after KTx.
Our results not only establish MDA as an early marker
of DGF but also demonstrate its predictive value as early as
8 to 12 hr after KTx in terms of the evolution of graft function
and the need for dialysis during the first week. In regard to
clinical application, a new biomarker should be more accurate
in predicting DGF than the current SCr. After this, ROC
analysis showed thatMDA levels are better suited than SCr for
predicting the need of renal replacement therapy within the
first week after KTx. Similar to serum CystC, MDA levels on
day 1 were highly accurate in predicting DGF and performed
better than SCr. This emphasizes the clinical value of MDA
levels as a diagnostic marker for the prediction of DGF, facil-
itating an earlier diagnosis compared with SCr.
Only a highly effective antioxidant system can coun-
teract the deleterious hydroxyl radicals formed during lipid
peroxidation. A wide range of protective substances, such
as antioxidant enzymes, might potentially elicit a protective
effect by limiting the production of ROS and the damage of
oxidative stress after I/R injury of a kidney graft. Conflicting
results have reported on the activities of antioxidant en-
zymes in KTx patients. Levels of antioxidant enzymes have
been reported to increase (23, 24), decrease (12, 16), or
remain unchanged (25, 26) after KTx. Because of this lack
of consensus, we aimed to examine the changes of antioxi-
dant activity during the early phase of KTx. Compared with
healthy controls, our patients presented with significantly
increased SOD and GR levels before KTx, likely in response to
significant oxidative stress levels in ESRD patients. However,
no significant changes were found after KTx, even when
stratifying by graft function.
The evaluation of TAS has been used as a biologi-
cal marker for monitoring oxidative stress. Measuring TAS
allows for the detection of the overall antioxidant capacity,
including the contribution of as of yet unknown antioxi-
dants and the synergism between them (27). In our study,
TAS levels did not exhibit any significant changes during the
first posttransplant week, even when we stratified the pa-
tients according to DGF. Although oxidative stress expressed
by MDA levels is most significantly pronounced in DGF
patients, our study highlights the observation that during
the first posttransplant week, the overall antioxidant status
and potential protection exerted by the antioxidant enzymes
are not enhanced to counteract the intensified oxidative
stress, specifically in DGF patients.
Immunosuppressive therapy, particularly cyclosporine,
represents an additional potential source of ROS generation
and enhanced renal lipid peroxidation after KTx (15, 28). In
our study, the effect of immunosuppression on plasma MDA
and antioxidant parameters was not assessed, as only one
patient was on a combined therapy with cyclosporine.
In various studies, it has been reported that oxidative
stress occurring in KTx might be implicated in the patho-
physiology of chronic transplant dysfunction (1, 11, 15, 17,
29). Djamali et al. (30) suggested that ROS represents an im-
portant fibrogenic factor in chronic allograft nephropathy
because oxidative stress is increased in the presence of the
interstitial fibrosis and tubular atrophy that generally precedes
chronic allograft failure. In experimental models of chronic
allograft tubular atrophy/interstitial fibrosis, increased intra-
graft MDA levels were detected, reflecting lipid peroxidation
(31). Therefore, we verified the effects ofMDA levels evaluated
within the first week on 1-year posttransplant allograft func-
tion. Together with time on dialysis and rehospitalizations
during the first year, MDA levels at day 7 were the best pre-
dictors of 1-year SCr. Higher MDA levels on day 7 were as-
sociated with worse graft function at 1 year, suggesting that
oxidative damage reflected by increased MDA levels on day 7
will reflect long-term injury.
This study has several strengths. We used a prospective
and longitudinal study design to determine the effects of DGF
on the progression of oxidative markers over time.Most of the
previous oxidative stress studies on KTx were cross-sectional
and included only stable patients. Longitudinal studies are
more helpful in understanding how subtle associations be-
tween factors of interest change over time, and we used this
methodology to consider five measurements of each oxidative
stress marker. Uncertainty remains concerning the determi-
nation of oxidative stress in KTx and the interpretation of the
potential variability. However, our study highlights the im-
portance of studying oxidative stress according to graft func-
tion because DGF can significantly modify the trajectory of
MDA changes. To the best of our knowledge, this is the first
study to demonstrate that MDA levels are strongly associated
with DGF and with poorer 1-year graft function.
Regardless of its several mentioned strengths, this study
has some limitations. This is a single centre study with a rela-
tively small sample size. Despite the encouraging results found,
the accuracy ofMDA levels as a diagnostic marker of renal graft
injury and prognostic value of MDA for DGF after KTx needs
to be assessed in a larger cohort and in other centers and
transplant recipients.
In KTx, numerous diagnostic biomarkers have been
evaluated in the past decade, but, so far, evidence to support
FIGURE 2. Relationship between serum creatinine and
plasma malondialdehyde at day 7 after kidney transplan-
tation (r=0.346, P=0.031). KTx, kidney transplantation; SCr,
serum creatinine.
* 2014 Lippincott Williams & Wilkins Fonseca et al. 1063
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their use in routine practice is limited. The discovery of
novel biomarkers can be complex and costly. In this study,
we demonstrated that a novel marker predicted who would
develop DGF with about the same degree of accuracy of serum
CystC and both with a diagnostic performance superior to
serum creatinine. Undoubtedly, CystC displays several good
characteristics that make it a viable biomarker for early de-
tection of DGF. Nonetheless, and particularly during the first
week when high doses of corticosteroids are used, glucocorti-
coid medication can be shortcoming in using serum CystC in
KTx, and it is important to take this into account when
interpreting this serum marker. Thus, a combination of bio-
markers may be more valuable for the diagnosis of DGF and
prognosis of graft function. Because DGF is a critical early
insult to the renal allograft that augments the risk of long-term
graft loss, and it is a complex process with multiple underlying
pathogenic mechanisms and confounding risk factors, it can
be prudent to predict DGF with more than a single biomarker,
at least in some situations. MDA can be a valuable marker as
an alternative or as a complement in the risk prediction, not
only in relation to serum CystC and any other serum/plasma
markers but also regarding urine biomarkers, like neutrophil
gelatinase-associated lipocalin, that cannot be measured if a
urine sample cannot be taken, particularly during transient
anuria that commonly occurs after KTx.
In conclusion, intensified oxidative stress persists during
the early phase of transplant, particularly in DGF recipients. The
antioxidant enzymes did not counterbalance the overload of
ROS by a compensatory increase in their activities. The present
study showed that MDA is a novel and a reliable biomarker for
the prediction of early and long-term graft damage.
SUBJECTS AND METHODS
Study Design and Patient Population
Consecutive patients with end-stage renal disease (ESRD), undergoing
living or deceased KTx at the Nephrology and Kidney Transplantation De-
partment of the Centro Hospitalar do Porto between December 2010 and
May 2011 were prospectively enrolled. Patients younger than 18 years or who
requiredmultiorgan transplants were not included. After transplant, recipients
with primary graft failure related to surgical causes were excluded. The insti-
tutional review board of Centro Hospitalar do Porto approved the study. Each
participant provided informed consent before enrollment.
Data Collection
At time of transplantation, several demographical and clinical parame-
ters were collected. During the first posttransplant year, the rehospital-
izations of KTx recipients were registered, as well as the length of the
hospital stays and outcomes (functioning allograft or graft failure).
Sampling and Laboratory
Blood samples for determining oxidative stress parameters were collected
as follows: 3 to 6 hr before transplant surgery (pretransplant); on the fol-
lowing morning, approximately 8 to 12 hr after graft reperfusion (day 1);
and then at second (day 2), fourth (day 4), and seventh day (day 7) after
transplant, for a total of five samples per patient. Blood samples were taken
by conventional procedures and immediately centrifuged. All samples were
aliquoted and frozen within 1 hr after collection and stored at Y80oˆ¤C until
further assay.
Measurements of SCr were performed by Jaffe´ method (Roche Diagnostics),
and CystC was measured with a particle enhanced immunonephelometric
method (Siemens Diagnostics) at the same time points as oxidative markers.
Plasma levels ofMDAweremeasured using a commercial high-performance
liquid chromatography kit (Chromsystems). superoxide dismutase levels were
measured in erythrocytes according to a protocol previously described by
Beauchamp and Fridovich (32) using the RANSOD kit; GR, GPx, and TAS
levels were measured in plasma/serum using a Randox Laboratories kit.
Definition of Variables
Delayed graft function was defined by the need for dialysis during the
first week. ‘‘Prompt’’ function (non-DGF) was considered if no dialysis was
required during the first posttransplantation week.
Graft function at 1 year was evaluated by the average of the two SCr levels
measured at 1 year posttransplant. Two grafts were lost at the seventh and
eighth months, and the last SCr presented by these patients before the re-
start of dialysis was considered as being the 1-year SCr.
Statistics
Distributions of continuous variables were analyzed, and Kolmogorov-
Smirnov tests were performed to assess their deviation from Normal distri-
bution. Quantitative variables were summarized as the mean and standard
deviation (SD), or as median and 25th and 75th quartiles (interquartile range
[IQR]) for variables exhibiting skewed distributions. Categorical variables
were reported as percentages.
Statistical analysis was performed in four steps. First, a cross-sectional
bivariate analysis was performed to compare groups and to study the as-
sociation between oxidative stress markers and demographic/clinical vari-
ables (t test). Correlations were assessed using Pearson correlation.
Second, a linear mixed-effects model was used to study the association of
DGF with serial changes of each oxidative marker, controlling for variables
associated by bivariate analysis. The interaction between DGF and the time-
course measurement of oxidative markers were included in the model, as
such a significant interaction would suggest that DGF affects the levels and
trajectory of each marker.
Third, ROC analysis was performed to estimate the sensitivity and
specificity of MDA levels (as well as SCr and CystC) to predict DGF. The
optimal cutoff points were determined by maximizing the sum of sensitivity
and specificity.
Fourth, multivariable stepwise linear regression was performed to assess
the independent association of MDA levels with SCr at 1 year posttransplan-
tation, including variables that generally predict graft function (donor status,
recipient and donor age, pretransplant time on dialysis, rehospitalization, and
acute rejection episodes throughout the first year). Linear regression models
used log-transformed 1-year SCr levels as the dependent variable. To avoid
collinearity, each time point of MDA was included separately in the dif-
ferent models.
Statistical analyses were performed using SPSS version 21.0, and a sig-
nificance level of 0.05 was considered significant.
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4.4. STUDY IV 
LEPTIN AND ADIPONECTIN: BIOMARKERS OF GRAFT DYSFUNCTION?  
 
Fonseca I, Oliveira JC, Santos J, Martins LS, Almeida M, Dias L, Pedroso S, Lobato L, 
Henriques AC, Mendonça D. Leptin and Adiponectin during the First Week after Kidney 
Transplantation: Biomarkers of Graft Dysfunction?  
(Accepted manuscript in Metabolism – Clinical and Experimental) 
Printed with permission, Elsevier© October, 2014 
Patients with impaired kidney function or chronic kidney disease have increased 
circulating levels of both pro-inflammatory and anti-inflammatory adipokines that may 
result from an increase in their systemic production and/or decrease in their renal 
clearance. Based on this evidence we addressed this study to examine the longitudinal 
changes of leptin and adiponectin during the first week post-transplant and to test the 
hypothesis that graft dysfunction would be associated with the accumulation of both 
adipokines due to their impaired clearance by the kidney. Therefore, we hypothesized that 
higher levels of leptin and/or adiponectin could serve as early biomarkers of DGF. 
The results are summarized as follows: 
  Pre-transplant hyperleptinemia was widely prevalent and the serum leptin levels 
exceeded the upper limit of the normal range in 32 patients (82%). After transplantation, 
the leptin levels decreased substantially, but at the end of the first week hyperleptinemia 
was still present in 64% of the patients. Regarding adiponectin, pre-transplant levels 
over 300 ng/mL were only detected in only 9 patients (22.5%) and following 
transplantation, the levels of adiponectin were within the normal range.  
  The time-course changes of both adipokines were examined according to graft function 
within the first week after transplantation, and, undoubtedly, the mean levels of leptin 
were consistently higher in DGF patients at all four timepoints compared to non-DGF 
recipients; no differences were noted in the mean levels of adiponectin. A linear mixed-
effects model was then used to analyze the longitudinal leptin and adiponectin changes, 
controlling for variables that were found to be associated according to the bivariate 
analysis (recipient age, gender, BMI and occurrence of DGF) and confirmed the 
independent association of DGF with the changes of leptinemia but not adiponectinemia 
during the first week after transplant. The time measurements of leptin, patient gender, 
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and BMI were the other associated independent factors. According to our estimation, the 
first mean leptin values after transplantation (day-1) will be approximately two times 
higher in DGF patients when controlling for the recipient gender and BMI. A significant 
interaction was observed between the recipient gender and BMI, which was retained in 
the model, meaning that the effect of BMI on leptin changes is different according to 
gender, i.e., the effect of an increase in BMI is more pronounced in males and 
attenuated in females. 
  The performance of leptin and adiponectin in discriminating the transplant recipients with 
DGF was evaluated by ROC analysis, which showed that leptin at day-1 was slightly 
better than SCr in predicting the need for dialysis within the first week post-transplant 
(AUC=0.76 for leptin vs. AUC=0.72 for SCr) but adiponectin was not. The results were 
similar when leptin was adjusted for BMI, but the performance of this adipokine 
improved considerably in the male gender after splitting the analysis by gender 
(AUC=0.86). 
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Context and Objective. Based on evidence that leptin and adiponectin are removed from
circulation primarily by the kidney, we designed a study to examine the longitudinal
changes of these adipokines during the first week after kidney transplantation (KTx) and to
test the hypothesis that higher levels of leptin and/or adiponectin could be early biomarkers
of delayed graft function (DGF = dialysis requirement during the first post-transplant week)
and acute rejection.
Study Design. Repeated-measures prospective study.
Material and Methods. Forty consecutive adult patients with end-stage renal disease who
were undergoing KTx. Leptin and adiponectin were measured in blood samples that were
collected before (day-0) and after KTx (days-1, 2, 4 and 7). Linear mixed-models, receiver
operating characteristic and area under curve (AUC-ROC) were used.
Results. At post-transplant day-1, leptinemia and adiponectinemia declined 43% and 47%,
respectively. At all times studied after KTx, the median leptin levels were significantly higher
in patients developingDGF (n = 18), but not adiponectin levels. Shortly after KTx (day-1), leptin
values were significantly higher in DGF recipients in contrast to patients with promptly
functioning kidneys, approximately two times higher when controlling for gender and BMI.
The leptin reduction rate between pre-tranplant and one-day after KTx moderately predicted
DGF (AUC = 0.73). On day-1, serum leptin predicted DGF (AUC-ROC = 0.76) with a performance
slightly better than serum creatinine (AUC-ROC = 0.72), even after correcting for BMI
(AUC-ROC = 0.73). Separating this analysis by gender showed that the performance of leptin
in predicting DGF for male gender (AUC-ROC = 0.86) improved.
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Conclusions. Kidney graft function is an independent determinant of leptin levels, but not
of adiponectin. Leptin levels at day-1 slightly outperformed serum creatinine in predicting
the occurrence of DGF, and more accurately in male gender. No significant association was
detected with acute rejection.
© 2014 Elsevier Inc. All rights reserved.
1. Introduction
White adipose tissue is now recognized as a multifunctional
organ [1]. In addition to its central role in lipid storage, white
adipose tissue has a major endocrine function by synthesiz-
ing a multitude of protein cytokines termed adipokines.
Leptin and adiponectin (ADPN) are two adipokines that elicit
generally opposing pro-inflammatory and anti-inflammatory
effects [1–4]. In chronic kidney disease, the clinical signifi-
cance and prognostic implications of leptin and ADPN are not
well understood. Patients with chronic kidney disease have
increased circulating levels of both adipokines that may result
from an increase in their systemic production and/or decrease
in their renal clearance [5–13].
The contribution of the kidney in the biodegradation and
elimination of leptin and adiponectin appears to be confirmed
in studies conducted in kidney transplantation (KTx),where the
circulating levels of these adipokines decrease after successful
transplantation [14–19]. Based on the growing evidence that
leptin and ADPN are removed from the circulation primarily by
the kidney, we designed the present study to examine the
longitudinal changes of these two adipokines during the first
week post-transplant and test the hypothesis that delayed graft
function (DGF)would be associatedwithhigher plasma levels of
leptin and due to their impaired clearance by the kidney.
Therefore, we hypothesized that higher levels of leptin and/or
ADPN could serve as early biomarkers of DGF (defined as
dialysis requirementwithin the firstweek after KTx). Due to the
role of leptin in the immune system [9,20–24], the performance
of leptin in predicting acute transplant rejection and allo-
immunity was also assessed.
2. Patients and Methods
2.1. Study Design and Patient Population
Consecutive patients with end-stage renal disease who were
undergoing living or deceased donor KTx between December
2010 and May 2011 were prospectively enrolled. Patients
under the age of 18 or who required multiorgan transplants
were not included. The Institutional Review Board of Centro
Hospitalar do Porto approved the study. Each participant
provided informed consent.
2.2. Laboratory Analyses
Blood samples were collected as follows: 3–6 h prior to
transplant surgery (pre-transplant); on the followingmorning,
approximately 8–12 h after graft reperfusion (day-1); and then
on the second (day-2), fourth (day-4) and seventh days (day-7)
after transplant, for a total of five samples per patient.
Serum levels of leptin and ADPN were measured by ELISA
based on the direct sandwich technique using kits from
Mercodia, Sweden. Standard values of leptin for normal weight
people were 2–5.6 ng/mL for male and 3.7–11.1 ng/mL for
female. Expected normal values for ADPN were 5–300 ng/mL.
2.3. Definitions
Delayed graft function was defined by the need for dialysis
during the first week after KTx.
Acute rejection was defined as either biopsy-proven rejec-
tion or anti-rejection treatment without biopsy.
Leptin/BMI ratio was calculated to measure the leptin level
while controlling for the BMI contribution.
2.4. Statistical Analyses
The distributions of continuous variables were analyzed
using Kolmogorov–Smirnov test and variables showing a
positively skewed distribution (leptin and SCr) were natural
logarithm transformed prior to parametric test analyses.
Statistical analysis was conducted in three steps. First, a
cross-sectional bivariate analysis was performed. Comparisons
of continuous variables between groups were carried out using
parametric (t-test) or nonparametric (Mann–Whitney) tests;
associations between categorical variables were analyzed using
the χ2 test and Fisher's exact test, as appropriate; correlations
were assessed using the Pearson or Spearman correlation.
Second, a linearmixed-effectsmodelwasused to evaluate the
associationofDGFwith serial changes of leptin (log-transformed)
and ADPN, controlling for the recipient’s age, gender and BMI.
Third, a receiver operating characteristic (ROC) curve
analysis was performed to assess the utility of the levels of
leptin and ADPN (as well as SCr) in predicting DGF. The
optimal cut-off points were determined.
Statistical analyses were performed using SPSS version
21.0, and a significance level of 0.05 was considered.
3. Results
3.1. Study Cohort
The final study cohort included 40 patients. Their demo-
graphic and transplant data are shown in supplementary
material (Table S1).
3.2. Leptin and Adiponectin
The time-course of leptin and ADPN levels during the first
post-transplant week is summarized in Table 1. Compared to
before the transplant, the median leptin levels declined
2 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L X X ( 2 0 1 4 ) X X X – X X X
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significantly at day-1, by approximately 47%, but on day-7, a
less-pronounced reduction of approximately 34% was ob-
served. With regard to ADPN, compared to before the
transplant, the mean levels of plasma ADPN declined by
approximately 47% at day-1 and 27% at day-7.
As expected, the leptin values were positively correlated
with BMI at all time points, whereas no correlation was found
with ADPN. Levels of leptin, but not ADPN, were significantly
higher in female patients, even after adjustment for BMI, and
correlated positively with the recipients’ ages at all time
points. Neither leptin nor ADPN was significantly correlated
with time on dialysis, age of the transplant donor, HLA
mismatches and cold ischemia time. Additionally, no signif-
icant differences were found in relation to the donor status or
any type or dose of the immunosuppressive drugs used.
3.3. Delayed Graft Function and Acute Rejection
Eighteen (45%) patients had DGF, whereas 22 (55%) patients
experienced prompt graft function. Ten recipients had an
acute rejection episode during their hospitalization for
transplantation, and acute rejection was more frequently
diagnosed in patients with DGF than in those with prompt
graft function (44% vs. 9%, P = 0.025). Only 2 of the non-DGF
patients experienced an acute rejection episode.
3.4. Longitudinal Changes in the Levels of Leptin and
Adiponectin According to Graft Function
Prior to transplantation, no significant differences were found
between patients with DGF or non-DGF with regard to any of
the adipokines evaluated. After transplantation, the mean
levels of leptin were consistently higher in DGF patients at all
time points compared to non-DGF recipients (Table 1 and
Fig. 1), whereas no differences were noted in the mean levels
of ADPN.
A linear mixed-effects model was used to analyze the
longitudinal changes in leptin and ADPN in the two groups of
patients (DGF and non-DGF) by controlling for variables found
to be associated by the bivariate analysis (recipient age,
gender and BMI) and confirmed the independent association
of DGF with the longitudinal changes of leptinemia but not
adiponectinemia. Regarding leptin, the age of the recipients
was no longer statistically significant and was removed from
the final model. The time measurements of leptin, patient
Table 1 – Time course of the circulating levels of leptin (ln) and adiponectin within the first post-transplantation week.
Before KTx 1st Day ⁎ 2nd Day 4th Day 7th Day
Leptin (ng/mL) Overall 15.9 [8.6–31.7] 8.4 [5.3–20.0] 8.0 [3.4–14.7] 8.4 [0.8–25.2] 10.5 [2.9–25.2]
Median [IQR] DGF 27.4 [12.9–57.7] 12.8 [7.5–22–6] 13.0 [8.7–27.2] 23.1 [1.6–36.7] 16.0 [9.7–26.8]
Non-DGF 11.6 [5.6–41.2] 5.5 [2.2–10.0] 4.2 [2.4–10.0] 0.8 [6-0–15.6] 1.7 [5.3–23.1]
Adiponectin (ng/mL) Overall 226 (72) 119 (35) 114 (33) 139 (35) 165 (29)
Mean (S.D) DGF 250 (80) 110 (39) 105 (37) 130 (39) 157 (32)
Non-DGF 209 (62) 126 (30) 120 (29) 146 (30) 170 (25)
The values shown are the medians and interquartile ranges or the means and standard deviations;
Abbreviations: KTx = kidney transplantation; DGF = delayed graft function; SD = standard deviation.
⁎ 1st day = 8–12 h after surgery.
Fig. 1 – Longitudinal changes of the pre-transplant and one-
week post-transplant circulating levels of leptin and
adiponectin regarding graft function.Evolution of mean and
median values of adiponectin and leptin, respectively,with 95%
confidence intervals; measurements were performed preoper-
atively (day 0), and then at first (day 1), second (day 2), fourth
(day 4) and seventh (day 7) days after kidney transplantation.
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gender, BMI and DGF were independent factors associated
with leptinemia (Table S2). Even after adjusting for recipient
gender and BMI, the DGF remained significantly associated
with the longitudinal changes of leptinemia: the recipients
with prompt graft function presented lower average
leptinemia at all times studied. According to our estimation,
the first mean leptin values after transplantation will be
approximately two times higher in DGF patients when
controlling for recipient gender and BMI. A significant
interaction was observed between the recipient gender and
BMI, whichwas retained in themodel, meaning that the effect
of BMI on leptin changes is different according the gender, i.e.,
the effect of an increase in BMI is more pronounced in males
and attenuated in females.
3.5. Predicting DGF Using Leptin and Adiponectin
Receiver operating characteristic (ROC) analysis was conduct-
ed to evaluate the performance of leptin and ADPN in
discriminating the transplant recipients with DGF. This
analysis showed that leptin at day-1 was moderately accurate
in predicting the need for dialysis within the first week post-
transplant, whereas ADPN was not. The area under the curve
(A.UC) for the prediction of DGF was 0.76 (P = 0.007; 95% CI:
0.60–0.92) for leptin on day-1, which was slightly better than
the diagnostic performance of SCr (AUC = 0.72, P = 0.012; 95%
CI: 0.59–0.90) (Fig. 2). When adjusted for BMI (leptin/BMI ratio),
the performance of one-day leptin in predicting DGF was
similar (AUC = 0.73, P = 0.017; 95% CI: 0.57–0.90). The potential
of pre-transplant leptin levels (day-0) in predicting DGF was
also assessed due to higher levels of leptin in DGF vs. non-DGF
patients before KTx, but this variable performed poorly
having a non-significant AUC of 0.62.
An ROC curve was also created to evaluate the perfor-
mance of the reduction in serum leptin levels between pre-
transplant and day-1 (Δleptin day 1−day0) in predicting DGF and
resulted in an AUC of 0.73 comparable to one-day SCr (Fig. 2).
In analyzing the ROC curve of Δleptin day 1−day0, the optimal
sensitivity and specificity were achieved at a leptin reduction
ratio of 41.7% (sensitivity: 81%; specificity: 62%; positive and
negative predictive values of 68 and 77, respectively).
In analyzing the ROC curve of leptin on day-1, the optimal
sensitivity and specificity were achieved at a leptin concen-
tration of 10.8 ng/mL (sensitivity: 73%; specificity: 77%;
positive and negative predictive values of 76 and 74, respec-
tively). Separate analysis by gender, showed that the perfor-
mance of leptin at day-1 in diagnosing DGF improved
considerably for male gender (AUC = 0.86, P = 0.004; 95% CI:
0.70–1.00), and the optimal sensitivity and specificity were
achieved at a leptin concentration of 6.4 ng/mL (sensitivity:
89%; specificity: 79%; positive and negative predictive values
of 81 and 88, respectively). Due to small number of female
recipients (n = 14), this analysis was not done separately for
female gender.
3.6. Predicting Acute Rejection and Post-Transplant Anti-
HLA Antibodies Using Leptin
The predictive power of serum leptin in acute rejection was
also analyzed, but no significant ability to predict acute
rejection was found at any time-point considered. Pre-
transplant anti-HLA screening was positive in 9 patients
(22.5%) and in 12 patients (30%) during the first year following
KTx; in 2 patients (5.0%) they were detected before transplant
only, in 5 patients (12.5%) after transplant only, and in 7
patients (17.5%) both before and after transplantation. No
significant association between leptin levels and anti-HLA
positivity was showed.
4. Discussion
To date, most of the research on leptin and ADPN has been
focused on its association with metabolic and cardiovascular
health. Up to know, no reported study has examined the
clinical utility of these adipokines in the diagnosis of graft
dysfunction after KTx. We studied the performance of leptin
and ADPN levels in predicting DGF using ROC analysis and
compared these results with the routinely used SCr. Leptin
AUC (95% CI) P Value
Day 0 (pre-transplant)
Serum leptin (ng/mL) 0.62 (0.43 -0.81) 0.220
Day 1 (8 to 12 h after surgery)
Serum leptin (ng/mL) 0.76 (0.60-0.92) 0.008
Serum creatinine (mg/dl) 0.72 (0.59-0.90) 0.012
Serum adiponectin (ng/mL) 0.51 (0.31–0.72) 0.676
Leptin reduction rate (%) 
Leptinday 1-day0(%) 0.73 (0.57-0.90) 0.017∆
Fig. 2 – Receiver operating characteristic curves for the serum
levels of pre-transplant leptin, and leptin, adiponectin and
creatinine measured on the first day after KTx, for predicting
delayed graft function (DGF). The table lists the areas under
the ROC curves of leptin, adiponectin and creatinine for
predicting DGF.Abbreviations: SCr = serum creatinine;
ADPN = adiponectin; AUC = area under the ROC
curve.ΔLeptin day1−day0 = percentage changes in serum leptin
between day-1 and day-0.
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levels at day-1, but not ADPN, slightly outperformed the
traditional biomarker SCr in assessing the prognosis of DGF.
Contrary to our expectations, leptinemia did not add sub-
stantially to the early discriminative or predictive power of
SCr for the detection of DGF. Although degradation pathways
of leptin have not been clearly elucidated, it has been
suggested that endogenous leptin is rapidly cleared from
circulation by glomerular filtration and by renal uptake and
degradation [6,25–27]. However, it is possible that other
factors that coexist in the immediate post-transplant period
might stimulate leptin synthesis and delay its elimination.
Inflammation [28] has been implicated in augmenting
leptin secretion. Surgical stress is also associated with an
increase in serum leptin concentration [29,30]. Both of these
conditions concur in KTx. Kidney transplantation is a surgical
procedure that involves an inevitable ischemia-reperfusion
injury with consequent deleterious activation of cellular
oxidases causing oxidative damage, tissue injury and inflam-
mation [31]. Leptin is an acute phase reactant that is involved
in the cytokine network of acute inflammation and stress
response [29]. It is possible that inflammatory cytokines
resulting from the organ transplant process can stimulate
leptin synthesis and attenuate its clearance from circulation,
mainly in recipients with graft dysfunction. This would also
explain why the decrement of plasma leptin concentration in
the immediate post-transplant period did not reach normal
levels in most of patients, even in those with prompt graft
function. At day-7, 64% of our recipients still had levels that
exceeded the upper limit of leptin reference range, or 40%
considering only the recipients with prompt graft function.
Some other studies show the maintenance of elevated serum
concentrations of leptin in KTx recipients [32,33].
This study was designed based upon the assumption that
impaired clearance of leptin (and ADPN) could signal graft
dysfunction earlier than SCr. Of the two adipokines mea-
sured, leptin most closely fulfilled our initial hypothesis.
Adiponectinemia was not significantly higher in recipients
with graft dysfunction andwas not a predictor of DGF. At least
during the first week, graft dysfunction did not reflect
impaired clearance of ADPN, suggesting that factors other
than renal function may be involved. A study from Song and
coworkers [34] demonstrated a decline in circulating ADPN
levels during the initial 72 h after a subtotal nephrectomy in
mice with renal failure, associated to down regulation of
ADPN. Following this reasoning, we can also speculate that
the decrease of circulating ADPN levels observed within the
first week after KTx could be due to two differentmechanisms
according to graft function: enhanced filtration of circulating
ADPN and urinary excretion in prompt graft patients; and
decline in local expression of ADPN in glomerular endotheli-
um as a result of amplified ischemia-reperfusion injury that
usually describes DGF.
Ischemia/reperfusion injury is undoubtedly an important
variable that can influence the outcome of the transplanted
kidney since it is a major risk factor for the development of
DGF and acute rejection [35,36]. In fact, there is an apparent
synergy between the initial injuries of ischemia/reperfusion
and acute graft rejection [37], and because of innate immune
response this deleterious condition can lead to graft dysfunc-
tion [38]. Hence, the immune response against a transplanted
organ may not solely involve a major histocompatibility
complex specific alloimmune response, but in addition, an
immediate nonspecific inflammatory response caused by
ischemia/reperfusion injury [39]. Recent studies highlight
the role of leptin in the immune system [9,20–24], therefore
and beyond DGF we assessed leptin ability to predict acute
rejection and anti-HLA antibodies following KTx. Possibly
because of the small number of patients with acute rejection
and anti-HLA antibodies no significant predictive value was
found. Few studies [22] have addressed the influence of leptin,
or other adipose tissue-derived products, on the allograft
response and outcome, and to the best of our knowledge none
in KTx.
In summary, the findings from the present study clearly
demonstrate the importance of graft function in the clearance
of leptin from the circulation, but not that of ADPN. Graft
function was a stronger determinant of leptinemia, and the
levels of this adipokine slightly outperformed SCr in
predicting DGF. The maintenance of elevated levels of leptin
in KTx and the role of this adipokine in allo-immunity are
some of the questions that arise from this study, showing that
much is still unknown in this field [40].
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4.5. STUDY V 
COMBINING BIOMARKERS IN KIDNEY TRANSPLANTATION  
Fonseca I, Reguengo H, Oliveira JC, Martins LS, Malheiro J, Almeida M, Santos J, Dias L, 
Pedroso S, Lobato L, Henriques AC, Mendonça D. A Triple-Biomarker Approach for the 
Detection of Delayed Graft Function using Serum Creatinine, Cystatin C, and 
Malondialdehyde  
(Submitted) 
 
One biomarker can be very adept at diagnosing a disease, but the combined power of two 
or more biomarkers can be even better. Newly introduced biomarkers should complement 
and have incremental diagnostic and prognostic value over and above the current 
established markers. Utilizing the same prospective cohort, our primary goal for the 
current study was to investigate the value of combining these new markers with the widely 
used SCr level in predicting DGF.  
  Based on the previous research focused on single biomarkers for DGF diagnosis, this 
study identified a simple and clinically applicable tool for detecting graft dysfunction 
earlier than SCr alone.  
  A triple-biomarker approach, using SCr, CysC, and MDA measured 8 to 12 h after 
Kidney transplantation, was the most informative combination, resulting in an increased 
ability (AUC=0.96) to distinguish patients with graft damage and those who would 
require dialysis within the first week. 
  A formula was achieved by fitting a multiple logistic regression model for combining SCr, 
MDA, and CysC measured 8 to 12 hours after kidney transplantation. Using this formula 
and calculating the predicted values, the optimal sensitivity and specificity occurred at a 
value of 0.278 (sensitivity: 100%; specificity: 86%; positive and negative predictive 
value: 88% and 100%, respectively; and positive and negative likelihood ratios of 7.35 
and 0, respectively).  
  Combining biomarkers from different pathophysiologic pathways seems to be rational 
and a reliable strategy for optimizing sensitivity and specificity and obtaining additive 
diagnostic and prognostic information. 
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ABSTRACT 
Serum creatinine (SCr) alone does not allow for the early diagnosis of delayed graft 
function (DGF) following kidney transplantation (KTx). The diagnostic utility of urinary 
neutrophil gelatinase-associated lipocalin (uNGAL), serum leptin, malondialdehyde 
(MD.A), and cystatin C (CysC) for the early detection of DGF was previously evaluated by 
our group in a prospective cohort study of 40 consecutive adults undergoing KTx. 
Because no single biomarker achieved adequate sensitivity or specificity for practical 
purposes, this study was designed to evaluate the combined use of new markers with 
SCr. Urine and blood samples were collected 8-to-12 h after KTx (day-1). Logistic 
regression was used to combine the biomarkers, and receiver operating characteristic 
curves and areas under the curve (AUC-ROC) were generated. 
Eighteen recipients developed DGF (dialysis requirement during the first post-transplant 
week). On day-1, the AUC for SCr to predict DGF was 0.73, 0.88 for uNGAL, 0.90 for 
MDA, 0.76 for leptin, and 0.91 for CysC. Adding new biomarkers to SCr enhanced the 
performance of DGF prediction, and the best combination was achieved with SCr, MDA, 
and CysC (AUC=0.96, sensitivity=100%; specificity=86%). A combination of graft damage 
biomarkers outperformed SCr in the early diagnosis of DGF, and the best performance 
was achieved by a triple-marker approach, using SCr, MDA, and CysC. 
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INTRODUCTION 
Delayed graft function (DGF) is a clinical diagnosis that describes kidney dysfunction 
immediately after kidney transplantation (KTx), usually related to ischemic damage to the 
graft. The rate of DGF after KTx varies from 2% to 50%, depending on the definition and 
the center’s practice, and it is one of the most important risk factors for both acute 
rejection and impaired renal function at one year [1-4]. Ischemia/reperfusion injury after 
organ transplantation is a major cause of DGF, which is associated with prolonged 
hospital stay, additional invasive procedures, supplementary costs and greater risk of 
early and long-term graft loss. Much research effort has been devoted to the search for 
DGF predictors, also called markers, that would allow for early determination of allograft 
function and of prognoses for one-year and long-term graft survival. Unfortunately, the use 
of baseline characteristics alone (donor and recipient age, pre-transplant dialysis time, 
HLA mismatches, etc.) has limited accuracy in predicting both early and late graft 
outcomes. Several clinical algorithms have been proposed to predict DGF based on pre-
operative risk factors, but none has been used routinely in clinical practice [5-7]. 
Currently, although inadequate for timely diagnosis and prognosis, serum creatinine (SCr) 
is an established and most commonly used clinical indicator of kidney function [8]. Recent 
insights have suggested that allograft injury and recovery could be better characterized by 
new biomarkers. In KTx, numerous biomarkers have been evaluated over the past 
decade, but thus far, the evidence to support their use in routine practice has been limited 
[9-12]. Newly introduced biomarkers should complement and have incremental diagnostic 
and prognostic value over and above the current established markers. It would be ideal to 
discover a single marker with very high discriminatory accuracy, defined in terms of test 
sensitivity and specificity [13, 14]. However, for most diseases, and particularly for KTx, 
single markers might not reflect all of the facets of initial graft dysfunction, and they do not 
have adequate sensitivity or specificity for practical purposes. One approach to increasing 
the clinical value of biomarkers and improving their screening sensitivity is to identify 
additional biomarkers and to combine them because a multimarker strategy might better 
characterize the complexity of DGF [15]. 
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We recently demonstrated, in a prospective cohort study, that urinary neutrophil 
gelatinase-associated lipocalin (uNGAL) [16], serum cystatin C (CysC) and 
malondialdehyde (M.DA) [17], and serum leptin (ongoing study) within the first 24 h 
following KTx predicted DGF better than SCr levels or changes in SCr levels. Utilizing the 
same cohort, our primary goal for the current study was to investigate the value of 
combining these new markers with the widely used SCr level in predicting DGF (defined 
as dialysis requirement within the first week after KTx). 
 
PATIENTS AND METHODS 
Study Design and Patient Population  
Consecutive patients with end-stage renal disease, who were undergoing living or 
deceased donor KTx in the Department of Nephrology and Kidney Transplantation of 
Centro Hospitalar do Porto between December 2010 and May 2011, were prospectively 
enrolled. Patients younger than the age of 18 years old or who required multiorgan 
transplants were not included. After transplantation, recipients with primary graft failure 
were excluded. The Institutional Review Board of Centro Hospitalar do Porto approved 
this study. Each participant provided informed consent. 
 
Sample Collection and Biomarker Measurements  
Blood and urinary samples were collected as follows: 3 to 6 h prior to transplant surgery 
(pre-transplant); on the following morning, approximately 8 to 12 h after graft reperfusion 
(day-1); and then on the second, fourth, and seventh days after transplant, for a total of 
five samples per patient. All samples were immediately centrifuged, aliquoted and frozen 
within one hour after collection. Subsequently, they were stored at -80°C until analysis, 
which was performed approximately one to two weeks after collection. 
The candidate biomarkers were measured using the following methods. Neutrophil 
gelatinase-associated lipocalin was measured in urine (uNGAL) using a two-step 
chemiluminescent microparticle immunoassay on a standardized clinical platform 
(ARCHITECT, Abbott Diagnostics, Germany). Malondialdehyde was measured in plasma 
using a commercial high-performance liquid chromatography kit (Chromsystems, Munich, 
Germany). Leptin was measured in serum by ELISA, based on the direct sandwich 
technique using kits from Mercodia (Sweden). Cystatin C was measured in serum (CysC) 
by particle-enhanced nephelometric immunoassay (Siemens Diagnostics, Germany).  
 
Definitions  
Delayed graft function was defined by the need for dialysis during the first week after KTx. 
“Prompt” function (non-DGF) was characterized by no dialysis session being required 
CHAPTER 4     Results	  
 91 
during the first post-transplantation week.  
Percentage change in SCr (rSCr) was calculated individually for each subject as the 
difference between SCr on day-1 and day-0 divided by SCr on day-0 (or difference 
between day-2 and day-1 divided by SCr on day-1), multiplied by 100. 
  
Statistical Analyses 
The distributions of continuous variables were analyzed, and the Kolmogorov-Smirnov 
test was performed to assess their deviation from the normal distribution. Variables 
showing a positively skewed distribution, such as SCr, uNGAL, and serum leptin, were 
natural logarithm transformed (ln) prior to parametric test analyses. Normally distributed 
variables are presented as the mean values and standard deviations (SDs), and variables 
exhibiting skewed distributions are presented as the medians and 25th-75th quartiles 
(IQR=interquartile range). Categorical variables are reported as percentages.  
Correlations between biomarkers were assessed using Pearson’s correlation coefficient, 
and SCr, uNGAL, and serum leptin levels were log-transformed before analysis to 
normalize the distribution.  
Receiver-operating characteristics (ROC) curves were generated to analyze single and 
multiple biomarkers, and the areas under the curve (AUCs) were calculated. For joint 
analysis of multiple biomarkers, a fitted multiple logistic regression model (with DGF as 
the dependent variable) was used to yield maximum sensitivity and specificity. Pre-
transplant variables known to be associated with DGF and considered potential 
confounders were included in the models. Multicollinearity among covariates was 
examined through the correlations of regression coefficients. The optimal cut-off points 
were determined by the largest sum of sensitivity and specificity, and the positive and 
negative likelihood ratios were calculated as follows: sensitivity/(1–specificity) and (1–
sensitivity)/specificity, respectively [18]. 
Statistical analyses were performed using the SPSS software, version 22.0, and a 
significance level of 0.05 was considered. 
 
RESULTS 
During the recruitment period, 42 patients were enrolled consecutively. Two recipients had 
primary graft failure and were excluded. Therefore, the final study cohort included 40 
patients. Their demographic and transplant data are shown in Table 1. 
Eighteen (45%) patients had DGF, whereas 22 (55%) patients experienced prompt graft 
function. The rate of DGF was higher in kidney grafts from deceased donors, but this 
difference was not statistically significant (51.7% vs. 27.3%, P=0.286). In terms of the 
traditional predictors of DGF, except for cold ischemia time and recipient age, no 
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significant differences were found between the DGF and non-DGF groups regarding the 
baseline characteristics or induction therapy (Table 1).  
 
Table 1. Summary of the demographic and clinical characteristics of the kidney transplant donors and 
recipients (total patient cohort and separated into delayed or prompt graft function)  
Values are expressed as means ± standard deviations or as absolute numbers and percentages. Comparisons of 
continuous variables between groups were analyzed using parametric (t-test) or nonparametric (Mann-Whitney) 
tests; the associations between categorical variables were analyzed using the χ2 test and Fisher's exact test. 
Abbreviations: HLA, human leukocyte antigen; BMI, body mass index; PRA, panel reactive antibody. 
 
 
 
  
 TOTAL  
(n=40) 
DGF  
(n=18) 
NON-DGF 
(n=22) P-VALUE 
DONOR     
Age (yr) 51.2 ± 11.4 51.1 ± 13.4  51.2 ± 9.9 0.172 
Male sex 26 (65) 14 (78) 12 (54.5) 0.125 
Living donor 11 (27.5) 3 (16.7) 8 (36.4) 0.165 
Expanded criteria donors 3 (7.5) 1 (5.6) 2 (9.1) 0.541 
Serum creatinine (mg/dl) 0.81 ± 0.18 0.85 ± 0.21 0.78 ± 0.16 0.318 
DONOR-RECIPIENT     
HLA mismatches 3.39 ± 1.24 3.38 ± 1.07 3.41 ± 1.46 0.941 
Cold ischemia time (h) 12.1 ± 7.9 15.2 ± 7.8 9.6 ± 7.3 0.035* 
Living donor 2.8 ± 0.5 2.5 ± 0.5 3.0 ± 0.5 0.204 
Deceased donor 16.2 ± 5.9 18.1 ± 5.1 14.1 ± 6.2 0.088 
RECIPIENT      
Age (yr) 49.2 ± 15.2 56.3 ± 10.9 43.3 ± 15.9  0.006* 
Male sex 26 (65) 11 (61) 15 (68) 0.641 
Caucasian  40 (100) 18 (100) 22 (100) - 
BMI (kg/m2) 24.8 ± 4.9 26.2 ± 4.4 23.6 ± 5.0 0.091 
Previous kidney transplant 2 (5) 0 (0) 2 (9.1)  
Time on dialysis (yr) 4.4 ± 4.7 5.6 ± 6.2 3.4 ± 2.3 0.135 
Pre-transplant therapy     
Dialysis     38 (95) 18 (100) 20 (90.9) 
0.296 Pre-emptive transplantation 2 (5) 0 (0) 2 (9.1) 
Cause of kidney disease     
IgA nephropathy 7 (17.5) 2 (11.1) 5 (22.7) - 
Glomerulonephritis     6 (15.0) 4 (22.2) 2 (9.1) - 
Diabetic nephropathy     5 (12.5) 3 (16.7) 2 (9.1) - 
Autosomal-dominant polycystic kidney disease 3 (7.5) 3 (16.7) 0 (0) - 
Unknown 4 (10.0) 1 (5.6) 3 (13.6) - 
Others     15 (37.5) 5 (27.8) 10 (45.5) - 
Peak PRA (%) 5.5 ± 15.1 5.0 ± 15.0 5.9 ± 15.5 0.853 
0     29 (72.5) 14 (77.8) 15 (68.2) - 
1-25 8 (20.0) 3 (16.7) 5 (22.7) - 
26-75 3 (7.5) 1 (5.6) 2 (9.0) - 
Current PRA (%) 2.3 ± 8.6 3.1 ± 11.7 1.6 ± 4.9 0.585 
0     34 (85) 15 (83.3) 19 (86.4) - 
1-25 5 (12.5) 2 (11.1) 3 (13.6) - 
26-50 1 (2.5) 1 (5.6) 0 (0) - 
Induction regimen     
Antithymocyte globulin (ATG-F)  4 (10) 1 (5.6) 3 (13.6) 0.613 
Basiliximab/daclizumab     30 (75) 14 (77.8) 16 (72.7) 0.789 
Immunosuppression at the time of discharge     
Steroids     38 (95.0) 18 (100) 20 (90.9) 0.296 
Tacrolimus     38 (95.0) 17 (94.4) 21 (95.5) 0.886 
 Cyclosporine A 2 (0.05) 1 (5.6)  1 (5.6) 0.884 
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Candidate biomarkers for the detection of DGF 
Detailed results regarding each biomarker were previously reported [16, 17]. Briefly, levels 
of uNGAL, serum MDA, leptin and CysC were significantly higher in DGF patients. 
Longitudinal changes in the four biomarkers, according to graft function within the first 
week after KTx, are shown in Figure 1. The correlations between markers are displayed in 
table 2. All of the biomarkers were positively correlated, with the exception of leptin.  
 
 
 
 
 
 
 
Figure 1. Longitudinal changes in the four biomarkers during the first week after kidney transplantation 
according to graft function. Graphs show median levels of urinary neutrophil gelatinase-associated lipocalin 
(uNGAL), serum malondialdehyde, serum leptin, and serum cystatin C (CysC) at multiple time points and 
according to the occurrence or not of delayed graft function (DGF and non-DGF, respectively).  
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Table 2. Correlation between markers measured on the first day after kidney transplantation  
 SCr (ln) rSCrday1- 
day0 
rSCrday2- 
day1 
uNGAL (ln) MDA Leptin (ln) CysC 
SCr (ln)  - 0.17 0.07 0.55* 0.45* -0.10 0.51* 
rSCr day1- day0  0.17 - 0.42* 0.49 0.46* 0.02 0.60** 
rSCrday2- day1 0.07 0.42* - 0.63** 0.32† 0.16 0.45* 
uNGAL (ln) 0.55* 0.49* 0.63** - 0.52* 0.25 0.80** 
MDA 0.45* 0.46* 0.32† 0.52* - 0.12 0.58** 
Leptin (ln) -0.10 0.02 0.16 0.25 0.12 - 0.15 
CysC 0.51* 0.60** 0.45* 0.80** 0.58** 0.15 - 
Values are given as Pearson’s coefficients and relevant P-values. †P<0.05; *P<0.01; **P<0.001. Logarithm-transformed 
values of SCr, uNGAL, and leptin were used for analysis. 
Abbreviations: SCr = serum creatinine; uNGAL = urinary neutrophil gelatinase-associated lipocalin; MDA = serum 
malondialdehyde; CysC = serum cystatin C; ln = logarithm  
rSCr day1- day0 and rSCrday2- day1 = percentage changes in SCr between day-1 and day-0 and between day-2 and day-1.  
 
 
ROC analysis of day-1 SCr, uNGAL, and serum CysC, MDA, and leptin, individually 
and combined as early biomarkers for DGF detection 
Receiver operating characteristic curves were generated, and AUCs were calculated to 
estimate the diagnostic accuracy of each marker for DGF. Based on the logistic models, 
the predicted values of the combined predictors were calculated and analyzed using ROC 
curves. The performance of day-1 SCr alone and in association with each of the new 
markers (uNGAL, serum CysC, MDA, and leptin) in diagnosing DGF is illustrated in Table 
3. On the morning following KTx, the AUCs for the diagnosis of DGF using only SCr or 
rSCr were 0.732 and 0.755. When adding each of the new markers to SCr, the 
performance of the combined markers improved substantially over that of the SCr 
individually, and the AUCs were 0.914 for CysC, 0.902 for MDA, 0.878 for uNGAL, and 
0.792 for leptin. Combining SCr with the four new markers, the AUC was 0.95, and the 
best diagnostic performance was for SCr combined with serum CysC and MDA 
(AUC=0.96).  
After including SCr, CysC, and MDA in a logistic model for combining these markers, 
none of the pre-transplant variables traditionally associated with DGF, namely donor and 
recipient age, pre-transplant dialysis time, HLA mismatches, and cold ischemia time, were 
statistically significant, and they were removed from the final model by backward 
elimination (Table 4). Recipient and donor age were included in the models separately, 
due to multicollinearity observed when both variables were included. For the same 
reason, given the multicollinearity when pre-transplant time on dialysis and cold ischemia 
time were entered into the model, time on dialysis was included, and donor status was 
used instead of cold ischemia time.  
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Table 3. Areas under the curve (AUCs) for single and combined biomarkers measured on the first 
day after kidney transplantation  
  AUC (95% CI) P-value 
  Day 1 (8 to 12 h after KTx surgery)   
Single    
SCr (mg/dl)   0.732 (0.577 – 0.888) 0.012 
r SCr day 1- day0 (%)  0.755 (0.603 – 0.907) 0.006 
r SCrday 2- day1 (%)  0.783 (0.643 – 0.923) 0.002 
uNGAL (ng/mL)  0.884 (0.773 – 0.996) < 0.001 
MDA (µmol/L)  0.900 (0.807 – 0.994) < 0.001 
Leptin (ng/mL)  0.759 (0.597 – 0.921) 0.008 
CysC (mg/L)  0.914 (0.822 – 1.000) < 0.001 
Combined    
SCr + uNGAL  0.878 (0.763 – 0.992) < 0.001 
SCr + MDA  0.902 (0.811 – 0.992) < 0.001 
SCr + Leptin  0.792 (0.649 – 0.935) 0.003 
SCr + CysC  0.914 (0.820 – 1.000) < 0.001 
SCr + CysC + MDA  0.960 (0.905 – 1.000) < 0.001 
SCr + CysC + uNGAL  0.918 (0.823 – 1.000) < 0.001 
SCr + CysC + MDA + uNGAL  0.939 (0.863 – 1.000) < 0.001 
SCr + CysC + MDA + uNGAL + Leptin  0.950 (0.882 – 1.000) < 0.001 
Abbreviations: SCr = serum creatinine; uNGAL = urinary neutrophil gelatinase-associated lipocalin; MDA = 
serum malondialdehyde; CysC = serum cystatin C; ln = logarithm  
rSCr day1- day0 and rSCrday2- day1 = percentage changes in SCr between day 1 and day 0 and between day 2 
and day 1.  
 
 
 
Table 4. Results of multivariable logistic regression analysis of predictors of delayed graft function, after 
backward elimination of variables routinely associated to delayed graft function. 
 OR P-value  95% CI 
SCr (per unit increase) 1.164 0.572 0.688 – 1.970 
Cystatin C (per unit increase) 4.176 0.023 1.219 – 14.303 
MDA (per 10 units increase) 5.360 0.048 1.016 – 28.276 
Note: Results given by logistic regression. Recipient age, pre-transplant time on dialysis, HLA mismatches, and donor 
status (living/deceased) were not retained in the final model after backward elimination. Serum creatinine was forced to be 
included in the model, using the enter method.  
Abbreviations: OR= odds ratio; 95% CI (95% confidence interval); SCr = serum creatinine; MDA = Serum malondialdehyde; 
CysC = Serum cystatin C.  
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Performance of the Triple-Biomarker Approach, including SCr, MDA, and CysC  
For DGF (n=18) versus all non-DGF (n=22), the formula achieved by fitting the multiple 
logistic regression model for combining SCr, MDA, and CysC measured 8 to 12 hours 
after KTx was as follows: (−12.062 + 0.152 × SCr + 1.429 × CysC + 16.789 × MDA).  
Using this formula and calculating the predicted values, the optimal sensitivity and 
specificity occurred at a value of 0.278 (sensitivity: 100%; specificity: 86%; positive and 
negative predictive value: 88% and 100%, respectively; and positive and negative 
likelihood ratios of 7.35 and 0, respectively). 
 
 
DISCUSSION 
We investigated the usefulness of combining SCr with four new biomarkers for predicting 
DGF after KTx. A triple-marker approach, using SCr, CysC, and MDA measured 8 to 12 h 
after KTx, was the most informative combination, resulting in an increased ability 
(AUC=0.96) to distinguish patients with graft damage and those who would require 
dialysis within the first week.  
Delayed graft function burden is not only clinical but also financial due to the need for 
dialysis after transplant, additional laboratory and imaging studies, allograft biopsies, and 
longer hospital stays. In the long term, patients with DGF are 1.53 times more susceptible 
to graft loss at 5 years and have an overall 10% lower graft survival rate compared with 
patients with prompt graft function [1-3]. Because of the deleterious impact of DGF on 
perioperative care and graft outcomes, significant efforts have been undertaken to 
understand the pathogenesis of and the biological factors associated with this clinical 
condition. A variety of biological elements have been proposed for predicting DGF, but no 
suitable biomarkers are currently used routinely in clinical practice [9-11, 16, 17]  
Allograft function following KTx is commonly monitored using SCr, even given the 
inaccuracy of this marker due to the impact of age, sex, and muscle mass on creatinine 
generation and its inability to detect functional impairment of less than 50% [8, 19]. These 
limitations hamper SCr from being a precise index of renal allograft function and 
compromise its value as a sensitive and reliable tool in the clinical management of KTx 
recipients. Therefore, interest has arisen in alternative markers of renal function, and 
CysC is an emerging endogenous marker of glomerular filtration rate. Cystatin C is a 13.3-
kDa protein produced in all nucleated cells, which is released into the circulation at a 
constant rate and is not affected by other physiological or pathological changes and is 
then freely filtered by the glomeruli without tubular reabsorption or secretion. Cystatin C 
meets all of the criteria of a reliable marker of glomerular filtration rate, and several 
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studies have described the superiority of serum CysC over SCr for diagnosing filtration 
failure, both in native kidney disease patients [20-22] and in KTx recipients [23-25].  
Although not a marker of glomerular filtration, NGAL, in both the urine and plasma, has 
been considered a promising biomarker of AKI and DGF in several settings [26-28]. NGAL 
is a 25-kDa protein normally expressed at low levels in multiple tissues, and it is excreted 
in the urine in small amounts. Nevertheless, after renal insult, both urine and plasma 
NGAL are increased, as occurs following ischemia-reperfusion injury in transplanted 
kidneys. Induction of NGAL after kidney injury precedes the elevation of classical markers 
of kidney damage. Given these data, levels of NGAL were shown to predict dialysis 
requirements within the first week, notably preceding the postoperative peak in SCr levels, 
which only occurred between the second and fourth days [9, 16, 27, 29].  
Malondialdehyde was recently identified by our group as an early marker of graft 
dysfunction and a predictor of DGF [17]. Malondialdehyde is the most studied product of 
polyunsaturated fatty acid peroxidation [30, 31]; therefore, it has been frequently used as 
a biomarker of oxidative stress in several settings [32-36]. Oxidative stress is one of the 
most important components of the ischemia-reperfusion process [37-41], which is an 
inevitable phenomenon in KTx. Accordingly, we showed that elevated MDA levels 
reflected dysfunction of the kidney and predicted the need for renal replacement therapy 
within the first week following KTx better than SCr [17]. 
Along with MDA, leptin was another biomarker that was first hypothesized by our group to 
be an indicator of graft dysfunction. To date, most of the research on leptin has been 
focused on its associations with metabolic and cardiovascular health. So far, no reported 
studies have examined the clinical utility of leptin in the diagnosis of graft dysfunction after 
KTx. To the best of our knowledge, we addressed this question for the first time, and we 
confirmed that leptin levels slightly outperformed the traditional biomarker SCr in 
assessing the prognosis of DGF (ongoing study).  
Our previous research concentrated on single biomarkers for DGF diagnosis. The present 
study focused on combining biomarkers to diagnose DGF more efficiently. Due to the 
complexity and overlapping pathophysiological mechanisms contributing to DGF and the 
distinct expression of biomarkers, it is unlikely that a single biomarker would be sufficient 
for accurate and reliable diagnosis of graft damage and for determining DGF prognosis. 
Consequently, the incorporation of several markers into a diagnostic or prognostic panel 
will likely be required to profile acute graft injury and its effects [15, 42]. Malondialdehyde 
and CysC evaluate different aspects and/or areas of kidney injury: MDA appears to be a 
more specific marker of ischemic-reperfusion, whereas CysC is a more functional marker 
of the glomerular filtration rate rather than of injury. Given these findings, combining these 
two biological pathways through these markers seems to increase their predictive value 
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beyond that of SCr in providing an early diagnosis of DGF. We examined different 
biomarker combinations, and the performance of these three combined markers was the 
best one achieved.  
Although uNGAL has shown promising results as a predictor of DGF, the performance of 
the combinations that comprise uNGAL was lower than the triple-marker approach with 
SCr, MDA, and CysC. A possible explanation for the inferior performance of uNGAL might 
have been the lack of samples in some recipients with transient anuria. In our study, 5 
recipients were anuric the morning following graft reperfusion, resulting in 12.5% of our 
patients not having urine samples to measure uNGAL at that particular time point. These 
patients could not be included in any of the approaches that included uNGAL, which 
reduced the sample size and the performance of uNGAL combinations. We chose to 
measure NGAL in urine instead of blood because uNGAL more accurately represents 
tubule damage in the kidney than filtration from the blood and because of the non-invasive 
nature of sample collection and the reduced number of interfering proteins. However, 
despite the unquestionable value of urinary markers, their use in transplant recipients 
could also be a drawback because of possible transient graft anuria and, consequently, 
the inability to obtain a urine sample. 
This paper explored the optimal marker combination for DGF diagnosis using logistic 
regression. Combining multiple biomarkers for clinical use remains a challenge. The 
additional diagnostic and prognostic information gained by any biomarker over an 
established marker must be determined using adequate statistical tools. We focused 
particularly on improving the sensitivity and specificity in order to increase the accuracy of 
the diagnosis of acute graft dysfunction and of dialysis requirement prognosis. A very 
large number of biomarkers fail to be used in clinical practice due to the weakness of their 
clinical performance, namely, low sensitivity and low specificity [43]. After successful 
discovery and validation, some biomarkers fail in their ability to contribute decisively to 
patient care because they provide some incremental, but clinically not essential, 
information [44, 45]. The current study identified a simple and clinically applicable tool for 
detecting graft dysfunction earlier than SCr alone. For practical purposes, the 
concentrations of SCr, MDA, and CysC can be easily measured in routine blood samples, 
and the results can be replaced in the fitted formula. The final score would allow for the 
identification of kidneys with significant ischemia-reperfusion injury, which could result in 
easier clinical decision-making and more effective recipient management, thereby 
improving outcomes.  
We previously described the strengths and limitations of this observational study. Given 
our relatively small sample size, larger studies should be conducted in the transplant 
setting to verify our findings. We designed a prospective, longitudinal study to identify 
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early markers of graft dysfunction during the KTx peritransplant period and to investigate 
their accuracy in predicting DGF. Our group first hypothesized two of the four biomarkers 
tested as early markers of kidney graft dysfunction. Given these hypotheses, we believed 
that it would be imprudent and costly to recruit a larger cohort, particularly because each 
patient was subjected to five measurements of each marker.  
Despite these limitations, the current results suggested that the combined use of SCr, 
MDA, and CysC could be an important tool for the early determination of allograft function 
and thereafter for identifying individuals at the greatest risk of developing DGF. A major 
problem in selecting a biomarker profile is the proportional increase in economic burden. 
Thus, a “parsimonious” biomarker combination must be used in a cost-effective manner, 
and this consideration was an additional reason for choosing a combination of two, and 
not more, new markers to be added to the traditional marker.  
In summary, combining biomarkers from different pathophysiologic pathways seems to be 
rational and a reliable strategy for optimizing sensitivity and specificity and obtaining 
additive diagnostic and prognostic information. In this study, we used multiple logistic 
regressions to combine several biomarkers, and a triple-marker approach, using SCr, 
MDA, and CysC, showed added value for the early detection of DGF.  
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Delayed graft function is a common complication that affects kidney grafts immediately 
after transplantation. The impact of DGF in graft and patient survival is controversial. 
Some single-center studies have reported that DGF without rejection may have no impact 
on the long-term graft survival 273-275, but other investigators found that DGF is associated 
with a poor graft outcome independent of acute rejection 11, 32, 38. There are also some 
controversies about the DGF impact on patient survival. This study reviewed our kidney 
transplant experience over the past three decades and focused on the impact of DGF with 
or without rejection on patient and long-term graft survival using a customary Cox survival 
analysis and a novel approach with competing events.   
  Graft loss was defined as the absence of kidney function, occurring any time after 
transplantation due to either patient death with a functioning allograft (“patient death”) or 
irreversible graft injury requiring chronic dialysis and/or retransplantation (“graft failure”).  
  Survival analysis was performed for evaluating graft and patient survival. First, estimates 
of cumulative incidence function (CIF) that accounts for competing risks were calculated 
and compared with the routinely used complement of Kaplan-Meier estimate (1-KM). 
The appropriate competing risks approach to estimate CIF resulted in a lower estimate 
of cumulative incidence. In other words, the actual probabilities of graft failure and 
patient death is wrongly overestimated using Kaplan-Meier method and the longer the 
duration of follow-up the larger the difference between the estimated by these two 
methods.  
CHAPTER 4     Results 	  
	  
	  104 
  The application of subdistribution regression model for competing risks showed that 
DGF by itself and independent of acute rejection has a detrimental effect on long-term 
graft survival, but not on patient survival. 
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Abstract
Objective: In kidney transplantation, the impact of delayed graft function (DGF)
on long-term graft and patient survival is controversial. We examined the impact
of DGF on graft and recipient survival by accounting for the possibility that death
with graft function may act as a competing risk for allograft failure.
Study design and Setting: We used data from 1281 adult primary deceased-
donor kidney recipients whose allografts functioned at least 1 year.
Results: The probability of graft loss occurrence is overestimated using the com-
plement of Kaplan–Meier estimates (1-KM). Both the cause-specific Cox propor-
tional hazard regression model (standard Cox) and the subdistribution hazard
regression model proposed by Fine and Gray showed that DGF was associated
with shorter time to graft failure (csHR = 2.0, P = 0.002; sHR = 1.57,
P = 0.009), independent of acute rejection (AR) and after adjusting for tradi-
tional factors associated with graft failure. Regarding patient survival, DGF was a
predictor of patient death using the cause-specific Cox model (csHR = 1.57,
P = 0.029) but not using the subdistribution model.
Conclusions: The probability of graft loss from competing end points should
not be reported with the 1-KM. Application of a regression model for subdistri-
bution hazard showed that, independent of AR, DGF has a detrimental effect on
long-term graft survival, but not on patient survival.
Introduction
Delayed graft function (DGF) is the most common com-
plication affecting kidney allografts in the immediate
post-transplant period. The rate of DGF after kidney
transplantation (KTx) can vary from 2% to 50% depend-
ing on the definition and the practice center, and it is one
of the most important risk factors for both acute rejection
(AR) and impaired renal function at one year [1–4].
The impact of DGF on long-term graft survival is con-
troversial [4]. Some single-center studies have reported
limited or no impact of DGF on long-term graft survival in
the absence of AR [5–8] while others have associated DGF
with poor graft outcome independent of rejection [9–12].
Some authors have examined the association between DGF
and patient survival, also with conflicting findings. Some of
those studies reported no association between DGF with
patient death with a functioning graft [6, 13], whereas
738 © 2015 Steunstichting ESOT 28 (2015) 738–750
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others showed a negative effect of DGF on survival of KTx
recipients [9, 14–17].
Survival analysis is used to analyze time-to-event data
and is commonly used in medical research [18]. In KTx,
the Kaplan–Meier curves are one of the most used method-
ologies to study graft and patient survival, which censor all
but one type of outcome. However, a patient can be at risk
for more than one type of events and experience an event
different from the outcome of interest. For example, when
analyzing kidney allograft survival, the event of interest is
chronic graft loss, but other events can be observed, namely
patient death with graft function. These two events are
termed competing risk events. That is, a competing risk is
an event whose occurrence either precludes the occurrence
of another event under examination or fundamentally
alters the probability of occurrence of this other event [19,
20]. If a recipient dies, the decline and loss of graft function
cannot be observed. Graft failure and patient death are
competing end points that are mutually exclusive. Thus,
appropriate methods accounting for the presence of com-
peting risk events must be applied in the analysis and inter-
pretation of such data.
Inappropriate methods such as the complement of Kap-
lan–Meier estimate (1-KM) have been applied to estimate
probabilities of the occurrence of an event of interest in a
competing risks setting [21] [19, 21–23]. This method pro-
duces biased estimates of end point probabilities because
does not account for the various types of potential out-
comes [20, 24]. In other words, the probability of an event
of interest (e.g., graft failure) is estimated in an ideal world
in which the other types of events do not exist (patient
death, for example). Thus, when competing risks are pres-
ent, cumulative incidence function (CIF) is the appropriate
tool to analyse such data [22, 25]. Cumulative incidence
function for a specific event, also known as the subdistribu-
tion function, is defined as the probability of failing from a
given cause in the presence of competing events, given that
a subject has survived or has already failed from different
causes [20, 26, 27]. In other words, the cumulative inci-
dence denotes the expected proportion of patients with a
certain event over the course of time [22].
In the competing risks context and depending on the
purpose of the study, there are different methods to quan-
tify the effect of a covariate [22, 23]. The most common
methods are the regression on cause-specific hazards using
the competing risks analog to the Cox proportional hazards
model, and the regression model for the cumulative inci-
dence function proposed by Fine and Gray [26]. This
method is based on the hazard of the subdistribution, pro-
viding a simple relationship between covariates and CIF,
and is recommended for a competing risk approach [20,
26, 28]. As in any other regression analysis, modeling CIF
can be used to identify potential prognostic factors for a
particular failure in the presence of competing risks or to
assess a prognostic factor of interest after adjusting for
other potential risk factors in the model [27].
The kidney transplant program at our center began in
1983. From that time to the present, the rates of DGF var-
ied due to the distinctive immunosuppressive protocols
introduced, the inclusion of kidneys from living donors,
and more recently the inclusion of expanded-criteria
donors (ECD). We reviewed our KTx experience over the
past three decades to study what effect evolving DGF (with
and without AR associated) had on patient and long-term
kidney transplant outcomes. Our analysis further supple-
ments the current state of knowledge by assessing the
impact of DGF on graft and recipient survival and by
accounting for the possibility that death with graft function
may act as a competing risk for allograft failure.
Materials and methods
Subjects and study design
This retrospective single-center study used data from the
renal transplant database of the Department of Nephrology
and Kidney Transplantation of Centro Hospitalar do Porto.
Analyses were conducted on data from adult recipients
who received a primary deceased-donor kidney transplant
from August 1983 through December 2012 at this center
and had a functioning renal allograft for at least 1 year.
Exclusion criteria were (i) patients younger than 18 years
old (n = 144), (ii) multi-organ transplant recipients,
including kidney–pancreas (n = 169), (iii) retransplants
(n = 163), (iv) recipients of living kidney donor (n = 150),
and (v) recipients whose allografts functioned <1 year
(n = 196). Patients with missing data on DGF or AR were
also excluded from the analysis (n = 33, 2.5% of the final
cohort). Because organ donation after circulatory death is
not performed in our country, all donations occurred after
brain death.
All patients were followed up from the time of transplant
until death, graft failure or until December 31, 2013. The
study was approved for the Institutional Review Board of
Centro Hospitalar do Porto.
Definitions, variable categorization and main outcomes
The primary exposure of interest was the development of
DGF after transplantation, with or without AR. In the cur-
rent study, DGF was defined as the need for dialysis during
the first week after transplantation. This definition was the
same over the observation period of the three decades.
Acute rejection was defined as either biopsy-proven rejec-
tion or antirejection treatment without biopsy. A variable
“DGF-AR” was created with four categories: neither DGF
nor AR; only DGF; only AR; DGF and AR. The cause of
© 2015 Steunstichting ESOT 28 (2015) 738–750 739
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kidney disease was categorized into three groups represent-
ing glomerular disease, diabetes, and all other diseases.
The study sample was divided into four cohorts based on
the times in which immunosuppressive medications were
introduced into clinical practice (“Transplant Era”): “Era” 1,
before 1990, the time of azathioprine and cyclosporine, no mi-
croemulsion; “Era” 2, between 1990 and 1995, the era of
cyclosporine microemulsion; “Era” 3, between 1996 and 2000,
marked by mycophenolate mofetil introduction and by the
wide use of antithymocyte globulin; and “Era” 4, after 2000,
the time of sirolimus availability and wide use of tacrolimus.
Time on dialysis prior to transplant was categorized as <
and ≥5 years. Peak panel reactive antibody level (PRA-
peak) was categorized into two categories according to the
cutoff of 10%.
“Female-donor mismatch” was labeled when a male reci-
pient received a kidney from a female donor. Patients were
grouped as female donor to male recipient or all other
combinations (female to female, male to male, or male to
female).
The difference between donor and recipient age (recipi-
ent age subtracted from donor age) was divided into four
groups, each representing approximately 25% of the
patients according to quartiles (1stQ: <!15 years; 2ndQ:
≥!15 and ≤!4 years; 3rdQ: >!4 and ≤+6 years; 4thQ:
>+6 years). Donors over the age of 60 or donors over the
age of 50 with two of the following were classified as ECD:
history of high blood pressure, serum creatinine ≥1.5 mg/
dl, or death resulting from a stroke.
Graft loss was defined as the absence of kidney function
occurring any time after transplantation due to either
patient death with a functioning allograft (“patient death”)
or irreversible graft injury requiring chronic dialysis and/or
retransplantation (“graft failure”).
Statistical analyses
Descriptives of baseline characteristics that were identified
by univariate survival analysis (unadjusted) or traditionally
considered as potential confounders for graft loss were cal-
culated, and the results are shown across DGF-AR groups
(Table 1). The following potential confounders were exam-
ined in unadjusted and adjusted multivariable models: (i)
recipient factors (age, cause of ESRD, PRA-peak, time on
dialysis prior to transplant, HCV infection status); (ii)
donor factors (ECD versus standard deceased-donor); and
(iii) transplant factors (number of HLA mismatches,
donor-age difference, “female-donor mismatch”, and
Transplant Era). Continuous variables are expressed as the
mean and standard deviation (SD), and categorical vari-
ables are expressed as proportions.
Survival analysis was performed for analyzing graft and
patient survival. To analyze graft survival, the event of
interest was graft failure and the competing risk event was
patient death with graft function. To analyze patient sur-
vival, the event of interest was patient death with graft
function and the competing end point was graft failure.
Patients without any of these outcomes were censored at
the date of their last recorded visit or at the end of the study
period (December 2013).
First, estimates of CIF taking competing risks into
account were calculated and compared with the (1-km)
estimates. Second, regression models taking competing
risks into account were carried out to analyze the effect of
covariates in the graft and in the patient survival. This
analysis was performed considering two types of hazard:
cause-specific hazard and subdistribution hazard. Propor-
tional cause-specific hazard regression models were per-
formed using the standard Cox cause-specific hazard
regression model, censoring all patients without the event
of interest. An alternative model proposed by Fine and
Gray [26] was the approach used in the current study to
model the subdistribution hazard.
An exploratory analysis was performed to examine the
unadjusted effect of the traditional potential confounders
by fitting univariable models. The cause-specific hazard
ratio (csHR) and the subdistribution hazard ratio (sHR)
for graft loss either due to declining function or to
patient death according to the primary exposure of inter-
est (DGF-AR) were estimated in a multivariable analysis
adjusting for the influence of these potential confound-
ers. The group of categorical variables with lower pro-
portion of the end point (graft failure or patient death)
was considered as the reference class. Therefore, the 1st
and the 4th quartiles of donor-age difference were con-
sidered the reference classes in graft and patient survival,
respectively.
As the main objective of this study was to assess the
prognostic value of a specific variable of interest
(DGF-AR), we opted to study the impact of DGF-AR in
graft and patient survival after adjusting for other risk fac-
tors traditionally considered as potential confounders in
the model, even those that were nonsignificant. The impact
of DGF-AR on graft and patient survival was similar when
including in the model only the statistical significant vari-
ables (supplemental data).
About 37.4% (n = 479) of patients had at least one vari-
able missing. The main variable of interest DGF-AR and
the survival outcome (patient death and graft failure) pre-
sented no missing values. Missing data were considered to
be missing completely at random. Therefore, missing data
were dealt by carrying complete case analyses, in which
patients were excluded in multivariable analyses if the
required variables were missing.
Statistical analyses were performed using SPSS version
22.0 (IBM SPSS Statistics, IBM Corporation, Chicago,
740 © 2015 Steunstichting ESOT 28 (2015) 738–750
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Table 1. Patient demographic and clinical characteristics by DGF-AR occurrence (n = 1281).
Characteristic No DGF nor AR (n = 721) DGF only (n = 274) AR only (n = 175) DGF + AR (n = 111)
Recipient
Age (yr), mean (SD) 43.8 (12.3) 46.0 (12.3) 36.8 (12.2) 39.8 (12.4)
Gender
Male 427 (54.9) 175 (22.5) 111 (14.3) 65 (8.4)
Female 294 (58.4) 99 (19.7) 64 (12.7) 46 (9.1)
Cause of ESRD (n, %)
Glomerulonephritis 274 (57.7) 96 (20.2) 69 (14.5) 36 (7.6)
Diabetes 40 (56.3) 18 (25.4) 5 (7.0) 8 (11.3)
Other 407 (55.4) 160 (21.8) 101 (13.7) 67 (9.1)
Peak PRA (n, %)
<10 533 (60.4) 1784 (20.8) 99 (11.2) 67 (7.6)
≥10 92 (45.8) 50 (24.9) 34 (16.9) 25 (12.4)
Unknown/missing 96 (48.7) 40 (20.3) 42 (21.3) 19 (9.6)
Time on dialysis (mo)
Mean (SD) 3.9 (3.6) 4.2 (3.4) 3.3 (3.1) 4.0 (3.5)
≥ 5 years (n, %) 198 (57.6) 78 (22.7) 35 (10.2) 33 (9.6)
Unknown/missing 31 (57.4) 17 (31.5) 4 (7.4) 2 (3.7)
HCV infection (n, %)
HCV-negative 608 (56.6) 229 (21.3) 151 (14.1) 86 (8.0)
HCV-positive 58 (48.3) 36 (30.0) 12 (10.0) 14 (11.7)
Unknown/missing 55 (63.2) 9 (10.3) 12 (13.8) 11 (12.6)
Donor
Age (yr), mean (SD) 37.7 (14.5) 39.9 (14.9) 36.0 (12.9) 37.3 (12.4)
ECD (n, %) 84 (49.4) 55 (32.4) 18 (10.6) 13 (7.6)
Unknown/missing 9 (69.2) 2 (15.4) 1 (7.7) 1 (7.7)
Donor-Recipient
Cold ischemia time (h)
Mean (SD) 22.2 (8.6) 23.9 (4.9) 22.8 (4.1) 24.0 (4.6)
Unknown/missing (n, %) 389 (65.2) 107 (17.9) 63 (10.6) 38 (6.4)
HLA mismatches
A 1.23 (0.67) 1.17 (0.70) 1.22 (0.63) 1.22 (0.61)
Unknown/missing 42 (64.6) 11 (16.9) 11 (16.9) 1 (1.5)
B 1.21 (0.68) 1.24 (0.67) 1.35 (0.67) 1.29 (0.71)
Unknown/missing 39 (61.9) 12 (19.0) 11 (17.4) 1 (1.6)
DR 0.68 (0.69) 0.61 (0.66) 0.74 (0.73) 0.63 (0.64)
Unknown/missing 35 (54.7) 13 (20.3) 12 (18.8) 4 (6.3)
Female-donor mismatch
Yes 82 (33.2) 50 (20.2) 21 (8.5) 94 (38.1)
No 523 (61.4) 186 (21.8) 133 (15.6) 10 (1.2)
Unknown/missing 116 (63.7) 38 (20.9) 21 (11.5) 7 (3.8)
Donor-recipient age difference (n, %)
≤ !15 yr than recipient 183 (61.4) 67 (22.5) 31 (10.4) 17 (5.7)
!15.1 to !4 yr than recipient 162 (54.4) 69 (23.2) 39 (13.1) 28 (9.4)
!4.1 to +6 yr than recipient 157 (52.7) 59 (19.8) 49 (16.4) 33 (11.1)
> + 6 yr than recipient 150 (52.1) 57 (19.8) 50 (17.4) 31 (10.8)
Unknown/missing (n, %) 69 (77.5) 12 (13.5) 6 (6.7) 2 (2.2)
Transplantation Era
1983–1990 46 (29.5) 31 (19.9) 39 (25.0) 40 (25.6)
1990–1995 152 (49.4) 70 (22.7) 58 (18.8) 28 (9.1)
1996–2000 150 (55.8) 62 (23.0) 41 (15.2) 16 (5.9)
2001–2012 371 (69.2) 104 (19.4) 37 (6.9) 24 (4.5)
Percentages are calculated within DGF-AR status. ERSD, end-stage renal disease; ECD, expanded-criteria donors; HCV, Hepatitis C virus; SD, standard
deviation; yr, year. No missing values for the variables: recipient age and gender, cause of ERSD, and transplantation era.
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IL, USA) and R software using the packages coxph and
cmprsk. A significance level of 0.05 was considered.
Results
Sample
The final sample included 1281 primary adult kidney recipi-
ents transplanted between 1983 and 2012. About 60.7% were
male, and the overall mean age was 43.0 years (SD = 12.6).
Median follow-up was 9.8 years (range 1.0–30.2 years). A
total of 424 (33.1%) grafts were lost during the study period,
either as a result of loss of function (n = 258, 60.8%) or
patient death (n = 166, 39.2%). The main causes of patient
death with graft function were cardiovascular disease
(n = 63, 38.0%), followed by malignancies (n = 35, 21.1%)
and infection (n = 26, 15.7%).
Cumulative incidence function
Figure 1 summarizes the cumulative incidence estimates
for the two possible outcomes taking competing risks into
accounts (the survival plots were halted at 25 years because
the proportion of patients free of an event, but still in fol-
low-up, becomes small). The probabilities of experiencing
graft failure by 5, 10, and 20 years after KTx were 0.06,
0.14, and 0.32, respectively. The probabilities of death with
graft function were 0.03, 0.09, and 0.19, respectively.
Cumulative incidence estimates versus the complement of
Kaplan–Meier estimates
Figure 2 presents the curves for the CIF of the occurrence
of the event of interest obtained using two different meth-
ods: taking competing risks into account and the 1-KM.
The appropriate competing risks approach to estimate
CIF results in a lower estimate of cumulative incidence.
The magnitude of the difference in the incidence of graft
Number at risk 
Graft failure 1281 1000 722 506 301 191 
Patient death 1281 1029 773 575 393 284
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Figure 1 Cumulative incidence curves for all possible outcomes taking
competing risks into account. CIF, Cumulative incidence function.
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Figure 2 The complement of the Kaplan–Meier estimate and the cumulative incidence estimate for graft failure and death with graft function. CR,
competing risks; 1-KM, Complement of Kaplan–Meier estimate.
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failure and patient death, as calculated using the two meth-
ods, increases with the period of follow-up, mainly after the
tenth year. In other words, the actual probabilities of graft
failure and patient death are overestimated using the
Kaplan–Meier method. Furthermore, the longer the dura-
tion of follow-up is the larger the difference between the
estimates by these two methods.
Delayed graft function and acute rejection
The overall incidence of DGF was 30.1% (385 grafts)
and was not associated with AR in 274 grafts (21.4%)
and was associated with AR in 111 (8.7%). The overall
occurrence of DGF declined over decades from 45.5% in
Era 1 to 31.8% in Era 2, 29.0% in Era 3, and 23.9% in
Era 4. The overall incidence of AR similarly decreased
from 50.6% in Era 1 to 27.9% in Era 2, 21.2% in Era 3,
11.4% in Era 4. The characteristics of the recipients
according to DGF-AR status are summarized in Table 1.
The Fig. 3 displays the cumulative incidence curves for
graft failure and death with graft function according to
DGF-AR status. Differences were found between DGF-
AR status with regard to the graft failure: all three cate-
gories of the variable DGF-AR (DGF only, AR only, and
both DGF and AR) had a higher probability of graft
failure than the non-DGF/non-AR category. Concerning
patient survival, the differences between DGF-AR groups
were not so pronounced.
The impact of DGF on graft and patient survival by Cox
and Fine and Gray regression models
Tables 2 and 3 give a summary of the unadjusted and
adjusted effects of covariates for graft failure and patient
death with graft function based on the two types of models:
the cause-specific hazard model (standard Cox propor-
tional hazards regression) and the subdistribution hazard
model (Fine and Gray model).
Graft failure
No DGF nor AR
DGF only
AR only
DGF+AR
No DGF nor AR
DGF only
AR only
DGF+AR
Death with graft function
Number at risk at: (years) 0 5 10 15 20 25 
Graft failure 
No DGF nor AR 721 555 392 268 148 88 
DGF 274 221 166 115 78 55 
AR 175 144 101 76 39 25 
DGF + AR 111 80 63 47 36 23 
Patient Death 
No DGF nor AR 721 552 388 267 157 96 
DGF 274 228 173 123 88 65 
AR 175 159 135 120 89 74 
DGF + AR 111 90 77 65 59 49 
Years
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0 5 10 15 20 25
Years
0 5 10 15 20 25
C
IF
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
C
IF
Figure 3 Cumulative incidence curves for graft failure and death with graft function according to DGF-AR status. DGF, Delayed graft function; AR,
acute rejection.
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Graft survival
The variables identified as significant predictors of graft
failure in unadjusted cause-specific hazard models, and
unadjusted Fine and Gray models were similar (Tables 2
and 3). In both statistical approaches, all three categories of
the variable DGF-AR (DGF only, AR only, and both DGF
and AR) had a deleterious effect on graft survival compared
to the neither DGF nor AR category. The other covariates
associated with graft failure were the Transplant Eras (Eras
1 and 2 vs. 4), grafts from ECD, donor-recipient age differ-
ence (2nd, 3rd, and 4th quartiles vs. 1st quartile), cause of
ERSD (diabetes vs. other), positive HCV status (nearly
reaching the significance level in Fine and Gray model) and
recipient age.
In multivariable models (Tables 2 and 3, cause-specific
and subdistribution hazard models, respectively), DGF with
or without AR as well as AR only remained consistently
associated with graft failure. Furthermore, recipients whose
cause of ERSD was diabetes (nearly reaching the signifi-
cance level in the cause-specific hazard model), transplanta-
tion in Eras 1 and 2, kidneys from ECD or from donors
with an age difference of more than 6 years, were also asso-
ciated with poor graft survival. In both models, when the
donor-recipient age difference was added, the recipient’s
age became nonsignificant.
Patient survival
In relation to patient death with graft function, in the
unadjusted cause-specific hazard models and unadjusted
Fine and Gray models, the predictors of patient survival
were slightly different among models (Tables 2 and 3). In
the unadjusted cause-specific hazard models, the variables
DGF (isolated or associated to AR), Transplant Era, ECD,
donor-recipient age difference, cause of ERSD, pretrans-
plant time on dialysis, PRA-peak, HCV status, and recipi-
ent age were significantly associated with patient death
(Table 3). In the unadjusted Fine and Gray model, how-
ever, the variables identified as predictors of patient
Table 2. Cox proportional hazard regression (cause-specific hazard model) for all possible events.
Unadjusted models Adjusted model (n = 802)
csHR 95% CI P value csHR 95% CI P value
Graft Failure (censored for patient death) DGF-AR (reference: non-DGF and non-AR)
Only DGF 1.79 1.28–2.48 0.001 2.00 1.30–3.07 0.002
Only AR 2.99 2.17–4.10 <0.001 2.81 1.81–4.38 <0.001
DGF + AR 3.37 2.35–4.84 <0.001 2.60 1.58–4.27 <0.001
Transplant Era (reference: Era 4 > 2000)
Era 1 (<1990) 2.58 1.65–4.03 <0.001 3.21 1.47–7.04 0.004
Era 2 (1990–1995) 2.03 0.34–3.09 0.001 3.64 1.73–7.62 0.001
Era 3 (1996–2000) 0.92 0.57–1.49 0.74 1.66 0.78–3.55 0.19
ECD (yes vs. no) 2.41 1.73–3.34 <0.001 2.49 1.35–4.60 0.003
Donor-recipient age difference (reference: 1st Q: < - 15 yr)
2nd Q (≥!15 and ≤ !4 yr) 1.76 1.16–2.69 0.009 1.60 0.89–2.88 0.12
3rd Q (> - 4 and ≤ +6 yr) 2.35 1.56–3.53 <0.001 1.73 0.94–3.21 0.081
4th Q (> + 6 yr) 3.91 2.66–5.77 <0.001 2.62 1.32–5.20 0.006
Cause of ESRD (reference: others)
Diabetic nephropathy 1.71 1.01–2.89 0.046 1.21 0.47–3.12 0.069
Glomerulonephritis 1.12 0.87–1.45 0.38 0.75 0.75–1.47 0.77
Time on dialysis (>5 vs. <5 yr) 1.24 0.93–1.65 0.14 1.42 0.97–2.06 0.13
Peak PRA (>10 vs. <10) 1.26 0.92–1.73 0.15 0.93 0.63–1.35 0.69
HCV infection (positive vs. negative) 1.43 1.02–2.00 0.039 1.12 0.73–1.70 0.61
Female-donor mismatch (yes vs. no) 0.98 0.68–1.44 0.98 0.84 0.50–1.41 0.51
HLA MM A (reference: 0)
1 vs. 0 1.18 0.80–1.74 0.19 1.19 0.71–1.97 0.51
2 vs. 0 1.24 0.82–1.89 0.17 1.21 0.70–2.11 0.50
HLA MM B (reference: 0)
1 vs. 0 1.04 0.71–1.52 0.77 1.16 0.71–1.92 0.55
2 vs. 0 1.12 0.75–1.67 0.57 1.46 0.87–2.47 0.16
HLA MM DR (reference: 0)
1 vs. 0 1.02 0.79–1.33 0.75 1.00 0.72–1.41 0.97
2 vs. 0 0.65 0.36–1.15 0.11 0.74 0.34–1.59 0.44
Recipient age (1-yr increase) 0.97 0.96–0.98 <0.001 0.99 0.97–1.01 0.27
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survival were as follows: DGF (DGF only vs. non-DGF/
non-AR), Transplant Eras (Eras 1 and 2 vs. Era 4), donor-
recipient age difference (1st, 2nd, and 3rd quartiles vs. 4th
quartile), cause of ERSD (glomerulonephritis, associated
with decreased HR), time on dialysis, PRA-peak, and reci-
pient age.
Considering the multivariable regression models, the
cause-specific hazard model showed that DGF only, Trans-
plant Eras 1 and 2, diabetes as the cause of ESRD,
pretransplant time on dialysis ≥5 years, positive HCV
status and increasing recipient age had a deleterious effect
on patient survival (Table 3). In the Fine and Gray
adjusted model, only recipient age and Transplant Eras 1
and 2 were significantly associated with patient death
(Table 4). In both models, Transplant Era (Era 2 vs. Era
4) emerged as significant when adjusted for any of the
other variables included.
Unlike the adjusted cause-specific hazard model, the
adjusted Fine and Gray model found that DGF was not
significantly associated with patient death (csHR = 1.57,
95% CI = 1.05–2.35, P = 0.029 vs. sHR = 1.22, 95%
CI = 0.85–1.76, P = 0.28). These differences are related to
the different composition of the risk sets (in contrast to the
cause-specific model where the DGF recipients who lost
their graft were censored and removed from the risk set, in
the subdistribution model, these same patients are main-
tained in the risk set) and to the increased risk of graft fail-
ure found for the recipients with DGF (these recipients had
a 57% higher hazard risk of graft failure compared to non-
DGF/non-AR: sHR = 1.57 95% CI = 1.12–2.21,
P = 0.009).
Discussion
In this study, application of a regression model for subdis-
tribution hazard showed that DGF, alone and independent
of AR, has a significant detrimental effect on long-term
graft survival but not on patient survival. Despite the
Table 2. continued
Unadjusted models Adjusted model (n = 802)
csHR 95% CI P value csHR 95% CI P value
Patient Death (censored for graft failure) DGF-AR (reference: non-DGF and non-AR)
Only DGF 1.95 1.41–2.68 <0.001 1.57 1.05–2.35 0.029
Only AR 1.29 0.85–1.95 0.23 1.19 0.69–2.03 0.54
DGF + AR 2.36 1.57–3.54 <0.001 1.34 0.76–2.34 0.31
Transplant Era (reference: Era 4 > 2000)
Era 1 (< 1990) 2.63 1.69–4.08 <0.001 5.29 2.59–10.8 <0.001
Era 2 (1990–1995) 1.39 0.90–2.14 0.139 3.11 1.58–6.12 0.001
Era 3 (1996–2000) 0.73 0.45–1.20 0.214 1.12 0.56–2.23 0.76
ECD (yes vs. no) 1.58 1.05–2.37 0.027 0.82 0.39–1.70 0.59
Donor-recipient age difference (reference: 4th Q: > +6 yr)
1st Q (<!15 yr) 1.54 1.04–2.28 0.03 0.55 0.28–1.11 0.55
2rd Q (≥!15 and ≤ !4 yr) 1.10 0.72–1.68 0.65 0.70 0.38–1.31 0.70
3rd Q (> - 4 and ≤ +6 yr) 1.14 0.74–1.74 0.56 0.79 0.45–1.38 0.79
Cause of ESRD (reference: others)
Diabetic nephropathy 2.56 1.60–4.11 <0.001 4.07 2.03–8.18 <0.001
Glomerulonephritis 0.76 0.57–1.02 0.071 0.90 0.62–1.32 0.60
Time on dialysis (>5 vs. <5 yr) 1.71 1.28–2.29 <0.001 1.49 1.01–2.20 0.048
Peak PRA (>10 vs. <10) 1.46 1.06–2.01 0.021 1.29 0.89–1.86 0.18
HCV infection (positive vs. negative) 1.87 1.32–2.65 <0.001 1.56 1.00–2.41 0.048
Female-donor mismatch (yes vs. no) 1.06 0.72–1.58 0.76 1.27 0.80–2.04 0.31
HLA MM A (reference: 0)
1 vs. 0 0.75 0.51–1.10 0.15 0.86 0.53–1.39 0.53
2 vs. 0 0.83 0.55–1.25 0.32 1.17 0.69–1.98 0.56
HLA MM B (reference: 0)
1 vs. 0 1.27 0.82–1.98 0.47 1.19 0.69–2.03 0.54
2 vs. 0 1.37 0.86–2.17 0.58 1.40 0.81–2.41 0.23
HLA MM DR (reference: 0)
1 vs. 0 1.08 0.81–1.45 0.67 0.95 0.66–1.37 0.78
2 vs. 0 1.22 0.74–2.00 0.07 1.18 0.65–2.14 0.59
Recipient age (1-yr increase) 1.04 1.02–1.05 <0.001 1.05 1.03–1.08 <0.001
csHR, cause-specific hazard ratio; ERSD, end-stage renal disease; ECD, expanded-criteria donors; HCV, Hepatitis C virus; PRA, panel reactive antibody;
HLA MM, HLA mismatches; yr, year; Q, quartile. The bold printed covariables indicate statistical significance in the multivariable model.
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common use in clinical cancer research, the estimation of
CIF and the application of competing risks models in
nephrology is relatively recent [23, 29–38]. To the best of
our knowledge, this is the first study that used a competing
risks approach to address the impact of DGF on graft and
patient survival.
Some previous studies have suggested that DGF without
AR may have no impact on long-term graft survival [5–8].
Consistent with other reports [9–11], using both of the sta-
tistical approaches, our findings support that DGF per se is
an independent predictor of graft failure. In fact, after
adjusting for most of the factors traditionally associated
with graft failure, early kidney dysfunction has a clear
adverse effect on long-term graft survival meaning that the
presence or absence of DGF will give an indication of the
life expectancy of the kidney graft.
In addition to the DGF-AR status, the other factors inde-
pendently associated with graft failure were, as expected,
Transplant Eras 1 and 2, grafts from ECD donors, diabetes
as a cause of ERSD and increasing donor-recipient age
difference. Compared to donors who were more than
15 years younger than their recipients, all other categories
showed a trend toward an increased risk of graft failure,
including the category of donors who were 4–15 years
younger than the recipient, with a near significant hazard
of failure by the subdistribution approach. This finding was
somewhat unexpected. The donor-recipient age difference
was studied mostly in recipients from living donors. Grafts
donated by live donors who were significantly older than
recipients had similar graft and patient survival compared
to recipients who received organs of a similar vintage [29,
39]. Shin et al. [40] evaluated whether the effect of donor
age was different according to recipient age (≤!21, !20 to
!1, 0–20, and ≥ 21 years) in kidneys from deceased
donors. The authors confirmed that a negative donor-reci-
pient age difference (recipients receiving kidneys from a
donor younger than the recipient) was associated with
greater death-censored graft survival. Our findings are in
the line with this study. However, we did not expect that
the narrow difference of donor-recipient age that we
Table 3. Fine and Gray model (hazard of the subdistribution model) for all possible events.
Unadjusted models Adjusted model (n = 802)
sHR 95% CI P value sHR 95% CI P value
Graft Failure DGF-AR (reference: non-DGF and non-AR)
Only DGF 1.69 1.21–2.35 0.002 1.57 1.12–2.21 0.009
Only AR 3.09 2.24–4.27 <0.001 2.57 1.85–3.56 <0.001
DGF + AR 3.26 2.28–4.67 <0.001 2.26 1.52–3.37 <0.001
Transplant Era (reference: Era 4 > 2000)
Era 1 (< 1990) 2.69 1.74–4.18 <0.001 1.87 1.11–3.14 0.019
Era 2 (1990–1995) 2.23 1.49–3.33 0.001 1.93 1.23–3.03 0.004
Era 3 (1996–2000) 1.02 0.64–1.65 0.93 0.96 0.58–1.60 0.88
ECD (yes vs. no) 2.10 1.51–2.92 <0.001 1.73 1.09–2.74 0.019
Donor-recipient age difference (reference: 1st Q: < !15 yr)
2nd Q (≥!15 and ≤ !4 yr) 1.82 1.20–2.76 0.005 1.56 0.97–2.50 0.066
3rd Q (>!4 and ≤ +6 yr) 2.36 1.60–3.50 <0.001 1.65 1.01–2.70 0.049
4th Q (> + 6 yr) 4.06 2.79–5.90 <0.001 2.52 1.44–4.41 0.001
Cause of ESRD (reference: others)
Diabetic nephropathy 1.71 1.01–2.89 0.046 2.23 1.27–3.92 0.005
Glomerulonephritis 1.12 0.87–1.45 0.38 1.08 0.83–1.41 0.57
Time on dialysis (≥5 vs. <5 yr) 1.13 0.86–1.49 0.39 1.27 0.93–1.73 0.13
Peak PRA (>10 vs. <10) 1.16 0.86–1.56 0.34 1.00 0.70–1.42 0.99
HCV infection (positive vs. negative) 1.38 0.99–1.91 0.058 1.27 0.88–1.84 0.21
Female-donor mismatch (yes vs. no) 0.96 0.66–1.42 0.85 1.02 0.69–1.49 0.94
HLA MM A (reference: 0)
1 vs. 0 1.29 0.89–1.87 0.19 1.00 0.69–1.45 1.00
2 vs. 0 1.33 0.89–1.99 0.17 1.12 0.75–1.68 0.57
HLA MM B (reference: 0)
1 vs. 0 1.05 0.74–1.51 0.77 1.08 0.73–1.59 0.71
2 vs. 0 1.12 0.76–1.63 0.57 1.31 0.88–1.96 0.19
HLA MM DR (reference: 0)
1 vs. 0 1.04 0.81–1.35 0.75 1.08 0.82–1.43 0.57
2 vs. 0 0.64 0.37–1.11 0.11 0.80 0.47–1.37 0.42
Recipient age (1-yr increase) 0.97 0.96–0.98 <0.001 0.99 0.97–1.01 0.20
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Table 3. continued
Unadjusted models Adjusted model (n = 802)
sHR 95% CI P value sHR 95% CI P value
Patient
Death
DGF-AR (reference: non-DGF and non-AR)
Only DGF 1.53 1.08–2.19 0.018 1.22 0.85–1.76 0.28
Only AR 0.80 0.49–1.30 0.370 0.84 0.50–1.41 0.51
DGF + AR 1.29 0.78–2.15 0.320 1.10 0.63–1.93 0.74
Transplant Era (reference: Era 4 > 2000)
Era 1 (< 1990) 1.80 1.09–2.95 0.021 3.74 2.00–7.02 <0.001
Era 2 (1990–1995) 1.29 0.81–2.04 0.280 2.13 1.25–3.62 0.005
Era 3 (1996–2000) 0.75 0.44–1.27 0.280 1.03 0.59–1.78 0.93
ECD (yes vs. no) 1.14 0.70–1.85 0.60 0.88 0.49–1.71 0.70
Donor-recipient age difference (reference: 4th Q: > +6 yr)
1st Q (<!15 yr) 3.07 1.90–4.95 <0.001 1.20 0.65–2.20 0.57
2rd Q (≥!15 and ≤ !4 yr) 1.71 1.01–2.88 0.044 1.19 0.68–2.08 0.56
3rd Q (>!4 and ≤ +6 yr) 1.82 1.07–3.10 0.027 1.54 0.90–2.65 0.12
Cause of ESRD (reference: others)
Diabetic nephropathy 1.41 0.75–2.64 0.28 1.84 0.97–3.49 0.064
Glomerulonephritis 0.62 0.44–0.88 0.007 0.76 0.54–1.07 0.12
Time on dialysis (≥ 5 vs. <5 yr) 1.62 1.17–2.24 0.004 1.24 0.86–1.78 0.25
Peak PRA (>10 vs. <10) 1.61 1.14–2.27 0.007 1.29 0.89–1.86 0.18
HCV infection (positive vs. negative) 1.39 0.92–2.11 0.12 0.99 0.62–1.57 0.95
Female-donor mismatch (yes vs. no) 1.21 0.80–1.85 0.37 1.37 0.91–2.07 0.13
HLA MM A (reference: 0)
1 vs. 0 0.74 0.49–1.11 0.15 0.79 0.52–1.19 0.26
2 vs. 0 0.80 0.51–1.25 0.32 0.84 0.53–1.35 0.47
HLA MM B (reference: 0)
1 vs. 0 1.18 0.75–1.86 0.47 1.09 0.70–1.71 0.70
2 vs. 0 1.14 0.71–1.83 0.58 1.00 0.62–1.62 0.99
HLA MM DR (reference: 0)
1 vs. 0 1.08 0.77–1.5 0.67 1.00 0.72–1.41 0.98
2 vs. 0 1.62 0.97–2.71 0.07 1.43 0.85–2.42 0.18
Recipient age (1-yr increase) 1.05 1.04–1.06 <0.001 1.06 1.04–1.08 <0.001
sHR, subdistribution hazard ratio; ERSD, end-stage renal disease; ECD, expanded-criteria donors; HCV, Hepatitis C virus; PRA, panel reactive antibody;
HLA MM, HLA mismatches; yr, year; Q, quartile. The bold printed covariables indicate statistical significance in the multivariable model.
considered would have a significant effect. We believe that
this result emphasizes the advantage of young donors for
long-term graft survival.
No clear effect of DGF on patient outcome has been
reported. Some studies highlight the association between
DGF and mortality, [9, 14, 17] whereas others [6, 8, 13]
have not found a significant effect. None of these studies
accounted for competing risks.
In our study, we confirmed this association using a stan-
dard Cox proportional hazards regression, but not when
modeling cumulative incidence of the failure types (Fine
and Gray models). Both approaches are valid, and the choice
of the appropriate approach depends on the research ques-
tion. To better understand and discuss this finding, we first
give an overview of competing risks in the context of KTx.
Survival analysis involves the statistical analysis of the
time to the occurrence of an event. However, in biomedical
research, the need to address multiple potential outcomes
is nearly ubiquitous. Competing risks are used to model a
situation in which subjects under investigation are exposed
to several causes of failure, such as graft failure or death
with graft function. These two events are mutually exclu-
sive, and only the first event that occurs is observed. Thus,
the analysis and interpretation of competing risk data differ
from survival analysis with only a single cause of failure. As
such appropriate methods must be applied.
The estimated cumulative incidence of an event of inter-
est using the 1-KM estimate is, in general, higher than esti-
mates obtained when accounting for competing risks [19,
41, 42]. This is because when an individual experiences a
competing risk event, this individual is treated as censored
and is eliminated from the risk set. Censored patients are
considered to have the same probability of experiencing the
event as patients who remain under follow-up [41]. How-
ever, a subject who is censored due to failure from a com-
peting risk (e.g., patient death) will clearly not experience
the event of interest (allograft loss functioning). Because
subjects who will never fail (by the failure of interest) are
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treated as if they could fail (they are censored), the 1-km
estimator overestimates the probability of failure and
underestimates the corresponding survival probability [19,
42]. We confirmed this finding, especially after the 10th
year of follow-up when the probability of graft failure and
patient death increases.
In the competing risk context, there are different
approaches to quantifying the effect of covariates in the
presence of competing events [26, 43]. In the current study,
the influence of DGF was evaluated using the cause-specific
Cox proportional hazards regression model (modeling the
cause-specific hazard) and the Fine and Gray regression
model (modeling the subdistribution hazards). We found
that the effect of this covariate differed between these two
approaches. Both results are valid, but their interpretation
is different and depends on the purpose of the study
(etiology vs. prediction) [23, 42, 44, 45].
If the primary interest in the etiological question of how
the covariates affect the event of interest, the cause-specific
hazards model would be most appropriate, because they
directly model the covariate effect on event rates among
subjects at risk [28]. Using this approach in the current
study, DGF significantly increases the risk of mortality
(csHR = 1.57, P = 0.029). This hazard can be interpreted
among those recipients who did not experience the event of
interest (patient death), that is, those recipients who were
censored because they were alive or had already been trans-
ferred for dialysis due to graft failure (competing event),
but they were alive when they were censored for graft fail-
ure. Considering our example, the csHR of 1.57 means that
a DGF recipient has a hazard of dying that is 1.57 higher
than non-DGF recipients, when considered among recipi-
ents who were alive and who did not experience graft fail-
ure at that time.
For the purposes of prognosis and medical decision-
making, the primary interest is in the absolute risks of the
event of interest; therefore, the subdistribution hazards
model would be more relevant [46]. This competing risk
analysis allows splitting the contribution of a covariate of
each event type separately. For our example, the effect of
DGF did not reach conventional significance. Furthermore,
the estimated effect (sHR = 1.22, P = 0.28) was smaller
than the corresponding DGF effect obtained by standard
Cox analysis (csHR = 1.57). The major advantage of the
competing risks approach is that the effects of each risk fac-
tor can be estimated and formally compared across differ-
ent end points.
The conflicting findings of the impact of DGF on graft
and patient survival results not only from the ambiguity in
the definition of DGF but also from the statistical method-
ology used to study its effect. The impact of DGF on two
types of graft loss was assessed in this study using specific
methods designed for the competing risks analysis and was
compared with the results of the standard survival analysis
methods. Accounting for the Fine and Gray model, DGF
was not significantly associated with patient death. How-
ever, it has a significant adverse effect on the hazard of graft
failure, independent of AR. The results stress the impor-
tance of using appropriate statistical methods if competing
risks are present.
This article also presents an overview of competing risks
concepts in the context of KTx, including the bias in the
standard Kaplan–Meier estimator. Competing risks are
clearly important for medical research, and their negligence
has important clinical implications. The naive interpretation
of Kaplan–Meier estimates in the presence of competing
risks as estimates of actual risks leads to potential overesti-
mation of the actuals probabilities of graft failure and patient
death and overestimation and inappropriate risk stratifica-
tion in prognostic models. This is markedly important in a
field such as kidney transplantation, where changes in sur-
vival-influencing factors, such as immunosuppression prac-
tices, organ allocation policies, or surgical techniques, may
occur rapidly and where competing events are pervasive.
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Table S1.  Cox proportional hazard regression (cause-specific hazard model) for all possible events 
  Unadjusted models Adjusted model (n=1127) 
  csHR 95% CI p value csHR 95% CI p value 
Graft 
Failure 
(censored 
for patient 
death) 
DGF-AR (reference: non-DGF and non-AR)       
Only DGF  1.79 1.28 - 2.48  0.001 1.50 1.06 - 2.13  0.023 
Only AR  2.99 2.17 - 4.10  <0.001 2.50 1.79 – 3.50  <0.001 
DGF + AR  3.37 2.35 - 4.84  <0.001 2.28 1.55 - 3.36  <0.001 
Transplant Era (reference: Era 4 > 2000)       
 Era 1 (< 1990) 2.58 1.65 - 4.03  <0.001 2.94 1.66 – 5.21  <0.001 
 Era 2 (1990-1995) 2.03 0.34 - 3.09 0.001 2.73 1.60 – 4.67 <0.001 
 Era 3 (1996-2000) 0.92 0.57 - 1.49 0.74 1.32 0.73 – 2.36  0.360 
 ECD (yes vs. no) 2.41 1.73 - 3.34  <0.001 1.60 1.09 – 2.35 0.015 
 Donor-recipient age difference (reference: 1st Q: < - 15 yr)      
 2nd Q (≥ -15 and ≤ -4 yr) 1.76 1.16 - 2.69  0.009 1.88 1.21 - 2.94  0.005 
 3rd Q (> - 4 and ≤ +6 yr) 2.35 1.56 - 3.53  <0.001 2.09 1.36 - 3.22  0.001 
 4th Q (> + 6 yr) 3.91 2.66 - 5.77  <0.001 3.18 2.06 - 4.92  <0.001 
  Cause of ESRD (reference: others)       
 Diabetic nephropathy  1.71 1.01 - 2.89 0.046 2.55 1.44 - 4.52 0.001 
 Glomerulonephritis  1.12 0.87 - 1.45 0.38 1.03 0.79 - 1.35 0.819 
 Time on dialysis (>5 vs. <5 yr) 1.24   0.93 - 1.65 0.14 1.51   1.13 - 2.04 0.006 
  Unadjusted models Adjusted model (n=1182) 
  csHR 95% CI p value csHR 95% CI p value 
Patient 
Death 
(censored 
for graft 
failure) 
DGF-AR (reference: non-DGF and non-AR)       
Only DGF  1.95 1.41 - 2.68 <0.001 1.50 1.08 - 2.09 0.017 
Only AR 1.29 0.85 - 1.95 0.23 1.03 0.66 - 1.62 0.90 
DGF + AR  2.36 1.57 - 3.54 <0.001 1.49 0.94 - 2.37 0.094 
Transplant Era (reference: Era 4 > 2000)       
 Era 1 (< 1990) 2.63 1.69 - 4.08 <0.001 2.66 1.53 - 4.64 0.001 
 Era 2 (1990-1995) 1.39 0.90 - 2.14 0.139 1.57 0.97 - 2.55 0.069 
 Era 3 (1996-2000) 0.73 0.45 - 1.20 0.214 0.81 0.48 - 1.36 0.42 
  Cause of ESRD (reference: others)       
 Diabetic nephropathy  2.56 1.60 - 4.11 <0.001 3.41 2.04 - 5.69 <0.001 
 Glomerulonephritis  0.76 0.57 - 1.02 0.071 0.92 0.67 - 1.26 0.61 
 HCV infection (positive vs. negative) 1.87 1.32 - 2.65 <0.001 1.56 1.08 - 2.25 0.017 
 Recipient age (1 yr increase) 1.04 1.02 - 1.05 <0.001 1.06 1.04 - 1.07 <0.001 
csHR=cause-specific hazard ratio; ERSD= end-stage renal disease; ECD= expanded-criteria donors; HCV=Hepatitis C virus; yr= year; 
Q= quartile. The bold printed covariables indicate statistical significance in the multivariable model. 	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Table S2.  Fine and Gray model (hazard of the subdistribution model) for all possible events 
  Unadjusted models Adjusted model (n=1127) 
  sHR 95% CI p value sHR 95% CI p value 
Graft DGF-AR (reference: non-DGF and non-AR)       
Failure Only DGF  1.69 1.21 - 2.35  0.002 1.54 1.07 - 2.15  0.01 
 Only AR  3.09 2.24 - 4.27  <0.001 2.53 1.84 - 3.48 <0.001 
 DGF + AR  3.26 2.28 - 4.67  <0.001 2.30 1.57 - 3.38  <0.001 
 Transplant Era (reference: Era 4 > 2000)       
 Era 1 (< 1990) 2.69 1.74 - 4.18  <0.001 2.10 1.32 - 3.35  0.002 
 Era 2 (1990-1995) 2.23 1.49 - 3.33 0.001 2.08 1.38 - 3.14 <0.001 
 Era 3 (1996-2000) 1.02 0.64 - 1.65 0.93 1.00 0.62 - 1.63 0.99 
 ECD (yes vs. no) 2.10 1.51 - 2.92  <0.001 1.47 1.01 - 2.16 0.047 
 Donor-recipient age difference (reference: 1st Q: < - 15 yr)      
 2nd Q (≥ -15 and ≤ -4 yr) 1.82 1.20 - 2.76  0.005 1.67 1.09 - 2.56  0.018 
 3rd Q (> - 4 and ≤ +6 yr) 2.36 1.60 - 3.50  <0.001 1.92 1.28 - 2.87  0.001 
 4th Q (> + 6 yr) 4.06 2.79 - 5.90  <0.001 2.97 1.98 - 4.45  <0.001 
  Cause of ESRD (reference: others)       
 Diabetic nephropathy  1.71 1.01 - 2.89 0.046 2.11 1.22 - 3.65 0.008 
 Glomerulonephritis  1.12 0.87 - 1.45 0.38 1.12 0.86 - 1.45 0.40 
  Unadjusted models Adjusted model (n=1182) 
  sHR 95% CI p value sHR 95% CI p value 
Patient  DGF-AR (reference: non-DGF and non-AR)       
Death Only DGF  1.53 1.08 - 2.19 0.018 1.24 0.87 - 1.77 0.23 
 Only AR  0.80 0.49 - 1.30 0.370 0.88 0.53 - 1.44 0.61 
 DGF + AR  1.29 0.78 - 2.15 0.320 1.10 0.64 - 1.90 0.72 
 Transplant Era (reference: Era 4 > 2000)       
 Era 1 (< 1990) 1.80 1.09 - 2.95 0.021 3.73 2.10 - 6.62 <0.001 
 Era 2 (1990-1995) 1.29 0.81 - 2.04 0.280 2.01 1.23 - 3.30 0.006 
 Era 3 (1996-2000) 0.75 0.44 - 1.27 0.280 0.98 0.57 - 1.67 0.93 
 ECD (yes vs. no) 1.14 0.70 - 1.85 0.60    
 Donor-recipient age difference (reference: 4th Q: > +6 yr)      
 1st Q (< -15 yr) 3.07 1.90 - 4.95 <0.001 1.47   
 2rd Q (≥ -15 and ≤ -4 yr) 1.71 1.01 - 2.88 0.044    
 3rd Q (> - 4 and ≤ +6 yr) 1.82 1.07 - 3.10 0.027    
  Cause of ESRD (reference: others)       
 Diabetic nephropathy  1.41 0.75 - 2.64 0.28 1.76 0.92 - 3.36 0.088 
 Glomerulonephritis  0.62 0.44 - 0.88 0.007 0.77 0.55 - 1.08 0.14 
sHR=subdistribution hazard ratio; ERSD= end-stage renal disease; HCV=Hepatitis C virus; yr= year; Q=quartile. The bold printed 
covariables indicate statistical significance in the multivariable model. 
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4.7. REVIEW ARTICLE 
 
BIOMARKERS IN KIDNEY TRANSPLANTATION: TRANSLATING TO CLINICAL PRACTICE 
Fonseca. I. Biomarkers in kidney transplantation: Translating to clinical practice (Review 
Article). Port J Nephrol Hypert 2013; 27: 143-151 
 
Improving long-term graft survival is a major challenge in kidney transplantation. Delayed 
graft function complicates the post-transplant management and has a negative impact on 
both the short and long-term outcomes. Numerous biomarkers in kidney transplantation 
have been evaluated in the past decade, but evidence to support their use in routine 
practice is currently limited. 
This review was undertaken to discuss the current status of three biomarkers for the early 
diagnosis and prognosis of delayed graft function, namely uNGAL, oxidative stress and 
CysC and to reflect on our own interpretation and experience.   
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ABSTRACT
Improving long-term graft survival is a major challenge in kidney transplantation. Ischaemia-reperfusion 
injury is a critical early allograft insult that enhances the risk of delayed graft function, which is common 
in deceased-donor transplantation. Delayed graft function complicates the post-transplant management and 
has a negative impact on both short and long-term outcomes. The development of effective interventions 
to prevent and attenuate the injury caused by ischaemia-reperfusion is constricted by the limited ability of 
early detection of kidney damage. In recent years, clinical and translational research has focused on improve-
ments in the diagnosis of acute kidney injury and provided prognostic information that is helpful in the 
post-transplant care. Numerous biomarkers in kidney transplantation have been evaluated in the past 
decade, but, so far, evidence to support their use in routine practice is limited. The purpose of this review 
is to examine the current status of three biomarkers for early diagnosis and prognosis of delayed graft 
function, namely urinary neutrophil gelatinase-associated lipocalin, oxidative stress and cystatin C. In addi-
tion, the concept of a biomarker is addressed, as well as the existing challenges and perspectives for 
developing a biomarker. This review discusses current literature and reflects the author’s own interpretation 
and experience.
Keywords: Biomarker, Delayed graft function, Kidney transplantation
RESUMO
Melhorar a sobrevivência do transplante renal a longo prazo é um desafio. A lesão provocada pela 
isquemia e reperfusão constitui uma agressão precoce do enxerto renal e aumenta o risco de atraso de 
função do enxerto, que é comum no transplante de dador cadáver. A ocorrência de atraso de função do 
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INTRODUCTION
Late failure of kidney transplants remains an 
important clinical problem and one of the leading 
causes of end-stage renal disease. Despite significant 
improvements in one-year kidney allograft survival, 
the rate of chronic graft loss after the first year 
remains significant and the actual kidney allograft 
half-life only showed a marginal improvement over 
the past decade1. The reasons for this slight improve-
ment remain unclear. It is possible that some impor-
tant determinants of long-term graft survival may not 
have changed sufficiently to improve the overall 
outcomes of kidney transplantation2. Patient death 
with a functioning allograft and chronic allograft 
failure are the two major causes of late transplant 
loss. The causes of chronic allograft failure are mul-
tifactorial and influenced by numerous immunological 
and non-immunological factors1,2. Generally, kidney 
transplants stabilize after recovering from the stress 
of implantation until declining of graft function due 
to specific diseases or conditions, such as recurrent 
renal disease, antibody-mediated rejection or a com-
mon process involving interstitial fibrosis and tubular 
atrophy the entity encompassed by the previous 
descriptive term “chronic allograft nephropathy”, and 
more recently simply ‘fibrosis/atrophy’2,3.
Improving long-term graft survival is a major chal-
lenge in kidney transplantation. A patient submitted 
to a renal transplant would wonder if his or her 
transplanted kidney will work well and how long will 
it last. When will it be possible to identify valuable 
markers to distinguish patients at increased risk of 
graft dysfunction or of losing their transplant? Can 
biomarkers signal early transplant dysfunction, a 
process that is often undetectable? Can biomarkers 
help clinicians fine-tune their prognoses?
As in every other domain in medicine, in organ 
transplantation early diagnosis and timely interven-
tion will improve outcomes. Clinicians need and 
continually look for tools to aid them on clinical 
assessment and to enhance their ability to identify 
the “vulnerable” patient at risk for graft dysfunction. 
Biomarkers are one such tool. They will allow to 
better identify high-risk individuals, to diagnose 
dysfunction promptly and accurately, and to effec-
tively prognosticate outcomes and treat patients with 
a tailored and more individualized intervention.
WHAT IS A BIOMARKER?
Biomarker is a very broad term that can be used 
to describe any indicator of a biological state. The 
term biomarker, or biological marker, was introduced 
in 1989 as a Medical Subject Heading (MeSH) term 
and it was defined as a “measurable and quantifiable 
Isabel Fonseca
enxerto condiciona a evolução do pós-transplante e tem um impacto negativo nos resultados imediatos e 
a longo prazo do transplante renal. O desenvolvimento de intervenções eficazes na prevenção e atenuação 
da lesão causada pelo processo de isquemia-reperfusão do órgão transplantado tem estado limitado pela 
ausência de marcadores precoces da lesão e disfunção renal.
Nos últimos anos, a investigação clínica e de translação tem conseguido melhorar a capacidade de 
diagnóstico da lesão aguda do enxerto renal e fornecido alguma informação de prognóstico, que pode ser 
útil no seguimento pós-transplante. Nas últimas décadas têm sido investigados inúmeros biomarcadores 
no transplante renal, mas a sua translação para a prática clínica não tem sido escassa. Esta revisão tem 
como objetivo a descrição do contexto atual de três biomarcadores para o diagnóstico precoce de atraso 
na função do enxerto: a lipocalina associada à gelatinase dos neutrófilos (NGAL), o stress oxidativo e a 
cistatina C. Adicionalmente serão abordados alguns conceitos básicos e as perpetivas de desenvolvimento 
de um biomarcador, com base numa revisão da literatura e na interpretação e experiencia pessoal de uma 
investigação em curso nessa área.
Palavras-chave: Atraso de função do enxerto, Biomarcadores, Transplante Renal
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biological parameters (eg, specific enzyme concentra-
tion, specific hormone concentration, specific gene 
phenotype distribution in a population, presence of 
biological substances), which serve as indices for 
health- and physiology-related assessments.” More 
recently, in 2001, the definition was standardized by 
the Biomarker Definitions Working Group4 as “a 
characteristic that is objectively measured and evalu-
ated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses 
to a therapeutic intervention”. In practice, biomarkers 
can improve understanding about a disease and 
provide new knowledge of pathological mechanisms, 
making possible the earlier diagnosis and the deliv-
ery of more efficacious and safer therapies. Presently, 
it is not well established how biomarkers are catego-
rized. Within the field of health care, biological mark-
ers are commonly classified based on the sequence 
of events from exposure to disease5: biomarkers of 
exposure, which are used in risk prediction, and 
biomarkers of disease, which are used in screening, 
diagnosis and prognosis.
To be clinically useful and prevent false-positive 
screening tests, a biological marker should be highly 
sensitive and specific in detecting disease or any 
other outcome. Regardless of the purpose for its 
use, it should be accurate, reproducible and stan-
dardized across different clinical units. Furthermore, 
it should be easily measured in a standard biological 
source (as blood or urine), obtained from a person 
(as blood pressure or electrocardiogram), or image-
based (echocardiogram or computerized tomography 
scan), so that the information would be readily avail-
able and easy to interpret by clinicians5,6. In sum-
mary and according to the Food and Drug Adminis-
tration, an ideal biomarker should be specific, 
sensitive, predictive, robust, simple, accurate, and 
inexpensive.
 BIOMARKERS IN KIDNEY 
TRANSPLANTATION
In organ transplantation, initial graft dysfunction is 
one of the most important early post-operative prob-
lems, mainly due to the unavoidable ischemia-reper-
fusion injury that occurs in the transplanted organ. In 
kidney transplantation, ischemic injury of the renal 
allograft is a critical early insult that augments the risk 
of acute tubular necrosis and long-term graft loss7,8. 
The development of effective interventions is con-
stricted by the limited ability of early detection of graft 
dysfunction. Current clinical indicators of kidney injury, 
like serum creatinine, are inadequate for timely diag-
nosis and prognosis. Thus, application of biomarkers 
in the field of kidney transplantation will allow to 
detect incipient graft dysfunction or rejection, will refine 
diagnoses and enable more effective post-transplant 
management, and thereby potentially improve short-
term (e.g., delayed graft function, acute rejection) and 
long-term (e.g., allograft failure) outcomes.
Discovery of biomarkers is expanding at an unprec-
edented rate. Numerous biomarkers in kidney trans-
plantation have been evaluated in the past decade, 
but, so far, evidence to support their use in routine 
practice is limited. In this article, we review the 
promising role of three biomarkers of delayed graft 
dysfunction, namely, neutrophil gelatinase-associated 
lipocalin, oxidative stress, and cystatin C.
 NEUTROPHIL GELATINASE-
ASSOCIATED LIPOCALIN
Neutrophil gelatinase-associated lipocalin (NGAL) 
is one the most promising biomarkers of acute kid-
ney injury in a variety of acute clinical settings9-11. 
Neutrophil gelatinase-associated lipocalin, also 
known as human neutrophil lipocalin or lipocalin-2, 
is a 25-kDa glycoprotein belonging to the lipocalin 
family and originally it was found covalently bound-
ed to gelatinase in activated neutrophils. This lipoc-
alin behaves as a bacteriostatic agent in acute 
infections and it is released to blood from activated 
neutrophils during inflammatory processes. It was 
demonstrated that NGAL exists in two separate body 
pools, the systemic and the renal one. In the sys-
temic pool, NGAL is normally expressed at very low 
concentrations in several human tissues. After glom-
erular filtration, circulating NGAL is reabsorbed in 
the proximal tubules, catabolized and finally released 
with urine in small quantities. In the renal pool, 
NGAL is rapidly released from renal tubular cells in 
response to various insults to the kidney. Thus, in 
steady situations, NGAL is found in urine only in 
trace. In contrast, when massive NGAL quantities are 
expressed and excreted in urine this usually indicates 
injury and damage of proximal tubular cells, due to 
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ischaemia-reperfusion injury, hypoxia, nephrotoxins 
or chronic progressive changes12,13.
Ischaemia-reperfusion injury is an inevitable con-
sequence of kidney transplantation procedure and 
can be considered a form of post-transplantation 
acute kidney injury. For this reason, several studies 
investigated the utility of NGAL for the diagnostic 
and prognostic of acute graft dysfunction following 
kidney transplantation, with promising results14-19. 
Recently, the prognostic value of NGAL on graft 
function at one year post-transplantation was also 
examined18,20.
The larger study on this subject is from Hollmen 
and colleagues18. These researchers demonstrated 
that urinary NGAL (uNGAL) is an early predictor of 
delayed graft function (DGF) following renal trans-
plantation, in a prospective cohort study of 176 adult 
recipients transplanted with deceased-donor kid-
neys. Urine was collected before transplant, at then 
at days 1, 3, 7 and 14, and NGAL was measured at 
each time point. The uNGAL measured in the first 
morning following transplantation predicted DGF 
(defined as the need for dialysis during the first 
week after transplantation), particularly in cases 
where early graft function was expected on the basis 
of diuresis and decreasing plasma creatinine con-
centration. Patients who needed dialysis in the first 
post-transplant week had a slower decrease in 
uNGAL compared with recipients without DGF, and 
levels of uNGAL at day-1 predicted DGF (area under 
the curve (AUC) of 0.75). In 15 of 112 cases with 
urine output higher than 1L at day-1, uNGAL was a 
predictor of DGF, as well in 19 of 86 cases with a 
day-1 decrease in creatinine over than 1 mg/dl (AUC 
0.74). Other authors showed also prominent results. 
Parikh et al. in a prospective study that included 53 
consecutive patients undergoing living or deceased-
donor transplantation (children and adults), mea-
sured NGAL in urine samples collected within the 
first 24 hours after transplantation and reported an 
AUC-ROC of 0.9 in predicting DGF14. Hall and cowork-
ers evaluated uNGAL within 6h after transplantation 
in a 91-patient cohort of adults with a kidney graft 
from a deceased-donor, and predicted subsequent 
DGF with an AUC-ROC of 0.8116.
Across a range of clinical studies, both urine and 
plasma NGAL has been shown to be a useful dis-
criminatory marker of renal injury and an early 
predictor of DGF, with a performance greater than 
serum creatinine, the most commonly used surrogate 
measurement of glomerular filtration rate. In our 
experience, and similarly to other authors14,18, we 
have chosen to measure NGAL in urine (uNGAL), 
instead of blood, since uNGAL represents tubule 
damage in the kidney rather than filtration from 
blood13,21. Although plasma NGAL is freely filtered 
by the glomerulus, it is largely reabsorbed in proxi-
mal tubules by efficient megalin-dependent endocy-
tosis11. Thus, any urinary excretion of NGAL is likely 
only when there is concomitant proximal renal tubu-
lar injury that precludes NGAL reabsorption and/or 
increases de novo NGAL synthesis. Accordingly, an 
increased level of NGAL in urine usually indicates 
injury and damage of tubular cells and seems to be 
more specific compared to serum NGAL, which can 
be produced by other organs and released into the 
circulation following a transplant surgery21. The non-
invasive nature of sample collection and the reduced 
number of interfering proteins were also other 
advantages taken in account when we choose to 
measure this biomarker in urine10.
However, despite the undoubtedly value of uri-
nary markers of kidney injury, their use in transplant 
recipients can be also a drawback because of pos-
sible transient graft anuria, which may preclude the 
availability of urine and consequently the lack of 
sample to measure NGAL. The persistent urine pro-
duction by the native kidneys and the usual fluctua-
tions of hydration status in these patients can also 
induce potential changes in urinary biomarker con-
centration, which can be another inconvenience to 
measure NGAL in urine. The genesis and sources of 
plasma and urinary NGAL require further clarification. 
However, despite the uncertainty of whether NGAL 
level performs better in urine or plasma/serum, both 
plasma/serum and urine NGAL levels appear to per-
form similarly well and provide a relevant advantage 
compared with serum creatinine, which is an insen-
sible marker of kidney injury9.
OXIDATIVE STRESS
Oxidative stress is one of the most important 
components of the ischaemia-reperfusion process22-24. 
It reflects an imbalance between reactive oxygen spe-
cies (ROS) and cellular mechanisms for detoxifying 
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the reactive intermediates or for repairing the result-
ing damage. Disturbances in the normal state can 
cause toxic effects through the production of perox-
ides and free radicals that damage all components of 
the cell.
Oxygen free radicals or, more generally, ROS are 
products of normal cellular metabolism. It has been 
estimated that the average person has around 10,000–
20,000 free radicals attacking each body cell every day. 
Free radicals are defined as molecules or molecular 
fragments containing one or more unpaired electrons 
in atomic or molecular orbitals, which gives a consider-
able reactivity to the free radical. The well-known radi-
cals derived from oxygen, such as superoxide (O2−·), 
hydrogen peroxide (H2O2) and the hydroxyl radical 
(OH·) represent the most important class of radical 
species generated in living systems25.
In physiological conditions, ROS are produced 
specifically to serve essential biological functions, 
as in defence against infections. In these conditions, 
the rates of free radical production and elimination 
are equal, leading to a steady state that is presum-
ably tolerated by the cell. The antioxidant defence 
mechanisms can be divided into two major groups: 
endogenous, mainly enzymes, such as superoxide 
dismutases (SOD), catalases, glutathione reductases 
(GR) and peroxidases (GPx) and small molecules, 
mostly exogenous, acting as free radical scavengers 
(vitamins A, C, and E, carotenoids and polyphenol)25. 
In some pathological conditions, an imbalance 
between ROS generation and antioxidant capacity 
leads to enhanced ROS activity and oxidative stress. 
When these antioxidant mechanisms cannot coun-
terbalance the amount of free radicals generated, 
cell damage and tissue injury can take place26.
Reactive oxygen species may cause tissue injury 
via several mechanisms. As they are potent oxidizing 
and reducing agents, ROS directly damage cellular 
membranes and modify several biological molecules, 
such as lipids, proteins, and nucleic acids. The by-
products of these reactions can serve as biomarkers 
of oxidative stress22,23. Of the many biological targets 
of oxidative stress, lipids are the most involved class 
of biomolecules. Lipid oxidation generates a huge 
variety of secondary products, including reactive car-
bonyl compounds, such as malondialdehyde (MDA). 
This aldehyde is the principal and most studied prod-
uct of polyunsaturated fatty acid peroxidation, and 
for this reason MDA is a marker widely used to assess 
lipid peroxidation25,26.
Markers of oxidative stress, including elevated 
levels of MDA and reduced antioxidant activity have 
been reported in renal patients27,28. There is huge 
amount of literature concerning oxidative stress and 
renal disease but data about kidney transplantation 
in the early stages are scarce. The restoration of 
kidney function after transplantation can lead to 
improvement of the oxidative stress29, but some 
studies report increased systemic biomarkers of 
oxidative stress in kidney transplant recipients30,31, 
specifically in the early phase of transplantation32,33 
and, thereafter, coexisting with chronic allograft 
tubular atrophy/interstitial fibrosis30,34.
It has long been suspected that oxidative stress 
contributes to injury of ischaemic and reperfused 
tissues. In the setting of kidney transplantation, not 
only are there ischaemic and reperfusion periods 
obligated by the preservation and implantation 
procedures, but placement of the kidney into an 
immune milieu can also act as an adjuvant for oxida-
tive damage. Reactive oxygen species are generated 
during both phases of ischaemia-reperfusion. As in 
other clinical conditions, if the scavenging capacity 
of kidney is beneath the excessive ROS generated, 
such oxidative imbalance may trigger a robust 
inflammatory response within the transplanted organ 
and lead to cellular destruction, tissue damage and 
graft dysfunction33,35. Thus, severe reperfusion injury 
is a risk factor for DGF and detection of ROS could 
be an early warning of graft injury. Waller and 
coworkers studied blood samples in porcine kidney 
allografts before and after reperfusion injury and 
demonstrated that both plasma carbonyl and 8-ispo-
rostane (product of protein and lipid damage by free 
radicals respectively) could be reliable biomarkers 
to predict the reperfusion injury36. To the author’s 
knowledge, no similar studies were done on this 
topic in human kidney transplantation.
A wide range of antioxidant enzymes may poten-
tially exert a protective influence by limiting the 
production of ROS and the damage of oxidative stress 
following ischaemia-reperfusion injury of kidney graft. 
Conflicting results are reported in the literature on 
the activities of antioxidant enzymes in kidney trans-
plant patients. Glutathione compounds and SOD have 
been reported to increase37,38 decrease31 or not 
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change39 following renal transplantation. Whitin et 
al.37 reported a rapid increase in plasma GPx activity 
after transplantation. The plasma GPx activity was 
two times higher 3 days after transplantation in adult 
patients who received a kidney transplant from a 
related donor; and rapidly increased over the first 2 
weeks post-transplant in adult recipients from a 
deceased-donor and paediatric patients undergoing 
kidney transplantation from related donors. Zachara 
et al.38 have shown that plasma GPx activity increased 
rapidly 3 days after renal transplantation, and dou-
bled two weeks later. Both of these studies suggested 
that monitoring plasma GPx might be a useful marker 
for monitoring transplanted kidney function and a 
valuable tool for post-operative detection of DGF.
Not only in the early post-transplant period but 
also at longer-term, oxidants and antioxidants can 
be as biomarkers of graft dysfunction with diagnostic 
accuracy. Oxidative stress is believed to be a com-
mon pathway that leads to both immunological and 
non-immunological stress in the setting of kidney 
transplantation and to the development or progres-
sion of chronic allograft nephropathy. Increased 
plasma and intragraft levels of MDA and reduced 
antioxidant activity were found in kidney allografts 
with chronic tubular atrophy/interstitial fibrosis, 
which suggests the possibility of early detection, 
even when graft dysfunction is undetectable by 
serum creatinine30,34,40.
The understanding about oxidative stress signifi-
cantly advanced in the last decade, but these experi-
mentally derived ideas have yet to be fully integrated 
into clinical practice. General evidence for involve-
ment of ROS in hypoxia-reoxygenation injury includes 
detection of lipid peroxidation. Malondialdehyde is 
an end-product of lipid peroxidation and it is a 
frequently measured biomarker of oxidative stress. 
Studies on this topic are limited in kidney transplan-
tation. Therefore, more research is needed to clearly 
define the role and clinical value of MDA and other 
oxidative stress markers in kidney transplantation.
CYSTATIN C
Cystatin C (CysC) is a low molecular mass protein 
that is produced at a constant rate by nearly all-
human nucleated cells. This cystatin is freely filtered 
through the normal glomerular membrane, almost 
completely reabsorbed and degraded by proximal 
tubular cells, but it is not secreted by the tubules. 
Although its clearance cannot be measured because 
of this catabolism, its plasma or serum concentration 
has been shown to be independent of muscular 
mass, inflammatory diseases, sex, age or diet, and 
these properties make it a good measure of glom-
erular filtration rate (GFR) compared to the tradi-
tional measurement of creatinine41,42. As a result of 
this finding, several prediction equations have been 
derived from both paediatric and adult patients to 
estimate GFR from the serum CysC concentra-
tion43,44. Most of the studies that compared CysC 
levels or CysC derived equations with gold standard 
methods found CystC to be superior or, at least, 
equivalent to serum creatinine42. Some studies on 
selected patient groups, whose muscle mass is either 
reduced or undergoes rapid changes, also demon-
strated CysC as a sensitive marker of GFR and 
independently of body composition41.
Renal transplant recipients are a target group for 
whom precise determination of GFR is crucial. 
Allograft function following renal transplantation is 
commonly monitored using serum creatinine. How-
ever, plasma creatinine is far from being an ideal 
marker of GFR, despite its convenience and low 
cost. Since the first publication in 199845, quite a 
few original clinical papers have addressed the 
question of the use of CysC in kidney transplanta-
tion. A good number of studies identified serum 
CysC (or CysC-based equations) as a promising, 
easily measurable marker to estimate GFR with a 
higher diagnostic value than serum creatinine (or 
creatinine-based equations) and 24-hour creatinine 
clearance for evaluation of GFR in the follow-up of 
adult kidney transplant patients46-48. Very recently, 
Masson et al.48 validated both of CysC-based CKD-
EPI equations (2012) in 670 kidney transplant 
recipients and concluded that both performed better 
than the serum creatinine-based CKD-EPI equation 
(2009).
Glucocorticoid medication can be shortcoming in 
using serum CysC in this population and it is impor-
tant to take into account when interpreting this 
serum marker. Glucocorticoid therapy is one of the 
few circumstances identified that have an impact on 
the production of CysC in a dose-dependent manner, 
leading to systematic underestimation of GFR49. Very 
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large doses of glucocorticoids have been described 
to increase the production of CysC49, whereas low 
and medium doses of glucocorticoids do not seem 
to alter the production of CysC50. This, however, 
does not preclude the use of CysC in detecting 
impaired renal function in renal transplant patients 
on glucocorticoids, given that many studies have 
shown CysC to be still significantly more accurate in 
detecting impaired renal function in this patient 
group49,50.
For kidney recipient follow-up, the ability to detect 
rapid changes in GFR is clinically more important 
than accuracy itself. For this reason, and due to the 
promising findings of CysC in kidney transplantation, 
the role of this marker in detecting post-transplant 
renal damage earlier than serum creatinine has been 
investigated51-54. Thervet et al.51 in a prospective 
study of 30 renal transplant patients found that CysC 
allowed earlier diagnosis of renal function recovery 
than serum creatinine, particularly in patients with 
DGF. In a prospective study that included 30 con-
secutive patients with end-stage renal disease 
undergoing renal transplantation, Le Bricon et al. 
evaluated CysC as a marker of allograft function 
during the early post-operative transplantation 
period. Serum CysC was more sensitive than serum 
creatinine for detecting decreases in GFR and predict-
ing DGF. Furthermore, a more prominent rise in 
plasma CycC values allowed a more rapid diagnosis 
of acute rejection or treatment nephrotoxicity, with 
the potential for more timely intervention52. Hall et 
al. also confirmed these findings in a cohort of 78 
deceased-donor renal recipients and shown that 
CysC outperformed serum creatinine as a predictor 
of poor early graft function and the need for dialysis 
within the first week of kidney transplantation. The 
authors also proved that CysC was a good prognostic 
marker of graft function at 3 months53. In a recent 
article published in June 2012, Liu et al. evaluated 
the clinical value of CysC for the diagnosis of an 
acute rejection episode after renal transplantation 
in 76 recipients and concluded that CysC can predict 
acute rejection episode after renal transplantation55. 
Urine CysC was also studied recently by Hall et al.54 
in a prospective multicenter study that included 91 
deceased-donor kidneys transplants. Serial urine 
samples were collected for 2 days following trans-
plant and on the first post-operative day urine CysC 
was a predictor of DGF and of 3-month allograft 
function.
Cystatin C displays several good characteristics 
that make it a viable biomarker for early detection 
of DGF. Of the three markers addressed in this 
review, serum CysC is probably the biomarker most 
used and closest to the clinical validation in kidney 
transplantation.
THE AUTHOR’S EXPERIENCE
The Renal Transplant Unit at the Centro Hospitalar 
do Porto conducted a prospective, longitudinal study 
in 40 consecutive end-stage renal disease patients 
undergoing living or deceased-donor kidney trans-
plantation, from December 2010 to May 2011. This 
study aimed to identify early markers of graft dys-
function in the peritransplant period and investigate 
their accuracy in predicting DGF (defined as dialysis 
requirement within the first week after transplanta-
tion). The receiver operating characteristic curve 
analysis is commonly used to evaluate biomarker 
utility in clinical diagnosis of disease, especially dur-
ing biomarker development research. Using this 
statistical tool, the present study demonstrated 
uNGAL, MDA and CysC as good diagnostic markers 
on identifying patients with graft dysfunction in the 
early post-transplant period and who required dialy-
sis in the first week (articles submitted or in draft). 
When analyzed separately, all three biomarkers pre-
dicted who would develop DGF with about the same 
degree of accuracy, and all of them with a diagnostic 
performance superior to serum creatinine.
Despite these encouraging results, this is not 
enough to certify any of these markers as diagnostic 
and prognostic biomarkers with wide clinical utility. 
Before each of these (or any other) biomarkers can 
be deployed in the clinic, they have to be repeatedly 
tested in hundreds of patients to assure that they 
serve as effective markers of acute graft dysfunction 
and prognostic indicators of dialysis-based DGF. It 
is a long and laborious pathway from identifying to 
validating a reliable biomarker.
Delayed graft function is a common complication 
affecting renal grafts immediately after transplanta-
tion. Since DGF has so many detrimental effects, 
accurate and early identification of features of DGF 
is remarkably important because it would allow more 
targeted and personalised treatment approaches. 
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Several studies were done in renal transplantation 
to identify biomarkers for the diagnosis of DGF. 
However, there is still no routine application of any 
of these markers in clinical transplantation. The first 
step was taken in the long march to translate a 
biomarker from the laboratory into the clinical prac-
tice. Generation of prospective data will now be 
necessary for validation and demonstration of the 
clinical utility of these markers in other centres and 
transplant recipients, across different practices and 
sets of variables. If validated, these biomarkers will 
be a major advantage for transplant recipients by 
allowing their care team to detect acute kidney injury 
before the risk of graft dysfunction becomes too 
high and the possibility of intervention less 
effective.
CONCLUSIONS
In renal transplant patients, early detection of 
impaired kidney function is critical so that efforts to 
prevent further deterioration of graft function or 
rejection can be instituted. Biomarker investigations 
are now an integral part of clinical research. The 
overall expectation of a biomarker is to enhance the 
ability to detect earlier an ongoing biological process 
and predict which patients will respond better to 
which interventions. To bring biomarkers to the 
clinic, it is mandatory to show a useful clinical appli-
cation that is supported by the validation data. In 
the field of kidney transplantation, some biomarkers 
have successively gone the process of discovery and 
of validation, but fall short in their ability to con-
tribute decisively to patient care. In a time of greater 
economic constraints and more personalized medi-
cine, biomarkers are certain to have a presence in 
transplant care and coordinated and collaborative 
efforts should be made to implement novel biomark-
ers into the clinical practice.
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DISCUSSION  	  
Transplantation is a revolutionary opportunity for end-stage renal disease patients to 
regain their normal daily life. During its history the surgical technique of transplantation 
became technically straightforward.276 In the current era, modern anesthesia and fine 
surgical materials support the surgical procedure, and the advances in postoperative 
immunosuppression in the past 20 years have attenuated the early-risk period and had a 
positive impact on short and long-term survival. Despite these progresses, a gradual but 
inevitable decline in allograft function at two or more years after transplantation is 
observed in approximately half of the patients who receive a kidney allograft transplant 
and these patients will lose their renal allografts within 10 to 12 years after transplantation 
because of the loss of functioning.2, 277-279  
We reviewed data from our kidney transplant experience over the past three decades and 
regarding the primary adult recipients transplanted from a deceased-donor with at least 
one-year of functioning; the main cause of late transplant loss was chronic allograft failure 
in approximately 61% of all of the graft losses. In 2013, 450 kidney transplantations were 
performed in Portugal. Currently, more than 1900 patients are waiting for an organ 
transplant, and each month approximately 30 patients are added to the waiting list. A 
significant number of patients on the waiting list are added as a result of the functional 
failure of a first transplant, which reflects our current inability to ensure long-term allograft 
function and survival and represents a major problem in transplantation medicine. 
The time to failure of a renal allograft is greatly determined by the initial function achieved 
after transplantation, the number and severity of insults to the graft, and a number of 
tissue characteristics. The inevitable ischemia-reperfusion injury, DGF occurrence, acute 
rejection episodes, drug-related nephrotoxicity, and de novo allosensitization to the donor 
are some of the insults that can occur after kidney transplantation. The individual 
susceptibility to injury and the ability of the tissue to repair the damages are other 
important characteristics that also affect graft survival.  
Delayed graft function is a clinical diagnosis that describes the acute transplant kidney 
dysfunction that occurs in the immediate postoperative phase after the transplantation 
procedure, which adversely impacts both short- and long-term renal allograft function.26, 30 
Several studies have demonstrated that DGF of the kidney results in an increased length 
of hospital stay and costs, an increased incidence of acute rejection and an inferior graft 
survival following kidney transplantation.24, 30, 32, 40, 280-283 The role of DGF in long-term graft 
and patient survival has not reached a consensus. Some single-center studies have 
reported that DGF without rejection may have no impact on long-term graft survival;273-275 
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however, other investigators have demonstrated that DGF is associated with a poor graft 
outcome independent of rejection.11, 32, 38 We evaluated the impact of DGF over the 
previous three decades of experience of our kidney transplant center using a competing 
events approach. We confirmed that DGF, independent of acute rejection, has a 
detrimental effect on long-term graft survival. After adjusting for most factors traditionally 
associated with graft failure, early kidney dysfunction has a clear adverse effect on long-
term graft survival, meaning that the presence or absence of DGF will provide an 
indication of the life-expectancy of the kidney graft.  
Some controversies also exist regarding the impact of DGF on patient survival, with 
several studies that support the adverse impact of DGF26, 36-38 and other studies that refute 
this effect.274, 284 Neither of these studies accounted for competing risks. In our study, 
using a cause-specific Cox proportional hazards regression model we confirmed the 
negative effect of DGF on patient outcome, but not when the analysis was based on the 
cumulative incidence of the failure types (Fine and Gray models). Both approaches are 
valid and the choice of the appropriate approach depends on the aim of the study 
(etiology vs. prediction).266, 270, 272 If the primary interest is focused on the etiological 
question of how the covariates affect the event of interest, the cause-specific hazard 
models would be most appropriate because they directly model the covariate effect on 
event rates in subjects at risk.285 Using this approach, our study showed that DGF 
significantly increased the risk of mortality (csHR=1.57, P=0.029). This hazard can be 
interpreted among the recipients who did not experience the event of interest (patient 
death), i. e., the recipients that were censored because they are alive or were previously 
transferred for dialysis because of graft failure (competing event). Considering our study, 
the csHR of 1.57 indicates that a DGF recipient has a hazard of dying 1.57 higher than 
non-DGF recipients, among recipients who were alive and that did not experience graft 
failure at the time.  For the purposes of prognosis and medical decision-making, the 
primary interest is focused on the absolute risks of the event of interest; thus, the 
subdistribution hazards model (Fine and Gray model) would be more relevant.286, 287 This 
competing risk analysis allows splitting the contribution of a covariate on each event type 
separately. For our study, the effect of DGF did not reach conventional significance and 
the estimated effect (sHR=1.22, P=0.28) was smaller than the corresponding DGF effect 
obtained by a cause-specific hazards model (csHR=1.57). The major advantage of the 
competing risks approach is that the effects of each risk factor can be estimated and 
formally compared across different endpoints. Graft failure and patient death are 
competing endpoints that are mutually exclusive. Therefore, because DGF is significantly 
associated with a higher probability of graft failure (the competing event is more frequent), 
the probability of experiencing an alternative competing risk (patient death) is lower and 
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the effect of DGF on patient survival is non-significant.  
It appears that the conflicting findings of the impact of DGF on graft and patient survival 
result not only from the ambiguity in the definition of DGF but also from the statistical 
methodology used to study its effects. Considering the subdistribution hazard models, 
DGF was not significantly associated with patient death; however, it had a significant 
adverse effect on the hazard of graft failure independent of acute rejection. 
We used a dialysis-based definition for DGF. There is no uniformly accepted definition for 
DGF; however, the dialysis requirement within the first postoperative week is likely the 
most common definition used.288, 289 It is true that dialysis requirements may not reflect 
allograft dysfunction. Patients may need dialysis despite good graft function because of 
hyperkalemia or fluid overload. Thus, a new graft in these patients can be inaccurately 
classified as DGF. Similarly, recipients with significant residual renal function prior to 
transplantation can be misclassified as not having DGF despite a very low GFR in the 
allograft. In these patients, it is not possible to differentiate the urine output from the native 
kidney and the transplanted kidney, which hides the presence of DGF. Therefore, the 
need for renal replacement therapy can be subjective and represents a clinical-dependent 
decision, which is a clear limitation of this definition.  
The other option is to use a creatinine-based definition for DGF. However, a post-
transplant interpretation of allograft function based on serum creatinine can also be 
difficult. Patients are not in a steady state, and a substantial amount of renal mass can be 
dysfunctional without appreciable changes in the SCr, which misclassifies patients as not 
having DGF. Moreover, the frequently performed hemodialysis session immediately prior 
to surgery to normalize the potassium levels of the patient may falsely lower the post-
transplant creatinine and hide a graft dysfunction, which also results in the 
misclassification of patients as not having DGF. Thus, a creatinine-based definition for 
DGF appears to be inadequate. Because the main cause of DGF is ischemia and 
reperfusion injury, which excludes other causes for DGF, such as acute rejection, 
calcineurin inhibitor toxicity and surgical complications we preferred to use a functional 
definition of DGF. Similar to other studies66, 67, 69, 71, 72, 77, 290 we used a “harder” outcome to 
define DGF: the need for dialysis in the first week after kidney transplantation, which has 
recently been reinforced to be universally adopted as the clinical definition of DGF and as 
a study endpoint.289 
The specific understanding of the importance of DGF in renal transplantation has long 
been hampered by the lack of specific and sensitive markers for this condition and the 
absence of studies with long-term follow-up. Long-term follow-up studies are difficult to 
achieve. Traditional study endpoints in kidney transplantation have focused on the first 
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year after transplantation. These endpoints are easier and more rapid to evaluate than the 
gold standard endpoints for long-term survival, which continues to be graft failure and 
patient death. Surrogate markers or endpoints can be used in place of conventional 
endpoints and represent a significant contribution to the early diagnosis, longitudinal 
prognoses, and outcome prediction. These surrogate markers or endpoints are used in 
lieu of the true endpoint to evaluate the outcome more rapidly, less expensively and/or 
less invasively. 
In the transplant community, there has been a research focus on the identification of a 
biomarker that may serve as a surrogate for late graft loss.291-293 A natural candidate for 
this surrogate endpoint is renal function. The creatinine levels and changes in the SCr 
levels within the first year post-transplantation are important parameters that influence and 
predict long-term graft survival.292, 294-299 However, not all studies support the validity of 
SCr as a predictor of long-term graft loss.45, 300, 301 As a result of this divergence and to 
proceed with the prospective study as planned, we examined the role of SCr in long-term 
graft survival at our center. Our results also highlighted that SCr at 1, 6, and 12 months as 
well as the changes between these months, had a significant relationship with the graft 
survival rate, which suggests that renal function within the first year after transplantation is 
an important parameter that influences long-term graft survival and is a reliable surrogate 
marker of late transplant outcome at our center. 
One of the concerns in current transplant research is to obtain insight into the factors that 
are associated with long-term graft loss and to identify early markers of allograft 
dysfunction, as well as potential interventional pathways. Thus, special attention in this 
dissertation was focused on early biomarkers of DGF with the aim to improve the 
diagnosis and prediction of the long-term outcome not only for renal grafts but also for 
patients. The prospects of a patient who returns to dialysis after kidney transplantation are 
poor not only with respect to their quality of life but also for their survival.302 Thus, nine 
candidate biomarkers were studied, including one biomarker in urine and eight biomarkers 
in blood. Some of these biomarkers were first examined by our group as early potential 
markers of kidney graft dysfunction.  
Neutrophil gelatinase-associated lipocalin was the only biomarker that we measured in 
urine. As previously stated, when we designed this study to explore the usefulness of 
NGAL as a marker of graft functional recovery in the field of kidney transplantation, few 
studies on this topic were published in kidney transplantation settings at the time. Since 
then, more than twenty studies have been published, and most of them, similar to our 
study, have shown NGAL’s significant predictivity for DGF.69, 71, 72, 164, 166, 169-171 Across a 
range of clinical studies, both urine and serum NGAL have been shown to be useful 
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discriminatory markers of renal injury and early predictors of DGF with better performance 
than SCr, which is the most commonly used surrogate measurement of the GFR rate. An 
additional advantage is that uNGAL was independently and significantly associated with 
one-year graft function as evaluated by SCr, which we have confirmed to be a surrogate 
marker of long-term survival in our center. In addition to the research by our group, two 
other studies confirmed this association.171, 172 
In our experience and similar to other authors,71, 72, 164, 171 we have chosen to measure 
NGAL in urine instead of blood because uNGAL represents tubule damage in the kidney 
rather than filtration from the blood.150, 303 Although plasma NGAL is freely filtered by the 
glomerulus, it is largely reabsorbed in the proximal tubules by efficient megalin-dependent 
endocytosis.119 Thus, urinary excretion of NGAL likely occurs only when there is 
concomitant proximal renal tubular injury that precludes NGAL reabsorption and/or 
increases de novo NGAL synthesis. Accordingly, an increased level of NGAL in the urine 
typically indicates injury and damage of the tubular cells and appears to be more specific 
compared with serum NGAL, which can be produced by other organs and released into 
the circulation following a transplant surgery.303 The non-invasive nature of sample 
collection and the reduced number of interfering proteins were other advantages 
considered when we chose to measure this biomarker in urine.123   
However, despite the undoubted value of urinary markers of kidney injury, their use in 
transplant recipients can also be a drawback because of potential transient graft anuria, 
which may preclude the availability of urine and, consequently, result in the lack of sample 
material to measure NGAL. The persistent urine production by the native kidneys and the 
typical fluctuations in the hydration status in these patients can also induce potential 
changes in the urinary biomarker concentration, which can be another inconvenience in 
the measurement of NGAL in urine. The genesis and sources of plasma and urinary 
NGAL require further clarification. However, despite the uncertainty of whether the NGAL 
level performs better in the urine or plasma/serum, both plasma/serum and urine NGAL 
levels appear to perform similarly well and provide a relevant advantage compared with 
SCr, which is an insensitive marker of kidney injury.61, 63, 304 
We also examined two adipokines as biomarkers of graft dysfunction. In chronic kidney 
disease, the clinical significance and prognostic implications of leptin and adiponectin are 
not well understood. To date, most of the research regarding leptin and adiponectin has 
focused on their associations with metabolic and cardiovascular health. To date and to the 
best of our knowledge, no reported study has examined the clinical utility of these two 
adipokines in the diagnosis of graft dysfunction after kidney transplantation. Thus, this 
study was designed based on the assumption that impaired clearance of leptin (and 
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adiponectin) could signal graft impairment earlier than SCr. Of the two adipokines 
measured, leptin most closely agreed with our initial hypothesis. The leptin levels shortly 
after transplantation and during the first week were anticipated to be significantly higher in 
patients who require dialysis, which suggests that higher leptinemia after kidney 
transplantation can reflect graft dysfunction. At day-1, leptinemia provided some albeit 
small, yet incremental prognostic information regarding the established marker. We 
expected that serum leptin would be rapidly cleared from circulation after kidney 
transplantation, faster than SCr, and anticipated a reduction of SCr in response to prompt 
graft function. It is possible that other factors that coexist in the immediate post-transplant 
period might stimulate leptin synthesis and delay its elimination. 
Inflammation 305 has been implicated in augmentation of leptin secretion. Surgical stress is 
also associated with an increase in serum leptin concentration 306, 307. Both of these 
conditions concur in kidney transplantation. Organ transplantation is a surgical procedure 
that involves an inevitable ischemia-reperfusion injury with a consequently deleterious 
activation of cellular oxidases that cause oxidative damage, tissue injury and 
inflammation.308 Leptin is an acute phase reactant that is involved in the cytokine network 
of acute inflammation and the stress response.306 It is possible that inflammatory 
cytokines that result from the organ transplant process can stimulate leptin synthesis and 
attenuate its clearance from circulation, primarily in recipients with graft dysfunction. 
These effects would also explain why the decrement of plasma leptin concentration in the 
immediate post-transplant period did not reach normal levels in most patients, even in the 
patients with prompt graft function. At day-7, 64% of our recipients still had levels that 
exceeded the upper limit of the leptin reference range; this percentage was 40% when 
only the recipients with prompt graft function were considered. 
It is noteworthy that the separate analysis of male and female patients indicated that in 
the latter group, the performance of leptin was considerably better than when all subjects 
were combined. Unfortunately, the small number of female patients precluded a sensitive 
analysis in this gender. This finding also strengthens the importance of gender as a 
determinant variable for an individual’s leptin status and the need for a stratified analysis 
of this variable. There is no uniformly accepted definition for “normal” leptin (or ADPN), 
and the classification of an individual’s “leptin status” is hampered by lack of published 
reference ranges.309 The current study reinforces that gender and body mass index are 
major determinants of circulating leptin levels and any attempt to provide ranges of 
expected leptin levels should account for at least these two variables.  
Adiponectinemia was not significantly higher in the recipients with graft dysfunction and 
was not a predictor of DGF. At least during the first week, graft dysfunction did not reflect 
an impaired clearance of adiponectin, which suggests that factors other than renal 
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function may be involved. A recent study from Song and co-workers310 demonstrated that 
a decline in circulating adiponectin levels during the initial 72 h after a subtotal 
nephrectomy in mice with renal failure was associated with the down regulation of 
adiponectin. According to this reasoning, we can also speculate that the decrease in the 
circulating adiponectin levels observed within the first week after kidney transplantation 
could be because of two different mechanisms according to graft function: an enhanced 
filtration of circulating adiponectin and urinary excretion in prompt graft patients and a 
decline in the local expression of adiponectin in the glomerular endothelium as a result of 
the amplified ischemia-reperfusion injury that typically characterizes DGF. Future studies 
on this topic are needed. Many factors remain unknown regarding adipokines in the field 
of kidney transplantation. 
We reported the independent association of high levels of plasma MDA with DGF and with 
poorer one-year allograft function. To the best of our knowledge, this study is the first to 
demonstrate this association in kidney transplantation recipients. Malondialdehyde is a 
naturally occurring end product of lipid peroxidation and the most studied product of 
polyunsaturated fatty acid peroxidation; therefore, it has been frequently used as a 
biomarker of oxidative stress.311-316 Oxidative stress is one of the most important 
components of the ischemia-reperfusion process,176, 196, 317 which is an inevitable 
phenomenon in kidney transplantation. During ischemia-reperfusion, high levels of free 
radicals are formed and increased levels of lipid peroxidation (and MDA) are detected. 
Accordingly, we showed that elevated MDA levels reflected kidney dysfunction and 
predicted the need for renal replacement therapy within the first week following kidney 
transplantation better than SCr.318  
A wide range of protective substances, such as antioxidant enzymes, may potentially 
exert a protective influence by limiting the production of ROS and the damage of oxidative 
stress following an ischemia-reperfusion injury of the kidney graft. Conflicting results have 
been reported regarding the activities of antioxidant enzymes in kidney transplantation 
patients. The levels of antioxidant enzymes have been reported to increase,205, 206 
decrease183, 319 or not change207, 320 following kidney transplantation. Compared with 
healthy controls, our patients had significantly higher levels of SOD and GR prior to kidney 
transplantation, which were most likely in response to the intensified oxidative stress of 
end-stage renal disease patients. However, no significant changes were observed 
following kidney transplantation even when stratified by graft function. Delayed graft 
function after kidney transplantation is a manifestation of acute kidney injury; thus, for an 
existing injury or one in progress, it is natural that higher quantities of ROS are released. 
Under normal conditions, endogenous antioxidant enzymes neutralize these radicals and 
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the enzyme activity subsequently decreases. Another possibility is that the capacity of the 
antioxidant defense system increases as a response to a higher production of oxidant 
radicals. Because neither of these two situations occurred, we hypothesized that in the 
first week after kidney transplantation, the antioxidant defense system does not effectively 
respond to the higher levels of oxidative stress detected in DGF. It is possible that similar 
to MnSOD, the major enzymes of the antioxidant system become inactivated during the 
early phase of ATP depletion that typically occurs in ischemia.202  
Regarding CysC, which is the most widely used “novel” marker and a potential 
replacement for SCr, we can highlight the very good performance of this biomarker in the 
diagnosis of graft dysfunction and prediction of dialysis need within the first week after 
transplantation. It is well known that moderate and high dose glucocorticoids can limit the 
usefulness of CysC soon after kidney transplantation.105 Nevertheless, we confirmed that 
CysC can signal graft dysfunction significantly better than SCr and we corroborated its 
performance not only as a single marker but also in combination with other markers (study 
V). This study summarizes the current usage of biomarker combinations for clinical 
purposes. The kidney transplant recipients and the graft injury process are complex and 
could not be deduced from the measurement of a single biomarker. Some biomarkers 
display low sensitivities or specificities, which prevent their translation to clinical practice. 
Therefore, combining biomarkers into a multimarker panel can improve the classification 
of patients and their clinical usefulness. 
Thus, based on the biomarkers studied, we explored the optimal marker combination for 
DGF diagnosis and identified a simple, accurate and clinically applicable tool with CysC, 
MDA and SCr (AUC=0.96, sensitivity=100%; specificity=86%). We assumed that even if a 
highly sensitive marker was discovered, SCr would continue to be used because it is the 
well-established marker. Thus, new biomarkers were complemented with the current 
established marker to increment the diagnostic and prognostic value. The best 
performance was achieved with this triple-biomarker approach.  
Although uNGAL has shown promising results as a predictor of DGF, the performance of 
the combinations that comprise uNGAL was lower than the triple-marker approach with 
SCr, MDA, and CysC. One potential explanation for the inferior performance of uNGAL 
might have been the lack of samples in some recipients with transient anuria. In our study, 
5 recipients were anuric the morning after graft reperfusion, which resulted in 12.5% of our 
patients without urine samples for measurement of uNGAL at this particular time point. 
These patients could not be included in any of the approaches that included uNGAL, 
which reduced the sample size and the performance of the uNGAL combinations.  
In kidney transplantation, numerous diagnostic biomarkers have been evaluated in the 
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previous decade; however, evidence to support their use in routine practice is currently 
limited. The discovery of novel biomarkers can be complex and costly. In this study, we 
demonstrated that a novel marker (MD.A) predicted who would develop DGF with 
approximately the same degree of accuracy as serum CysC and that both had a 
diagnostic performance that was superior to SCr. Undoubtedly, CysC displays several 
good characteristics that make it a viable biomarker for the early detection of DGF. 
Nonetheless and particularly during the first week when high-doses of corticosteroids are 
used, glucocorticoid medication can compromise the use of serum CysC in kidney 
transplantation, and it is important to considerer this effect when interpreting this serum 
marker. Thus, a combination of biomarkers may be more valuable for the diagnosis of 
DGF and the prognosis of graft function. Because DGF is a critical early insult to the renal 
allograft, which augments the risk of long-term graft loss, and it is a complex process with 
multiple underlying pathogenic mechanisms and confounding risk factors, it would be 
prudent to predict DGF with more than a single biomarker, at least in some situations. 
Malondialdehyde represents a valuable marker as an alternative or as a complement in 
the risk prediction not only in relation to the serum CysC and any other serum/plasma 
markers but also for urine biomarkers such as NGAL, which cannot be measured if a urine 
sample cannot be obtained, particularly during the transient anuria that commonly occurs 
after kidney transplantation.    
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CONCLUDING REMARKS  	  
The work presented in this dissertation describes the investigation and examination of 
nine biomarkers for the prediction of DGF. The studies have shown promising results that 
indicate that some of the candidate biomarkers have potential for the early detection of 
DGF and one-year graft function and are feasible for use in the clinical setting.  
As in every other field of medicine, early diagnosis and timely intervention will improve the 
outcomes of organ transplantation. Clinicians need and continually look for tools to aid 
them in clinical assessment and to enhance their ability to identify “vulnerable” patients 
who are at risk for graft dysfunction. Biomarkers are one such tool. They will enable us to 
better identify high-risk individuals, promptly diagnose dysfunction, accurately and 
effectively prognosticate outcomes, and treat patients with a tailored and more 
individualized intervention.   
It would be ideal to identify a single marker with a very high discriminatory accuracy, 
defined in terms of the test sensitivity and specificity. However, for most diseases, and 
particularly for kidney transplantation, single markers might not reflect all of the facets of 
initial graft dysfunction, and they do not have adequate sensitivity or specificity for 
practical purposes. One approach to increase the clinical value of biomarkers and improve 
their screening sensitivity is to identify additional biomarkers and to use a combination of 
them because a multimarker strategy might better characterize the complexity of DGF. 
During the research of this project several statistical tools were used and discussed, 
namely linear mixed models and survival analysis that accounted for competing risks. The 
reasons and advantages of using these methodologies were previously addressed; 
however, we should emphasize the importance of appropriate longitudinal and survival 
approaches in a field such as transplantation, where changes in survival-influencing 
factors, such as immunosuppression practices, organ allocation policies, or surgical 
techniques, may occur rapidly and where competing events are pervasive. Most studies in 
kidney transplantation use standard survival analysis methods, which treat patient death 
with a functioning graft as a censored event that is similar to patients lost to follow-up. 
However, this violates a principle of survival analysis, noninformative censoring, or the 
requirement that prognosis does not influence censorship. The predictors of graft failure 
are also shared with risk factors for death; thus, when patients are censored for death in 
traditional survival analyses, this relationship is neglected and it introduces bias into the 
overall analysis. Hence, a standard survival analysis is flawed and often overestimates the 
absolute risk in the presence of an informative competing event. Therefore, methods for 
competing risks should be used in transplant settings, with the choice of method guided 
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by the scientific question.  
The key findings that resulted from this thesis research can be summarized as follows: 
 
 
First-year renal function as a surrogate of long-term graft survival (Study I) 
- Of the large number of variables that were examined, the SCr levels at 1, 6 and 12 
months following kidney transplantation as well as the changes between 1 and 6 
months and between 6 and 12 months were independently associated with late graft 
failure. 
- These findings were important to establish SCr levels as a surrogate endpoint that will 
reflect long-term renal transplant outcomes and would be a reliable substitute for the 
subsequent prospective studies designed to identify earlier and more sensitive markers 
of graft dysfunction. 
 
NGAL (Study II) 
- Urinary NGAL appears to play a promising role as an early marker of graft functional 
recover and a predictor of DGF and one-year graft function. 
- The kinetics of uNGAL levels following kidney transplantation change according to graft 
function: recipients with graft damage and who went on to develop DGF had initial 
higher levels of uNGAL that rose further on the subsequent post-transplant days, which 
differs from patients with prompt graft function. 
- At each time-point measurement, 4 to 5 recipients were anuric, which resulted in 
approximately 12% of patients without a urine sample to determine uNGAL. Despite 
the clear value of uNGAL as a promising biomarker for allograft dysfunction, the use of 
a urinary marker in the perioperative period of kidney transplantation can also be a 
drawback because of the potential for transient graft anuria, which may preclude the 
availability of urine and consequently the lack of sample to measure NGAL.  
 
 
Oxidative stress markers (Study III) 
- Recipients who developed DGF presented increased MDA levels during the first week 
after kidney transplantation, which appear to reflect the postischemic tissue damage of 
DGF kidneys. Compared with pre-transplant, these patients presented higher MDA 
levels at 8-to-12 h following kidney transplantation, in contrast to recipients with prompt 
graft function whose MDA levels continuously decreased throughout the week. 
- Malondialdehyde is an early marker of DGF; however, it also demonstrated its 
predictive value as early as 8-to-12 h following kidney transplantation in terms of the 
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evolution of graft function and the need for dialysis during the first week. In regards to 
clinical application, a new biomarker should be more accurate in the prediction of DGF 
than the current SCr. 
- Levels of MDA at day-7 were one of the best predictors of one-year SCr: higher MDA 
levels on day-7 were associated with worse one-year graft function, which suggests 
that oxidative damage will reflect long-term injury. 
 
Adipokines (Study IV) 
- Circulating levels of leptin and adiponectin decrease after successful transplantation, 
although the values remained higher than the upper limits of the leptin and adiponectin 
reference ranges.  
- During the first post-transplant week, the recipients with graft impairment had higher 
leptin levels; the decline of leptin levels, but not adiponectin, depends on the function of 
the kidney allograft.   
- The leptin levels at day-1, but not adiponectin, slightly outperformed the traditional 
biomarker SCr in the assessment of DGF prognosis. 
 
Biomarker combination (Study V) 
ê A combination of biomarkers outperformed SCr in the early diagnosis of DGF, and the 
best performance was achieved by a triple-marker approach (AUC = 0.96, sensitivity = 
100%; specificity = 86%) that used SCr, MDA, and CysC, which can be simply 
measured in routine blood samples to result in easier clinical decision-making.  
 
Competing risks (Study VI) 
- In kidney transplantation, chronic graft failure and patient death with graft function are 
competing endpoints that are mutually exclusive. 
- In the presence of competing risk events the complement of the Kaplan-Meier estimate 
(1-KM) wrongly overestimates the probability of occurrence of the event of interest. 
- The application of a regression model for subdistribution hazard showed that DGF, 
alone and independent of acute rejection, has a significant detrimental effect on long-
term graft survival but not on patient survival. 
- The impact of DGF on long-term outcome is controversial. The different criteria used to 
define DGF, as well as the use of inappropriate statistical methods may be related to 
the divergence of opinions. 	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FUTURE DIRECTIONS  
 
The results presented in this dissertation open a number of possibilities for future 
research. Although the results from this thesis have contributed to and improved some 
aspects of our understanding regarding several potential biomarkers of early graft 
dysfunction, there is still significant work to be completed prior to their application in 
routine clinical practice.  
The literature is replete with proposed candidate biomarkers assessed in single cohorts; 
however, few biomarkers have been independently validated. This clearly highlights that 
biomarker development is a difficult venture and requires an iterative approach. Validation 
in an independent sample set and side-by-side evaluation of comparable biomarkers are 
essential to confirm or discard conclusions drawn from the discovery phase.  
Malondialdehyde was the most promising novelty that arose from this work. The next step 
is obviously to validate this marker, alone or in combination with a triple-marker approach 
with SCr and CysC, in an independent cohort with a substantially larger data set, and, if 
possible across multiple institutions. There is still a long way to go from the identification 
of a new biomarker to the implementation in a routine clinical assay.  
Prediction modeling takes multiple clinical and laboratory variables and converts them into 
a probability of disease. Nomograms and prognostic scores are increasingly utilized and 
practical tools that allows for the prediction of risk in clinical practice. These tools provide 
accurate individualized estimates of outcomes and summarize the amount of risk 
associated with each covariate of interest. Some prognostic scores have been previously 
published to predict DGF using several demographical and clinical variables. The addition 
of other prognostic markers, such as MDA and CysC, to the currently available 
nomograms might enhance predictive accuracy and refine management of recipients. 
Therefore, an important objective for future research is to construct a DGF nomogram 
including MDA and CysC and validate in an independent cohort as well as prospective 
analysis of patients undergoing kidney transplantation. 
Interest regarding MDA as a biomarker in kidney transplantation was triggered by our 
findings and led to a recent invitation to write a chapter of a book on the subject titled 
“Malondialdehyde as a biomarker in kidney transplantation” in “Biomarkers in Diseases of 
Kidney: Methods, Discoveries and Applications”. It is known that oxygen free radicals are 
one of the most likely agents responsible for initiating the damage associated with 
reperfusion injury in renal transplantation and more research is needed to answer the 
questions that arise from this study. We showed that MDA was an early marker of graft 
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damage and a predictor of DGF. It seems that the elevation of MDA levels results from 
graft damage. However, are the higher levels of MDA pathophysiology involved in the 
development of graft loss in renal transplant recipient?   
General evidence for the involvement of reactive oxygen species in hypoxia-
reoxygenation injury includes the detection of lipid peroxidation. Studies on this topic are 
limited regarding renal recipients. Malondialdehyde is an end product of lipid peroxidation 
and a biomarker of oxidative stress and early graft dysfunction. The prognostic value of 
MDA levels at the seventh day for one-year graft function was independent of the other 
significant predictors of one-year graft function. However, the implications of the increased 
production of MDA in the progression of allograft dysfunction are unknown. Since our 
group of 40 kidney recipients is an ongoing cohort and the MDA results were the first to be 
published from this cohort, the prospective clinical follow-up of these 40 recipients will 
allow us to evaluate MDA levels after the first year of graft functioning and thereby 
investigate whether these elevated levels persist and are associated with chronic kidney 
dysfunction and graft failure.  
In relation to the other biomarkers studied, the leptin results were the most intriguing. We 
focused our research in leptin as an early marker of graft dysfunction and we expected 
that serum leptin would be rapidly cleared from circulation after kidney transplantation, 
faster than SCr, and anticipate the reduction of SCr in response to prompt graft function. 
However, leptin levels only slightly outperformed SCr in identifying graft dysfunction. 
These results warrant further studies. Leptin is an acute phase reactant and other factors 
coexist in the immediate post-transplant period that can delay its elimination. Moreover, 
recent studies highlight an important and novel function for leptin: up-regulation of 
inflammatory immune responses. It will be interesting to investigate the possible impact of 
leptin in transplant rejection and its effect on boosting allo-immunity and not only as 
marker of kidney function.  
Therefore, more research is needed. Further integration of the multiple levels of biological 
information will be needed to achieve this goal. We look forward to a time when transplant 
recipients, who have already suffered from end-stage renal failure, can enjoy a new 
lifetime with their allograft. 
 	  
“Knowing is not enough; we must apply. 
Willing is not enough, we must do” 
Goethe
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ERRATA for PhD Thesis “Predictive factors of graft dysfunction and long-term kidney 
allograft failure” - Isabel Fonseca, May 21, 2015 
 
 
 
• Page 75. Paper III, Fig. 1, after the ROC curves graph and before the legend, the table with the 
biomarkers AUCs was not printed in the paper. 
 
  AUC (95% CI) P-Value 
  Day 1 (8-to-12 h after surgery)   
MDA (µmol/L)   0.90 (0.81 - 0.99)  < 0.001 
Serum Creatinine (mg/dl)  0.73 (0.58 - 0.89) 0.012 
Serum Cystatin C (mg/L)  0.91 (0.82 - 1.00)  < 0.001 
Change from pre-transplant to first day after KTx   
MDA (µmol/L)   0.84 (0.70 - 0.97)  < 0.001 
Serum Creatinine (mg/dl)  0.69 (0.52 - 0.87) 0.036 
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